

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Peer-mediated assisted partner notification services to identify and link to care HIV-positive and HCV-positive people who inject drugs: a cohort study protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-041083
Article Type:	Protocol
Date Submitted by the Author:	29-May-2020
Complete List of Authors:	<p>Monroe-Wise, Aliza; University of Washington, Mbogo, Loice; Kenyatta National Hospital Guthrie, Brandon; University of Washington Bukusi, David; Kenyatta National Hospital Sambai, Betsy; Kenyatta National Hospital Chohan, Bhavna; University of Washington; Kenya Medical Research Institute</p> <p>Scott, John; University of Washington Cherutich, Peter; Kenya Ministry of Health Musyoki, Helgar; Kenya Ministry of Health Bosire, Rose; Kenya Medical Research Institute; University of Washington</p> <p>Dunbar, Matthew; University of Washington Macharia, Paul; Kenya Ministry of Health Masyuko, Sarah; Kenya Ministry of Health; University of Washington Wilkinson, Eduan; University of KwaZulu-Natal De Oliveira, Tulio; University of KwaZulu-Natal Ludwig-Barron, Natasha; University of Washington Sinkele, Bill; Support for Addiction Prevention and Treatment in Africa Herbeck, Joshua; University of Washington School of Public Health, Farquhar, Carey; University of Washington</p>
Keywords:	HIV & AIDS < INFECTIOUS DISEASES, Hepatology < INTERNAL MEDICINE, International health services < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Epidemiology < INFECTIOUS DISEASES, Molecular diagnostics < INFECTIOUS DISEASES, VIROLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Peer-mediated assisted partner notification services to identify and link to care HIV-**
4 **positive and HCV-positive people who inject drugs: a cohort study protocol**
5
6
7
8
9
10
11
12
13
14

15 Aliza Monroe-Wise^a, Loice Mbogo^b, Brandon Guthrie^{a,c}, David Bukusi^b, Betsy Sambai^b, Bhavna
16 Chohan^{a,d}, John Scott^e, Peter Cherutich^f, Helgar Musyoki^f, Rose Bosire^d, Matthew Dunbar^g, Paul
17 Macharia^f, Sarah Masyuko^{a,f}, Eduan Wilkinson^h, Tulio de Oliveira^h, Natasha Ludwig-Barron^b,
18
19
20 Bill Sinkeleⁱ, Joshua Herbeck^{a*}, Carey Farquhar^{a,b,e*}
21
22
23
24
25
26
27
28

29 ^aUniversity of Washington Department of Global Health, ^bKenyatta National Hospital,
30

31 ^cUniversity of Washington Department of Epidemiology, ^dKenya Medical Research Institute,
32

33 ^eUniversity of Washington Department of Medicine, ^fKenya's Ministry of Health, ^gCenter for
34 Studies in Demography and Ecology, University of Washington, ^hKwaZulu-Natal Research and
35 Innovation Sequencing Platform, University of KwaZulu-Natal, ⁱSupport for Addiction
36 Prevention and Treatment in Africa
37
38
39
40
41
42
43
44
45
46

47 Corresponding author: Aliza Monroe-Wise, MD, MSc. Email: alizamw@uw.edu
48
49

50 University of Washington, 325 Ninth Avenue, Box 359909, Seattle, WA 98104-2499
51
52

53 *These authors share senior authorship.
54
55
56
57
58
59
60

Abstract

Introduction

Targeted, tailored interventions to test high-risk individuals for HIV and hepatitis C (HCV) are vital to achieving HIV control and HCV micro-elimination in Africa. Compared with the general population, people who inject drugs (PWID) are at increased risk of HIV and HCV and are less likely to be tested or successfully treated. Assisted partner notification services (APNS) increases HIV testing among partners of people living with HIV and improves case-finding and linkage to care. We describe a study in Kenya examining whether APNS can be adapted to find, test, and link to HIV and HCV care the sexual and injecting partners of HIV-positive PWID using a network of community-embedded peer educators (PEs).

Methods and analysis

This prospective cohort study leverages a network of PEs to identify 1,000 HIV-positive PWID for enrollment as index participants. Each index completes a questionnaire and provides names and contact information of all sexual and injecting partners from the past 3 years. PEs then use a stepwise locator protocol to engage partners in the community and bring them to study sites for enrollment, questionnaire completion and rapid HIV and HCV testing. Outcomes include number and type of partners per index who are mentioned, enrolled, tested, diagnosed with HIV and HCV and linked to care.

Ethics and dissemination

All potential index participants are screened for intimate partner violence (IPV) and those at high risk are not eligible to enroll. Those at medium risk are monitored for IPV following enrollment.

1
2
3 A community advisory board (CAB) meets biennially to engage in feedback and discussion
4
5 between the community and the research team. A safety monitoring board (SMB) meets biennially
6
7 to discuss study progress and review data, including IPV monitoring data. Dissemination plans
8
9 include presentations at quarterly Ministry of Health (MoH) working group meetings, local and
10
11 international conferences, and publications.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Strengths and limitations of this study

- This cohort study investigates the use of assistant partner notification services (APNS) for HIV and hepatitis C (HCV) to find, test, and link to care the sexual and injection partners of people who inject drugs (PWID) in Kenya—a high risk, difficult to reach population.
- Community embedded peer educators who are former drug users trained to provide harm reduction services and are known and trusted within the PWID community conduct partner tracing, and typically serve as the first point of contact with potential partner participants.
- An iris scanning biometric identification system ensures that each index participant enrolled is a unique individual and confirms that individual partner participants who enroll more than once in relation to different index participants are the same individual.
- Phylogenetic analysis of HIV and HCV viral sequences combined with APNS provides additional information about transmission dynamics within the cohort, including risk of onward transmission for different clusters and geographic regions.

Introduction

Of the UNAIDS 90-90-90 goals,¹ diagnosing 90% of those living with HIV remains the most elusive target worldwide,² and strategies to reach high-risk individuals who have never been tested for HIV is increasingly important.³ Sharing needles and other drug paraphernalia is the most efficient mode of HIV transmission, and accounts for 13% of new infections globally.^{4,5} In Kenya, prevalence of HIV among people who inject drugs (PWID) has been estimated at 15 – 50%^{5–9}—significantly higher than the general population prevalence of 4.9%,¹⁰ and up to 30% of PWID in Kenya have never tested for HIV.^{11,12} Multiple studies have demonstrated low knowledge of HIV

1
2
3 status and low engagement in care among Kenya's PWID.^{12,13} Retention in care and adherence to
4
5 ART are also both lower among drug users as compared with non-drug users worldwide,² and sub-
6
7 Saharan Africa (SSA) has the lowest rates of ART use among HIV-positive PWID anywhere in
8
9 the world.¹⁴
10

11
12
13 In addition to HIV, PWID are at high risk for hepatitis C virus (HCV) globally and have the highest
14
15 HCV prevalence of any group studied in Kenya, between 13-40%¹⁵⁻¹⁷ compared with the general
16
17 population prevalence of <1-4%.^{18,19} However, multiple barriers exist at individual, provider and
18
19 system levels resulting in low rates of testing, engagement in care, and completion of treatment
20
21 courses for PWID.²⁰⁻²² Although less than 20% of PWID with chronic HCV worldwide have
22
23 undergone antibody screening, the number who have completed PCR confirmatory testing is even
24
25 lower.²³ Despite the introduction of highly effective direct acting antivirals (DAAs) into Kenya in
26
27 2016, only a small fraction of HCV-infected individuals have been treated, prompting attention to
28
29 micro-elimination strategies.
30
31
32
33

34
35 Assisted partner notification services (APNS) for HIV is an evidence-based partner notification
36
37 strategy in which providers elicit information about the sexual or injecting partners of an HIV-
38
39 positive index client, and then contact, HIV test and link to care any partners found to be positive.²⁴
40
41 APNS has been shown to significantly and safely increase the uptake of HIV testing services
42
43 (HTS), case finding, and linkage to care for partners of HIV-positive people.²⁴⁻²⁶ APNS can also
44
45 reduce barriers to disclosing HIV status²⁷ and is cost-effective.²⁸ APNS has been successfully
46
47 implemented among HIV-positive patients from the general population in the USA,²⁹
48
49 Mozambique,³⁰ Malawi,^{31,32} and Kenya,²⁶ and has recently been incorporated into the World
50
51 Health Organization (WHO) guidelines for routine care for HIV-positive people worldwide.³³
52
53
54
55 While programs have introduced the practice of APNS in high-risk key populations (KPs) such as
56
57
58
59
60

1
2
3 female sex workers (FSW)³⁴ and men who have sex with men (MSM),^{35,36} this intervention has
4 not been well-studied among PWID, an extremely high risk group.^{24,37} Similar to FSW and MSM,
5 PWID engage in behavior that is criminalized³⁸ while experiencing high rates of marginalization
6 and displacement,³⁹ making them difficult to study. These factors and others also contribute to
7 significant barriers in the implementation of health programs targeting PWID.^{40–42}
8
9
10
11
12
13
14

15
16 Phylogenetic analysis is a method of identifying the role of specific risk groups and risk factors
17 for onward transmission of HIV and HCV using the genetic sequence of each virus.^{43–45} Viral
18 phylogenetics can provide additional information on patterns of transmission,^{46–48} epidemic
19 growth,^{49,50} risk groups,^{51–53} and risk factors associated with onward transmission.^{45,54–56}
20
21
22
23
24
25

26 Here we describe a prospective cohort study that seeks to determine whether and how APNS can
27 be implemented to find, test, and link to care the injection and sexual partners of HIV-positive
28 PWID in Kenya. Simultaneously, our study will use phylogenetic analysis to study genetic
29 sequences of HIV and HCV within our cohort to further understand transmission patterns and risk
30 for onward transmission. All index and partner participants are tested for HCV in addition to HIV.
31
32 In Kenya, the large majority of PWID do not have regular access to cellular telephones, which are
33 the typical communication modality for APNS in other populations. As such, our APNS model
34 relies on the utilization of community-embedded peer educators (PEs) to locate and communicate
35 with members of this difficult to reach population. We hypothesize that we will be able to employ
36 these customized APNS procedures to reach a large number of injection and sexual partners, and
37 that we will see differences in HIV and HCV testing, HIV and HCV prevalence, and engagement
38 in care between sexual and injection partners. Additionally, we hypothesize that we will identify
39 unique transmission patterns and risks for onward transmission in phylogenetic analysis.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Methods and analysis

Approach

APNS is a practice through which healthcare providers facilitate the notification, testing and linkage to care for partners who have been exposed to HIV or other sexually transmitted infections by an individual known to be positive. Typically, APNS is conducted by healthcare providers who elicit information about partners from an “index” patient and then call the partners over the telephone to alert them to their exposure and arrange testing. We have designed customized procedures to ensure and improve the safety and efficacy of APNS in the unique population of PWID in Kenya. Because PWID and their partners in Kenya rarely own cellular phones, we work with community-embedded peer educators (PEs) to find and engage with partners. Additionally, our protocol includes different APNS procedures among injection partners and for sexual partners, as these groups have different risk profiles and different relationships to index participants.

Study design

Our study is a prospective cohort study with two groups: index and partner participants (“indexes” and “partners”). We use tailored APNS procedures to identify, find, test and link to care the sexual and injection partners of HIV-positive PWID. All participants who are either HIV-positive or HCV-infected then complete a 6-month follow-up visit to assess linkage to and engagement in care.

Study sites/setting

Study procedures take place in eight main sites including public health centers, medically assisted therapy (MAT) centers, and needle and syringe programs (NSPs) in Nairobi, Kilifi, and Mombasa

1
2
3 Counties in Kenya (Figure 1). Each site is staffed by at least one clinical officer (mid-level
4 clinician) who works with the study team to ensure that indexes are HIV-positive. In Nairobi
5
6 County, the activities are centered at two NSP sites and one MAT center in the Mathare North
7
8 area. The NSP sites, run by Support for Addiction Prevention and Treatment in Africa (SAPTA),
9
10 offer routine HIV counseling and testing. Referrals are made to local clinics providing care for
11
12 those who test positive for HIV or HCV. We also recruit indexes from a government-run
13
14 methadone clinic in Nairobi in the Ngara area. The Ngara Health Center MAT clinic offers HIV
15
16 testing, care and treatment in addition to daily methadone administration, psychosocial services
17
18 and treatment for other health conditions. In Kilifi county, participant recruitment and enrollment
19
20 takes place at three needle and syringe program centers and one government hospital. The Omari
21
22 Project is located in Malindi town and offers HIV counseling, testing, care and treatment in
23
24 addition to harm reduction services. Malindi Sub-County Hospital's MAT center is a recruitment
25
26 site in Kilifi County within a mid-sized government hospital that offers a large range of medical
27
28 and social services. Malindi Sub-County Hospital also has a large laboratory that houses the
29
30 study's samples collected in both Kilifi and Mombasa Counties. The Muslim Education and
31
32 Welfare Association (MEWA) NSP sites in Kilifi and Mtwapa towns offer HIV counseling and
33
34 testing, in addition to HIV care and treatment and harm reduction services. In Mombasa county,
35
36 participants are recruited from the ReachOut Center, an NSP site in Mombasa city that offers a
37
38 full range of harm reduction services in addition to HIV counseling, testing, care and treatment.
39
40 All recruitment sites offer HCV testing when kits are available through specific donor-driven
41
42 projects.
43
44
45
46
47
48
49
50

51 Population

52
53
54
55
56
57
58
59
60

1
2
3 This study includes index participants and their sexual and injecting partners . All indexes are HIV-
4 positive PWID. Partners are either sexual partners or injecting partners of indexes. As such,
5
6 partners need not be PWID or HIV-positive but are defined by their relationships with indexes.
7
8
9

10
11 Indexes are largely recruited from organizations and clinics that provide services to PWID
12
13 populations, although they may also come from outreach efforts or informal referrals from other
14
15 participants. Partners are identified and recruited through peer-mediated APNS and may come
16
17 from any geographic area or community.
18
19
20

21 Study procedures

22 1. Peer educator recruitment and training

23
24
25
26
27
28 PEs are recovering PWID with established relationships in the PWID communities that they serve.
29
30 The majority are between the ages of 25 and 50, are enrolled in Kenya's methadone program and
31
32 have stopped injecting drugs, byself-report. These men and women have been identified by the
33
34 individual organizations at which they work as being key community members, and have
35
36 undergone extensive training for their roles as PEs. Training is an intensive 5-day course with
37
38 modules covering a broad spectrum of content including basics of drugs and drug-related harms,
39
40 harm reduction efforts including NSP and MAT, abscess prevention and management, overdose
41
42 prevention and management and behavior change communication. PEs have access to relatively
43
44 hidden PWID community spaces, and provide health counseling, linkage to support organizations,
45
46 information, and other services to this vulnerable population.
47
48
49
50

51
52 For this study, PEs who were actively carrying out basic duties were chosen by the leadership at
53
54 each organization based on several factors including awareness and knowledge of HIV in the
55
56
57
58
59
60

1
2
3 community and access to unique target populations (for instance, women who inject drugs are
4 more easily accessed by women PEs). Once identified, PEs underwent an intensive 1-day training
5
6 to educate them on the practice and ethics of research, study procedures, and their role in the study.
7
8 PEs participate in regular health education and harm reduction training and engage in quarterly
9
10 sessions with study leadership wherein PEs present barriers and lessons learned to the study team
11
12 so that study-related issues can be addressed.
13
14
15

16 17 18 2. Inclusion & exclusion criteria

19
20
21 Inclusion and exclusion criteria are different for indexes and partners (Table 1). Any interested
22
23 individuals who are under the age of 18 are referred to the site clinicians for routine counseling
24
25 and harm reduction services.
26
27
28

29 30 3. Index recruitment and enrollment

31
32 PEs work with clinicians at each site to identify potential indexes at NSP sites, MAT centers and
33
34 other areas where PWID congregate. Clinicians are employed by the sites, and are trained as
35
36 clinical officers (COs), or mid-level providers. For this study, HIV rapid testing is performed by
37
38 COs and takes place as part of standard clinic procedures. All potential indexes are re-tested using
39
40 HIV rapid tests (as per the national guidelines) to confirm HIV status prior to enrollment. If HIV-
41
42 seropositive, either newly diagnosed or known to be positive, clinicians either discuss the study
43
44 directly with potential participants or engage PEs to find individuals and bring them to the study
45
46 office. Importantly, PEs are not told whether participants are being traced as an index or a partner,
47
48 protecting the confidentiality of indexes' HIV status.
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Study staff health advisors (HAs) are the individuals responsible for conducting study procedures
4 including data collection, HIV and HCV testing, and the coordination of APNS efforts (Figure 2).
5
6 All HAs were trained and experienced in HIV counseling and testing prior to working for the
7
8 study, and many had previous experience working with PWID. All HAs underwent a week-long
9
10 training course at the beginning of the study in which they learned the basics and purpose of
11
12 research, research ethics, study procedures, unique ethical and logistical issues to consider when
13
14 working with PWID, and other topics. All HAs also completed the Collaborative Institutional
15
16 Training Initiative (CITI) course on Human Subjects Research and the Responsible Conduct of
17
18 Research. HAs explain the benefits and rationale for providing APNS, discuss the importance of
19
20 learning more about HIV and HCV, and describe the process of notifying partners without
21
22 revealing the identity of the index. They ask participants to provide written informed consent and
23
24 use an iris-scanning biometric device to record a unique identifier for each participant, thus
25
26 enabling the study team to confirm that a person does not enroll into the program as an index more
27
28 than once.
29
30
31
32
33
34
35

36 Indexes undergo a structured questionnaire administered by the HA using open data kit (ODK)
37
38 software on tablet devices (ODK, 2017, Seattle, WA, USA). Questionnaires cover a variety of
39
40 topics including demographics, sexual and injecting behaviors, drug use history, and HIV testing
41
42 and engagement history. Participants are then asked to recall all of their sexual and injecting
43
44 partners over the past three years, naming these partners one by one and assigning each partner a
45
46 letter (“A,” “B,” etc). Indexes are asked to give as much locator information as possible for each
47
48 partner, including names (which may be nicknames), phone numbers, and location of employment
49
50 or residence. Locator information is written on a paper form for each partner. Indexes then
51
52
53
54
55
56
57
58
59
60

1
2
3 complete a short ODK questionnaire about each partner mentioned, which includes information
4
5 about the relationship between the index and the partner.
6
7

8
9 Indexes then undergo rapid HCV antibody testing as part of routine study procedures. HAs conduct
10
11 pre- and post- test counseling and ensure individuals who test positive are available for follow-up
12
13 visits to discuss confirmatory HCV PCR testing and enrolling in a treatment program administered
14
15 by the Ministry of Health. All indexes then undergo phlebotomy with a sample of 10mL of blood
16
17 drawn for further testing (see section 6 below). Indexes receive 400 Kenya Shillings (KES,
18
19 equivalent to about \$4) as compensation for travel and time spent in the study procedures.
20
21
22

23 24 4. Peer-educator mediated assisted partner services and partner recruitment

25
26
27 For those partners who have phone numbers listed, HAs attempt phone communication first.
28
29 However, the vast majority of partners mentioned by indexes do not have working cellular phones;
30
31 therefore, with very few exceptions, PEs locate and conduct the study's first interaction with
32
33 identified partners. PEs are given paper forms containing names and locator information for
34
35 identified partners. They are never told which index referred the team to each partner, and that
36
37 information is not listed on locator forms or any other accessible file. PEs then locate and approach
38
39 potential participants in the community. Using a standardized script, PEs inform potential
40
41 participants that they have been identified as an individual who might be eligible for a research
42
43 study on HIV and HCV. They then accompany interested individuals to the nearest research office,
44
45 where the study's HAs conduct informed consent.
46
47
48
49

50 51 5. Partner enrollment

52
53
54
55
56
57
58
59
60

1
2
3 After informed consent and biometric identification, partners complete a structured questionnaire
4 similar to that of indexes, administered by HAs on a handheld device using ODK software.
5
6 Following the questionnaire, all partners undergo rapid antibody testing for both HIV and HCV.
7
8 Testing and counseling services are provided in accordance with national HIV testing and
9 counseling guidelines. Any partner found to be positive for either HIV or HCV antibodies
10 undergoes a 10mL blood draw. Those partners who test negative for both HIV and HCV are
11 finished with study procedures at this time, and are counseled on risk reduction measures and
12 linked to HIV and HCV prevention services before leaving the study site. All partners receive 400
13 Kenya Shillings (KES, equivalent to about \$4) as compensation for travel and time spent in the
14 study procedures.
15
16

17 HIV-positive partners are invited to undergo screening as an index once data collection procedures
18 for their partner enrollment are complete. If they meet eligibility criteria as an index, they may
19 enroll as an index. Study procedures are slightly amended for indexes that have previously enrolled
20 as partners. After undergoing informed consent and completing a short questionnaire that only
21 includes questions that were not a part of the partner enrollment questionnaire, they complete the
22 identification and data collection on each of their sexual and injection partners, identical to partner
23 identification procedures for indexes described above.
24
25
26

27 6. Laboratory Procedures

28
29 Blood samples from both index and partner enrollment visits are collected in EDTA vacutainer
30 tubes. Blood is mixed with the anticoagulant by inversion and the anticoagulated blood is stored
31 at room temperature at the sites for less than 4 hours. A motorcycle courier picks samples from
32 each site daily and brings them to the University of Nairobi Pediatric Research Laboratory in
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Nairobi or the Malindi Sub-County Hospital Laboratory for coast sites. At each laboratory,
4 samples are first used to prepare two Whatman 903 Protein Saver dried blood spot (DBS) cards
5 with 50ul of whole blood on each spot. Blood samples are then centrifuged and used to prepare 2
6 to 3 aliquots of 1ml of plasma in labeled serum vials. Plasma aliquots and air-dried DBS cards
7 (with desiccant in sealed Ziploc bags) are then stored at -80° Celsius and shipped on dry ice to the
8 University of KwaZulu-Natal laboratory. There, samples undergo HIV and HCV viral load testing
9 and amplification for sequencing.
10
11
12
13
14
15
16
17
18
19

20 7. Participant follow-up

21
22
23 All index and partner participants who were positive for HIV or HCV complete a six-month
24 follow-up visit. HAs identify which participants are due for follow-up visits on a weekly basis and
25 give PEs as list of these names. PEs then trace participants and bring them back to clinics where
26 data collection procedures are conducted.
27
28
29
30
31
32

33
34 Six-month visits are short, and involve only a brief questionnaire covering questions on testing for
35 HIV or HCV (if not infected with both on enrollment), enrollment in care and treatment,
36 engagement in care, and follow-up testing. The purpose of this visit is to assess whether
37 engagement in care has changed following APNS procedures.
38
39
40
41
42
43

44 8. Intimate partner violence (IPV) monitoring

45
46
47 Given historical concerns that APS may increase one's risk of experiencing intimate partner
48 violence, all potential participants undergo screening for IPV before enrollment. IPV is defined as
49 any physical, sexual or psychological harm inflicted on a person by a current or former sexual
50 partner. After answering a standardized set of six questions about physical, emotional and sexual
51
52
53
54
55
56
57
58
59
60

1
2
3 IPV and the timing of any previous experience of IPV based on published screening tools reviewed
4 by the Centers for Disease Control and Prevention,⁵⁷ potential participants are classified as low,
5
6 medium or high risk for IPV. Individuals are classified as at high risk for IPV if they report IPV
7
8 within the last month. Any potential index who is classified as high IPV risk is excluded from
9
10 study participation and provided with IPV counseling and resources. Any potential partner who is
11
12 classified as high IPV risk is allowed to enroll, but then receives special monitoring for IPV
13
14 following enrollment.
15
16
17
18
19

20 Potential participants are classified as at moderate risk for IPV if they report 1) IPV during their
21
22 lifetime either from a current or past partner; and/or 2) fear of IPV if they participate in the study.
23
24 All index or partner participants classified as moderate IPV risk receive special monitoring for
25
26 IPV following their enrollment in the study.
27
28
29

30 Potential participants are classified as at low risk for IPV if they report 1) no IPV during their
31
32 lifetime ; and 2) no fear of IPV if they participate in the study. These individuals undergo standard
33
34 study procedures which include completing the baseline IPV case report form and a follow-up IPV
35
36 case report to capture reports of any interim IPV.
37
38
39

40 9. Confidentiality and safety

41
42
43 *Participants:* All study procedures take place in private rooms at each study facility. To ensure the
44
45 safety and confidentiality of indexes, PEs who are tasked with finding partners are blinded to the
46
47 identity of the linked index through the use of partner locator forms that do not contain identifying
48
49 information about the index participant. Locator forms do contain a printed barcode label that are
50
51 then used by study staff to link the partner with the index who referred the partner.
52
53
54
55
56
57
58
59

1
2
3 Sexual partners are brought to independent facilities for enrollment rather than to centers that serve
4
5 PWID, in order to further protect the identity of the index participant who referred them. The
6
7 independent facilities are local healthcare clinics that serve the general population.
8
9

10
11 *Peer educators:* PEs have frequent interactions with police, and can be victims of harassment or
12
13 violence, both by police and by PWID. To reduce the risk of law enforcement troubles, PEs carry
14
15 identification showing that they are working on a study being conducted by the Ministry of Health.
16
17 Local law enforcement officials have also attended ongoing sensitization trainings by the Ministry
18
19 of Health and by organizations working with PWID.
20
21

22 23 10. Referrals to care

24
25
26
27 *HIV Counseling and Care:* Participants are provided with their HIV test results in the context of
28
29 post-test counseling, and are then referred to available medical and psychosocial care and support
30
31 facilities either within the research site or in close proximity to the research site or the participant's
32
33 home. Additionally, HIV-positive individuals are offered individual or group support sessions as
34
35 available within each site.
36
37

38
39
40 *HCV Counseling and Care:* Participants who test positive for HCV antibodies using rapid testing
41
42 are provided with their HCV antibody test results in the context of pre- and post-test counseling.
43
44 They are informed that they may have active HCV infection; however, further confirmatory testing
45
46 must be done prior to establishing the diagnosis. Confirmatory polymerase chain reaction (PCR)
47
48 testing is done in batches of samples at our partnering laboratory at the University of KwaZulu-
49
50 Natal, South Africa, and participants with active infection are later contacted for results and
51
52 counseling. Once notified, those with active infection are paired with a PE at their site to ensure
53
54
55
56
57
58
59

1
2
3 close contact is maintained. Study participants with active HCV infections will be eligible to
4 receive free treatment with direct acting antivirals, which the Kenyan MoH has procured.
5
6
7

8 9 Data management

10
11 After each study visit, HAs review their work for omissions or errors and all data are uploaded
12 into the study database. Electronic data are stored securely in an encrypted database on servers
13 using Open Data Kit Aggregate, within Kenya's Ministry of Health (MoH). All errors or omissions
14 identified at any step in the quality assurance/quality control process are revised by the staff
15 member who originally completed the document. All additions and corrections are initialed and
16 dated by the staff member who records the entry.
17
18
19
20
21
22
23
24

25
26 A link-log is separately encrypted to further ensure that data remains secure. Any data transferred
27 to investigators or MoH are de-identified and encrypted during the process of transfer from the
28 server. Each investigator maintains and stores secure, complete, accurate and current study records
29 throughout the study. A database manager performs regular data cleaning and resolves any
30 discrepancies that occur. Study sites also conduct quality control and quality assurance procedures.
31
32
33
34
35
36
37
38

39 Outcome measures

40
41
42 The primary outcomes of interest to assess the success of the APNS intervention are: a) number
43 of partners tested for HIV and HCV through APNS, identified by each index participant over the
44 course of the study period; b) number of partners newly testing positive for HIV and HCV, per
45 index participant; c) number of known HIV or HCV cases identified through APNS who are not
46 engaged in care; d) number of index and partner participants with HIV and/or HCV infection who
47 are linked to care; e) number of index and partners with HIV and/or HCV infection who remain in
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 care and are receiving appropriate treatment at 6 months after testing positive. Secondary outcomes
4 are linked to inclusion in phylogenetic clusters identified as high risk for onward transmission of
5 HIV and HCV.
6
7
8
9

10 11 Sample size and power analysis 12

13
14 We are enrolling 1000 HIV-positive indexes and their sexual and injecting partners . Based on
15 HCV data from MoH and our preliminary results, we estimate that 20% of PWID with HIV will
16 be co-infected with HCV and that each index will identify on average two partners who will accept
17 HIV and HCV testing, 20% of whom will be HIV-positive, and 20% of whom will be HCV-
18 infected. Thus, with provision of APNS to 1,000 HIV-positive indexes and testing of 2,000
19 partners, we will identify an estimated 600 indexes and partners infected with HCV and 400 HIV-
20 positive partners.
21
22
23
24
25
26
27
28
29

30 31 Statistical methods and analysis 32

33
34 To determine efficacy of the APNS intervention, we will use generalized estimating equations
35 (GEE) models with a Poisson link to compare the two arms of the study using the following
36 variables and offsets: 1) rate of HIV and HCV testing of partners: number of individuals tested for
37 HIV or HCV, offset by the number of partners located with locator information provided by the
38 index participant; 2) prevalence of HIV and HCV infection: number of individuals identified as
39 HIV or HCV-positive, offset by the number of individuals who were HIV tested; and 3) rate of
40 linkage to HIV and HCV care: individuals who test HIV or HCV-positive and link to care, offset
41 by the total number of individuals who test HIV or HCV-positive.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Additionally, using both GEE and phylogenetic analysis, we will determine the following: 1)
4 identifiable and individual risk factors linked to high rates of HIV and HCV transmission, 2) risk
5 factors linked to both needle-sharing and sexual transmission, and 3) identification of transmission
6 clusters among PWID for both HIV and HCV.
7
8
9
10
11

12 Phylogenetic analysis

13
14
15
16 HIV and HCV gene sequencing is attempted for all study participants who test positive for either
17 virus. Sequencing will be performed at the KwaZulu-Natal Research Innovation and Sequencing
18 Platform (KRISP) at the University of KwaZulu-Natal in Durban, South Africa. For HIV we will
19 subsequently combine our data with additional, publicly available, HIV sequences from Kenya
20 and perform phylogenetic and phylodynamic analyses to describe patterns and rates of viral
21 transmission among key populations in Kenya and identify traits associated with relative
22 infectiousness. For HCV we will use phylogenetic methods to characterize the modes and risk
23 factors for onward transmission among PWID.
24
25
26
27
28
29
30
31
32
33
34
35

36 Ethics and Dissemination

37 General ethical considerations

38
39
40
41
42 This study is registered at clinicaltrials.gov and has ethical approval from both the University of
43 Washington Human Subjects Division and the Kenyatta National Hospital Ethics and Research
44 Committee. It also has approval from Kenya's National Commission for Science, Technology and
45 Innovation.
46
47
48
49
50

51
52
53 Risks to study participants are minimal, as neither obtaining blood nor HIV testing is likely to
54 cause serious harm to the study participant. While IPV has the potential to cause harm, it has not
55
56
57
58
59
60

1
2
3 increased in other US or African studies when this intervention has been implemented.^{24,58,59} Study
4
5 staff are highly trained in counseling about risk behaviors, implications of testing HIV-positive,
6
7 and protecting confidentiality to avoid potential social harms. In addition, staff have undergone
8
9 extensive training on IPV counseling and ensure that resources have been identified in all sites so
10
11 we can safely refer participants who report abuse or are concerned for their safety. To further
12
13 monitor and protect against IPV, we collect IPV data on case report forms during interviews with
14
15 participants as described above.
16
17
18
19

20
21 A safety monitoring board composed of researchers and policy makers in both Kenya and the US
22
23 reviews study data twice per year. The board monitors enrollments, deaths, loss to follow up,
24
25 adverse events, and IPV monitoring data and makes recommendations of whether to continue
26
27 study procedures.
28
29

30
31 Ethical considerations surrounding the use of biometric identification systems among vulnerable
32
33 key populations in Kenya have been discussed extensively.⁶⁰ Despite early opposition from the
34
35 Key Populations Consortium and other organizations to the government's use of fingerprint-based
36
37 biometric data collection, the organizations and individuals working with PWID communities
38
39 continued to report no opposition to iris scanning for research purposes among PWID. In
40
41 November 2019, Kenya passed the Data Protection Bill, rendering it legal to collect biometric data
42
43 as long as the use of such data does not violate the subjects' rights.⁶¹ The use of biometrics is now
44
45 standard practice in many research and clinical settings, and has been found to be acceptable to
46
47 participants.⁶² Our participants have not reported any concerns, fears, or hesitations regarding the
48
49 use of an iris scanning biometric identification system.
50
51
52
53

54 Dissemination plan

55
56
57
58
59
60

1
2
3 Results from the study are presented on an ongoing basis at Kenya's quarterly MoH harm reduction
4 and key population technical working group meetings, and discussed at biannual community
5 advisory board meetings. Our study team includes several officials from the MoH. Ongoing study
6 analyses are also presented at national conferences annually, including Kenya's HIV clinicians'
7 society meeting, the Infectious Disease Society of Kenya (IDSK) biennial conference, or the
8 Annual University of Nairobi STD/HIV/SRH Collaborative Conference. Additionally, study
9 results are presented in at least one international conference per year, including the Conference on
10 Retroviruses and Opportunistic Infections (CROI), the International AIDS Conference, and the
11 College on Problems of Drug Dependence (CPDD) annual conference. Finally, the study team
12 reviews data on a weekly basis and any changes in data trends or other concerns are discussed
13 directly with the organizations through which study procedures take place.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

29 **Authors' contributions**

30
31
32 CF and JH conceived of the study; AMW, BG, BC, MD, PM, JH and CF contributed to the study
33 design and data collection structure; AMW, LM, DB, BSa, BC, JS, PC, HM, RB, PM, SM, EW,
34 TDO, JH and CF contributed to data collection; AMW, LM, BG, DB, BSa, PC, HM, RB, SM,
35 EW, TDO, NLB, JH and CF contributed to data analysis and dissemination; AMW, BG, JH and
36 CF wrote the manuscript; all authors reviewed the manuscript for content.
37
38
39
40
41
42
43
44

45 **Funding**

46
47
48 This work was supported by National Institutes of Drug Abuse, grant number R01 DA043409.
49
50

51 **Competing interests**

52
53
54
55 All authors state that they have no competing interests.
56
57
58
59
60

Patient and Public Involvement

Members of the community of PWID being researched were consulted in the development of research questions and design of the study. The study is supported by a Community Advisory Board (CAB) composed of members of the community, peer educators and employees of organizations that provide services to the population. The CAB meets with the study team regularly and helps inform dissemination plans.

References

1. UNAIDS. 90-90-90: An ambitious treatment target to help end the AIDS epidemic. Published October 2014. Accessed March 7, 2018. http://www.unaids.org/sites/default/files/media_asset/90-90-90_en.pdf
2. Levi J, Raymond A, Pozniak A, Vernazza P, Kohler P, Hill A. Can the UNAIDS 90-90-90 target be achieved? A systematic analysis of national HIV treatment cascades. *BMJ Glob Health*. 2016;1(2):e000010. doi:10.1136/bmjgh-2015-000010
3. Staveteig S, Croft TN, Kampa KT, Head SK. Reaching the 'first 90': Gaps in coverage of HIV testing among people living with HIV in 16 African countries. *PLOS ONE*. 2017;12(10):e0186316. doi:10.1371/journal.pone.0186316
4. Brodish P, Singh K, Rinyuri A, et al. Evidence of high-risk sexual behaviors among injection drug users in the Kenya PLACE study. *Drug Alcohol Depend*. 2011;119(1-2):138-141. doi:10.1016/j.drugalcdep.2011.05.030
5. Mathers BM, Degenhardt L, Phillips B, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. *Lancet Lond Engl*. 2008;372(9651):1733-1745. doi:10.1016/S0140-6736(08)61311-2
6. M. Odek-Ogunde, B. Lore, F. Owiti, S. Munywoki, J. Moor. Seroprevalence of HIV, HBC and HCV in injecting drug users in Nairobi, Kenya: World Health Organization Drug Injecting Study Phase II findings. In: ; 2004.
7. National AIDS Control Council NS and ACP. Kenya HIV Prevention Revolution Road Map: Count Down to 2030. Published online June 2014.

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
8. Kurth AE, Cleland CM, Des Jarlais DC, et al. HIV Prevalence, Estimated Incidence, and Risk Behaviors Among People Who Inject Drugs in Kenya. *J Acquir Immune Defic Syndr* 1999. 2015;70(4):420-427. doi:10.1097/QAI.0000000000000769
9. Ndetei, David M. A study on the linkages between drug abuse, injecting drug use and HIV/AIDS in Kenya: a rapid situation assessment. *U N Off Drugs Crime*.:45.
10. National AIDS Control Council. *Kenya HIV Estimates Report 2018*. Accessed February 21, 2019. <https://nacc.or.ke/wp-content/uploads/2018/11/HIV-estimates-report-Kenya-20182.pdf>
11. Tun W, Sheehy M, Broz D, et al. HIV and STI Prevalence and Injection Behaviors Among People Who Inject Drugs in Nairobi: Results from a 2011 Bio-behavioral Study Using Respondent-Driven Sampling. *AIDS Behav*. 2015;19(Suppl 1):24-35. doi:10.1007/s10461-014-0936-3
12. Lizcano, J. Testing and Linkage to Care for Injecting Drug Users. In: ; 2016.
13. Githuka G, Hladik W, Mwalili S, et al. Populations at Increased Risk for HIV Infection in Kenya: Results From a National Population-Based Household Survey, 2012. *J Acquir Immune Defic Syndr* 1999. 2014;66(Suppl 1):S46-S56. doi:10.1097/QAI.0000000000000137
14. Mathers BM, Degenhardt L, Ali H, et al. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. *Lancet Lond Engl*. 2010;375(9719):1014-1028. doi:10.1016/S0140-6736(10)60232-2
15. Akiyama MJ, Cleland CM, Lizcano JA, Cherutich P, Kurth AE. Prevalence, estimated incidence, risk behaviours, and genotypic distribution of hepatitis C virus among people who inject drugs accessing harm-reduction services in Kenya: a retrospective cohort study. *Lancet Infect Dis*. 2019;19(11):1255-1263. doi:10.1016/S1473-3099(19)30264-6
16. Muasya T, Lore W, Yano K, et al. Prevalence of Hepatitis C Virus and its genotypes among a cohort of drug users in Kenya. *East Afr Med J*. 2008;85(7). doi:10.4314/eamj.v85i7.9649
17. Odek-Ogunde M, Okoth, F, Lore, W, Owiti, F.R. Seroprevalence of HIV, HBC and HCV in Injecting Drug Users in Nairobi, Kenya: World Health Organization Drug Injecting Study Phase II Findings. In: ; 2004.
18. Bartonjo G, Oundo J, Ng'ang'a Z. Prevalence and associated risk factors of transfusion transmissible infections among blood donors at Regional Blood Transfusion Center Nakuru and Tenwek Mission Hospital, Kenya. *Pan Afr Med J*. 2019;34. doi:10.11604/pamj.2019.34.31.17885
19. Loarec A, Carnimeo V, Molfino L, et al. Extremely low hepatitis C prevalence among HIV co-infected individuals in four countries in sub-Saharan Africa. *AIDS Lond Engl*. 2019;33(2):353-355. doi:10.1097/QAD.0000000000002070
20. Litwin AH, Jost J, Wagner K, et al. Rationale and design of a randomized pragmatic trial of patient-centered models of hepatitis C treatment for people who inject drugs: The HERO study. *Contemp Clin Trials*. 2019;87:105859. doi:10.1016/j.cct.2019.105859

- 1
- 2
- 3
- 4 21. Treloar C, Hull P, Dore GJ, Grebely J. Knowledge and barriers associated with assessment and
- 5 treatment for hepatitis C virus infection among people who inject drugs. *Drug Alcohol Rev.*
- 6 2012;31(7):918-924. doi:10.1111/j.1465-3362.2012.00468.x
- 7
- 8 22. Enkelmann J, Gassowski M, Nielsen S, et al. High prevalence of hepatitis C virus infection and low
- 9 level of awareness among people who recently started injecting drugs in a cross-sectional study in
- 10 Germany, 2011-2014: missed opportunities for hepatitis C testing. *Harm Reduct J.* 2020;17(1):7.
- 11 doi:10.1186/s12954-019-0338-y
- 12
- 13 23. Day E, Hellard M, Treloar C, et al. Hepatitis C elimination among people who inject drugs:
- 14 Challenges and recommendations for action within a health systems framework. *Liver Int Off J Int*
- 15 *Assoc Study Liver.* 2019;39(1):20-30. doi:10.1111/liv.13949
- 16
- 17 24. Dalal S, Johnson C, Fonner V, et al. Improving HIV test uptake and case finding with assisted
- 18 partner notification services. *AIDS Lond Engl.* 2017;31(13):1867-1876.
- 19 doi:10.1097/QAD.0000000000001555
- 20
- 21 25. Kahabuka C, Plotkin M, Christensen A, et al. Addressing the First 90: A Highly Effective Partner
- 22 Notification Approach Reaches Previously Undiagnosed Sexual Partners in Tanzania. *AIDS Behav.*
- 23 2017;21(8):2551-2560. doi:10.1007/s10461-017-1750-5
- 24
- 25 26. Cherutich P, Golden MR, Wamuti B, et al. Assisted partner services for HIV in Kenya: a cluster
- 26 randomised controlled trial. *Lancet HIV.* 2017;4(2):e74-e82. doi:10.1016/S2352-3018(16)30214-4
- 27
- 28 27. Plotkin M, Kahabuka C, Christensen A, et al. Outcomes and Experiences of Men and Women with
- 29 Partner Notification for HIV Testing in Tanzania: Results from a Mixed Method Study. *AIDS Behav.*
- 30 2018;22(1):102. doi:10.1007/s10461-017-1936-x
- 31
- 32 28. Sharma M, Smith JA, Farquhar C, et al. Assisted partner notification services are cost-effective for
- 33 decreasing HIV burden in western Kenya. *AIDS Lond Engl.* 2018;32(2):233-241.
- 34 doi:10.1097/QAD.0000000000001697
- 35
- 36 29. Landis SE, Schoenbach VJ, Weber DJ, et al. Results of a randomized trial of partner notification in
- 37 cases of HIV infection in North Carolina. *N Engl J Med.* 1992;326(2):101-106.
- 38 doi:10.1056/NEJM199201093260205
- 39
- 40 30. Myers RS, Feldacker C, Cesár F, et al. Acceptability and Effectiveness of Assisted Human
- 41 Immunodeficiency Virus Partner Services in Mozambique: Results From a Pilot Program in a Public,
- 42 Urban Clinic. *Sex Transm Dis.* 2016;43(11):690-695. doi:10.1097/OLQ.0000000000000529
- 43
- 44 31. Brown LB, Miller WC, Kamanga G, et al. HIV partner notification is effective and feasible in sub-
- 45 Saharan Africa: opportunities for HIV treatment and prevention. *J Acquir Immune Defic Syndr*
- 46 *1999.* 2011;56(5):437-442.
- 47
- 48 32. Brown LB, Miller WC, Kamanga G, et al. Predicting partner HIV testing and counseling following a
- 49 partner notification intervention. *AIDS Behav.* 2012;16(5):1148-1155. doi:10.1007/s10461-011-
- 50 0094-9
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
33. World Health Organization. WHO | WHO recommends assistance for people with HIV to notify their partners. WHO. Accessed February 22, 2019. <http://www.who.int/hiv/pub/vct/who-partner-notification-policy/en/>
 34. Quinn C, Nakyanjo N, Ddaaki W, et al. HIV partner notification values and preferences among sex workers, fishermen, and mainland community members in Rakai, Uganda: a qualitative study. *AIDS Behav*. 2018;22(10):3407-3416. doi:10.1007/s10461-018-2035-3
 35. Rane V, Tomnay J, Fairley C, et al. Opt-Out Referral of Men Who Have Sex With Men Newly Diagnosed With HIV to Partner Notification Officers: Results and Yield of Sexual Partners Being Contacted. *Sex Transm Dis*. 2016;43(6):341-345. doi:10.1097/OLQ.0000000000000449
 36. Halkitis PN, Kupprat SA, McCree DH, et al. Evaluation of the relative effectiveness of three HIV testing strategies targeting African American men who have sex with men (MSM) in New York City. *Ann Behav Med Publ Soc Behav Med*. 2011;42(3):361-369. doi:10.1007/s12160-011-9299-4
 37. Malik M, Jamil MS, Johnson CC, Pasha MS, Hermez J, Qureshi S ul H. Integrating assisted partner notification within HIV prevention service package for people who inject drugs in Pakistan. *J Int AIDS Soc*. 2019;22(Suppl Suppl 3). doi:10.1002/jia2.25317
 38. DeBeck K, Cheng T, Montaner JS, et al. HIV and the criminalisation of drug use among people who inject drugs: a systematic review. *Lancet HIV*. 2017;4(8):e357-e374. doi:10.1016/S2352-3018(17)30073-5
 39. United Nations, Office on Drugs and Crime. *World Drug Report 2016.*; 2016.
 40. Molinaro S, Resce G, Alberti A, et al. Barriers to effective management of hepatitis C virus in people who inject drugs: Evidence from outpatient clinics. *Drug Alcohol Rev*. 2019;38(6):644-655. doi:10.1111/dar.12978
 41. Phillips KT. Barriers to practicing risk reduction strategies among people who inject drugs. *Addict Res Theory*. 2016;24(1):62-68. doi:10.3109/16066359.2015.1068301
 42. Heath AJ, Kerr T, Ti L, et al. Healthcare avoidance by people who inject drugs in Bangkok, Thailand. *J Public Health Oxf Engl*. 2016;38(3):e301-e308. doi:10.1093/pubmed/fdv143
 43. Frost SDW, Pillay D. Understanding Drivers of Phylogenetic Clustering in Molecular Epidemiological Studies of HIV. *J Infect Dis*. 2015;211(6):856-858. doi:10.1093/infdis/jiu563
 44. Brenner BG, Wainberg MA. Future of phylogeny in HIV prevention. *J Acquir Immune Defic Syndr* 1999. 2013;63 Suppl 2:S248-254. doi:10.1097/QAI.0b013e3182986f96
 45. Jacka B, Applegate T, Kraiden M, et al. Phylogenetic clustering of hepatitis C virus among people who inject drugs in Vancouver, Canada. *Hepatal Baltim Md*. 2014;60(5):1571-1580. doi:10.1002/hep.27310
 46. Grabowski MK, Lessler J, Redd AD, et al. The Role of Viral Introductions in Sustaining Community-Based HIV Epidemics in Rural Uganda: Evidence from Spatial Clustering, Phylogenetics, and

- 1
2
3 Egocentric Transmission Models. Hallett T, ed. *PLoS Med.* 2014;11(3):e1001610.
4 doi:10.1371/journal.pmed.1001610
5
6
7 47. Worobey M, Gemmel M, Teuwen DE, et al. Direct Evidence of Extensive Diversity of HIV-1 in
8 Kinshasa by 1960. *Nature.* 2008;455(7213):661-664. doi:10.1038/nature07390
9
10 48. de Oliveira T, Pillay D, Gifford RJ. The HIV-1 Subtype C Epidemic in South America Is Linked to the
11 United Kingdom. *PLoS ONE.* 2010;5(2). doi:10.1371/journal.pone.0009311
12
13 49. Hughes GJ, Fearnhill E, Dunn D, Lycett SJ, Rambaut A, Leigh Brown AJ. Molecular Phylodynamics of
14 the Heterosexual HIV Epidemic in the United Kingdom. *PLoS Pathog.* 2009;5(9).
15 doi:10.1371/journal.ppat.1000590
16
17 50. Hué S, Clewley JP, Cane PA, Pillay D. Investigation of HIV-1 transmission events by phylogenetic
18 methods: requirement for scientific rigour. *AIDS Lond Engl.* 2005;19(4):449-450.
19 doi:10.1097/01.aids.0000161778.15568.a1
20
21 51. Dennis AM, Hué S, Hurt CB, et al. Phylogenetic insights into regional HIV transmission. *AIDS Lond*
22 *Engl.* 2012;26(14):1813-1822. doi:10.1097/QAD.0b013e3283573244
23
24 52. Ambrosioni J, Junier T, Delhumeau C, et al. Impact of highly active antiretroviral therapy on the
25 molecular epidemiology of newly diagnosed HIV infections. *AIDS Lond Engl.* 2012;26(16):2079-
26 2086. doi:10.1097/QAD.0b013e32835805b6
27
28 53. Kouyos RD, Rauch A, Böni J, et al. Clustering of HCV coinfections on HIV phylogeny indicates
29 domestic and sexual transmission of HCV. *Int J Epidemiol.* 2014;43(3):887-896.
30 doi:10.1093/ije/dyt276
31
32 54. Fisher M, Pao D, Brown AE, et al. Determinants of HIV-1 transmission in men who have sex with
33 men: a combined clinical, epidemiological and phylogenetic approach. *AIDS.* 2010;24(11):1739-
34 1747. doi:10.1097/QAD.0b013e32833ac9e6
35
36 55. Brenner BG, Roger M, Routy J-P, et al. High rates of forward transmission events after acute/early
37 HIV-1 infection. *J Infect Dis.* 2007;195(7):951-959. doi:10.1086/512088
38
39 56. Kramer MA, Cornelissen M, Paraskevis D, et al. HIV transmission patterns among The Netherlands,
40 Suriname, and The Netherlands Antilles: a molecular epidemiological study. *AIDS Res Hum*
41 *Retroviruses.* 2011;27(2):123-130. doi:10.1089/aid.2010.0115
42
43 57. Centers for Disease Control and Prevention (CDC). Intimate Partner Violence and Sexual Violence
44 Victimization Assessment Instruments for Use in Healthcare Settings: (410572008-001). Published
45 online 2007. doi:10.1037/e410572008-001
46
47 58. Monroe-Wise A, Maingi Mutiti P, Kimani H, Moraa H, Bukusi DE, Farquhar C. Assisted partner
48 notification services for patients receiving HIV care and treatment in an HIV clinic in Nairobi,
49 Kenya: a qualitative assessment of barriers and opportunities for scale-up. *J Int AIDS Soc.*
50 2019;22(Suppl Suppl 3). doi:10.1002/jia2.25315
51
52
53
54
55
56
57
58
59
60

- 1
2
3 59. Goyette MS, Mutiti PM, Bukusi D, et al. Hiv Assisted Partner Services Among Those with and
4 Without A History of Intimate Partner Violence in Kenya. *J Acquir Immune Defic Syndr 1999*.
5 Published online February 5, 2018. doi:10.1097/QAI.0000000000001638
6
7
8 60. KELIN and the Kenya Key Populations Consortium. "Everyone Said No:" *Biometrics, HIV and Human*
9 *Rights – A Kenya Case Study*. KELIN; 2018. Accessed April 10, 2020.
10 <https://www.kelinkkenya.org/everyonesaidno/>
11
12 61. Gathura G. Biometrics system for identifying people living with HIV ready. *The Standard*.
13 [https://www.standardmedia.co.ke/article/2001349675/biometrics-system-for-identifying-people-](https://www.standardmedia.co.ke/article/2001349675/biometrics-system-for-identifying-people-living-with-hiv-ready)
14 [living-with-hiv-ready](https://www.standardmedia.co.ke/article/2001349675/biometrics-system-for-identifying-people-living-with-hiv-ready). Published November 17, 2019. Accessed April 10, 2020.
15
16 62. Anne N, Dunbar MD, Abuna F, et al. Feasibility and acceptability of an iris biometric system for
17 unique patient identification in routine HIV services in Kenya. *Int J Med Inf*. 2020;133:104006.
18 doi:10.1016/j.ijmedinf.2019.104006
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Inclusion and Exclusion Criteria

<u>Group</u>	<u>Inclusion</u>	<u>Exclusion</u>
<i>Index</i>	<ul style="list-style-type: none"> • 18 years of age or older • Recent intravenous drug use as defined by injecting at least once in the past year • HIV-positive 	<ul style="list-style-type: none"> • Classified as at high risk for IPV (described below)

	<ul style="list-style-type: none">• Willing and able to provide locator information for sexual and/or injecting partners• Willing and able to provide informed consent	
<i>Partner</i>	<ul style="list-style-type: none">• 18 years of age or older• identified by an index as either having injected with the index in the past 3 years or had sexual intercourse with the index in the past three years HIV-positive• Willing and able to provide informed consent	None

Figure 1. Map of Study Sites





Figure 2. Study Flow Diagram

BMJ Open

Peer-mediated assisted partner notification services to identify and link to care HIV-positive and HCV-positive people who inject drugs: a cohort study protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-041083.R1
Article Type:	Protocol
Date Submitted by the Author:	23-Oct-2020
Complete List of Authors:	Monroe-Wise, Aliza; University of Washington, Mbogo, Loice; Kenyatta National Hospital Guthrie, Brandon; University of Washington Bukusi, David; Kenyatta National Hospital Sambai, Betsy; Kenyatta National Hospital Chohan, Bhavna; University of Washington; Kenya Medical Research Institute Scott, John; University of Washington Cherutich, Peter; Kenya Ministry of Health Musyoki, Helgar; Kenya Ministry of Health Bosire, Rose; Kenya Medical Research Institute; University of Washington Dunbar, Matthew; University of Washington Macharia, Paul; Kenya Ministry of Health Masyuko, Sarah; Kenya Ministry of Health; University of Washington Wilkinson, Eduan; University of KwaZulu-Natal De Oliveira, Tulio; University of KwaZulu-Natal Ludwig-Barron, Natasha; University of Washington Sinkele, Bill; Support for Addiction Prevention and Treatment in Africa Herbeck, Joshua; University of Washington School of Public Health, Farquhar, Carey; University of Washington
Primary Subject Heading:	HIV/AIDS
Secondary Subject Heading:	Addiction, Epidemiology, Evidence based practice, Global health, Gastroenterology and hepatology
Keywords:	HIV & AIDS < INFECTIOUS DISEASES, Hepatology < INTERNAL MEDICINE, International health services < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Epidemiology < INFECTIOUS DISEASES, Molecular diagnostics < INFECTIOUS DISEASES, VIROLOGY

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Peer-mediated assisted partner notification services to identify and link to care HIV-**
4 **positive and HCV-positive people who inject drugs: a cohort study protocol**
5
6
7
8
9
10
11
12
13
14

15 Aliza Monroe-Wise^a, Loice Mbogo^b, Brandon Guthrie^{a,c}, David Bukusi^b, Betsy Sambai^b, Bhavna
16 Chohan^{a,d}, John Scott^e, Peter Cherutich^f, Helgar Musyoki^f, Rose Bosire^d, Matthew Dunbar^g, Paul
17 Macharia^f, Sarah Masyuko^{a,f}, Eduan Wilkinson^h, Tulio de Oliveira^h, Natasha Ludwig-Barron^b,
18
19
20 Bill Sinkeleⁱ, Joshua Herbeck^{a*}, Carey Farquhar^{a,b,e*}
21
22
23
24
25
26
27
28

29 ^aUniversity of Washington Department of Global Health, ^bKenyatta National Hospital,

30 ^cUniversity of Washington Department of Epidemiology, ^dKenya Medical Research Institute,

31 ^eUniversity of Washington Department of Medicine, ^fKenya's Ministry of Health, ^gCenter for

32 ^hStudies in Demography and Ecology, University of Washington, ^hKwaZulu-Natal Research and

33 ⁱInnovation Sequencing Platform, University of KwaZulu-Natal, ⁱSupport for Addiction

34 ^{Prevention and Treatment in Africa}

35
36
37
38
39
40
41
42
43
44 Corresponding author: Aliza Monroe-Wise, MD, MSc. Email: alizamw@uw.edu

45
46
47 University of Washington, 325 Ninth Avenue, Box 359909, Seattle, WA 98104-2499

48
49
50 *These authors share senior authorship.

51
52
53 V2.0 13/10/20

Abstract

Introduction

Targeted, tailored interventions to test high-risk individuals for HIV and hepatitis C (HCV) are vital to achieving HIV control and HCV micro-elimination in Africa. Compared with the general population, people who inject drugs (PWID) are at increased risk of HIV and HCV and are less likely to be tested or successfully treated. Assisted partner notification services (APNS) increases HIV testing among partners of people living with HIV and improves case-finding and linkage to care. We describe a study in Kenya examining whether APNS can be adapted to find, test, and link to HIV and HCV care the sexual and injecting partners of HIV-positive PWID using a network of community-embedded peer educators (PEs). Our study also uses phylogenetic analysis to determine risk factors for onward transmission of both viruses.

Methods and analysis

This prospective cohort study leverages a network of PEs to identify 1,000 HIV-positive PWID for enrollment as index participants. Each index completes a questionnaire and provides names and contact information of all sexual and injecting partners. PEs then use a stepwise locator protocol to engage partners in the community and bring them to study sites for enrollment, questionnaire completion and rapid HIV and HCV testing. Outcomes include number and type of partners per index who are mentioned, enrolled, tested, diagnosed with HIV and HCV and linked to care.

Ethics and dissemination

1
2
3 Potential index participants are screened for intimate partner violence (IPV) and those at high risk
4 are not eligible to enroll. Those at medium risk are monitored for IPV following enrollment. A
5
6 community advisory board engages in feedback and discussion between the community and the
7
8 research team. A safety monitoring board discusses study progress and reviews data, including
9
10 IPV monitoring data. Dissemination plans include presentations at quarterly Ministry of Health
11
12 working group meetings, local and international conferences, and publications.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Strengths and limitations of this study

- This cohort study investigates the use of assisted partner notification services (APNS) for HIV and hepatitis C (HCV) to find, test, and link to care the sexual and injection partners of people who inject drugs (PWID) in Kenya—a high risk, difficult to reach population. The study offers APNS to HIV-positive index participants; partner services were not offered to HIV-negative, HCV-positive clients to identify those exposed to HCV but not HIV.
- Community embedded peer educators formerly used drugs and have been trained to provide harm reduction services. They are known and trusted within the PWID community conduct partner tracing, and typically serve as the first point of contact with potential partner participants. While this approach has proved largely successful, there are limitations including logistical challenges and concerns for client confidentiality and safety of both the client and peer educator.
- An iris scanning biometric identification system ensures that each index participant enrolled is a unique individual and confirms that individual partner participants who enroll more than once in relation to different index participants are the same individual.
- Phylogenetic analysis of HIV and HCV viral sequences combined with APNS provides additional information about transmission dynamics within the cohort, including risk of onward transmission for different clusters and geographic regions.

Introduction

Of the UNAIDS 90-90-90 goals,¹ diagnosing 90% of those living with HIV remains the most elusive target worldwide,² and strategies to reach individuals at high-risk for HIV who have never been tested is increasingly important.³ Sharing needles and other drug paraphernalia is the most efficient mode of HIV transmission, and accounts for 13% of new infections globally.^{4,5} In Kenya, prevalence of HIV among people who inject drugs (PWID) has been estimated at 15 – 50%⁵⁻⁹—significantly higher than the general population prevalence of 4.9%,¹⁰ and up to 30% of PWID in Kenya have never tested for HIV.^{11,12} Multiple studies have demonstrated low knowledge of HIV status and low engagement in care among Kenya's PWID.^{12,13} Retention in care and adherence to ART are also both lower among PWID as compared with others worldwide.²

In addition to HIV, PWID are at high risk for hepatitis C virus (HCV) globally and have the highest HCV prevalence of any group studied in Kenya at 13-40%^{9,14,15}. This is especially high when compared to the general population HCV prevalence in Kenya of <1-4%.^{16,17} However, multiple barriers exist at individual, provider and system levels resulting in low rates of testing, engagement in care, and completion of treatment courses for PWID.¹⁸⁻²⁰ Although less than 20% of PWID with chronic HCV worldwide have undergone antibody screening, the number who have completed PCR confirmatory testing is even lower.²¹ Despite the introduction of highly effective direct acting antivirals (DAAs) into Kenya in 2016, only a small fraction of individuals living with HCV have been treated, prompting attention to micro-elimination strategies.

Assisted partner notification services (APNS) for HIV is an evidence-based partner notification strategy in which providers elicit information about the sexual or injecting partners of an HIV-positive index client, and then contact, HIV test and link to care any partners found to be positive.²²

1
2
3 APNS has been shown to significantly and safely increase the uptake of HIV testing services
4 (HTS), case finding, and linkage to care for partners of HIV-positive people.²²⁻²⁴ APNS can also
5 reduce barriers to disclosing HIV status²⁵ and is cost-effective.²⁶ APNS has been successfully
6 implemented among HIV-positive patients from the general population in the USA,²⁷
7 Mozambique,²⁸ Malawi,^{29,30} and Kenya,²⁴ and has recently been incorporated into the World
8 Health Organization (WHO) guidelines for routine care for HIV-positive people worldwide.³¹
9 While programs have introduced the practice of APNS in high-risk key populations (KPs) such as
10 female sex workers (FSW)³² and men who have sex with men (MSM),^{33,34} this intervention has
11 not been well-studied among PWID,³⁵ an extremely high risk group.^{22,36} Similar to FSW and
12 MSM, PWID engage in behavior that is criminalized³⁷ while experiencing high rates of
13 marginalization and displacement,³⁸ making them difficult to study. These factors and others also
14 contribute to significant barriers in the implementation of health programs targeting PWID.³⁹⁻⁴¹

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Phylogenetic analysis is a method of identifying the role of specific risk groups and risk factors
for onward transmission of HIV and HCV using the genetic sequence of each virus.⁴²⁻⁴⁴ Viral
phylogenetics can provide additional information on patterns of transmission,⁴⁵⁻⁴⁷ epidemic
growth,^{48,49} risk groups,⁵⁰⁻⁵² and risk factors associated with onward transmission.^{44,53-55}

Here we describe a prospective cohort study that seeks to determine whether and how APNS can
be implemented to find, test, and link to care the injection and sexual partners of HIV-positive
PWID in Kenya. Simultaneously, our study will use phylogenetic analysis to study genetic
sequences of HIV and HCV within our cohort to further understand transmission patterns and risk
for onward transmission. All index and partner participants are tested for HCV in addition to HIV.
While many partner contact methods for conducting APNS have been used,²² cellular telephones
are the most common first-line communication modality for reaching partners in other

1
2
3 populations.^{23,24,28,56} In Kenya, however, the large majority of PWID do not have regular access to
4 cellular telephones. As such, our APNS model relies on the utilization of community-embedded
5 peer educators (PEs) to locate and communicate with members of this difficult to reach population.
6
7 We hypothesize that we will be able to employ these customized APNS procedures to reach a large
8 number of injection and sexual partners, and that we will see differences in HIV and HCV testing,
9
10 HIV and HCV prevalence, and engagement in care between sexual and injection partners.
11
12 Additionally, we hypothesize that we will identify unique transmission patterns and risks for
13
14 onward transmission in phylogenetic analysis.
15
16
17
18
19
20
21

22 **Methods and analysis**

23 *Approach*

24
25
26 APNS is a practice through which healthcare providers facilitate the notification, testing and
27 linkage to care for partners who may have been exposed to HIV or other sexually transmitted
28 infections by an individual known to be positive. Typically, APNS is conducted by healthcare
29 providers who elicit information about partners from an “index” patient and then call the partners
30 over the telephone to alert them to their exposure and arrange testing. We have designed
31 customized procedures to ensure and improve the safety and efficacy of APNS in the unique
32 population of PWID in Kenya. Because PWID and their partners in Kenya rarely own cellular
33 phones, we work with community-embedded peer educators (PEs) to find and engage with
34 partners. Additionally, our protocol involves referrals to different facilities for injection partners
35 and for sexual partners, as a precaution to ensure safety and confidentiality of index participants.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51

52 *Study design*

1
2
3 Our study is a prospective cohort study with two groups: index and partner participants (“indexes”
4 and “partners”). We use tailored APNS procedures to identify, find, test and link to care the sexual
5 and injection partners of HIV-positive PWID. All participants who are diagnosed with either HIV
6 or HCV- then complete a 6-month follow-up visit to assess linkage to and engagement in care.
7
8
9

10 11 12 13 *Study sites/setting*

14
15
16 Study procedures take place in eight main sites including public health centers, medically assisted
17 therapy (MAT) centers, and needle and syringe programs (NSPs) in Nairobi, Kilifi, and Mombasa
18 Counties in Kenya (Figure 1). Each site is staffed by at least one clinical officer (mid-level
19 clinician) who works with the study team to ensure that indexes are HIV-positive. In Nairobi
20 County, the activities are centered at two NSP sites and one MAT center in the Mathare North
21 area. The NSP sites, run by Support for Addiction Prevention and Treatment in Africa (SAPTA),
22 offer routine HIV testing services. Referrals are made to local clinics providing care for those who
23 test positive for HIV or HCV. We also recruit indexes from a government-run methadone clinic in
24 Nairobi in the Ngara area. The Ngara Health Center MAT clinic offers HIV testing, care and
25 treatment in addition to daily methadone administration, psychosocial services and treatment for
26 other health conditions. In Kilifi county, participant recruitment and enrollment takes place at three
27 needle and syringe program centers and one government hospital. The Omari Project is located in
28 Malindi town and offers HIV counseling, testing, care and treatment in addition to harm reduction
29 services. Malindi Sub-County Hospital’s MAT center is a recruitment site in Kilifi County within
30 a mid-sized government hospital that offers a large range of medical and social services. Malindi
31 Sub-County Hospital also has a large laboratory that houses the study’s samples collected in both
32 Kilifi and Mombasa Counties. The Muslim Education and Welfare Association (MEWA) NSP
33 sites in Kilifi and Mtwapa towns offer HIV counseling and testing, in addition to HIV care and
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 treatment and harm reduction services. In Mombasa county, participants are recruited from the
4 ReachOut Center, an NSP site in Mombasa city that offers a full range of harm reduction services
5
6 in addition to HIV counseling, testing, care and treatment. All recruitment sites offer routine HCV
7
8 testing when kits are available through specific donor-driven projects.
9
10

11 12 13 *Population*

14
15
16 This study includes index participants and their sexual and injecting partners . All indexes are HIV-
17
18 positive PWID. Partners are either sexual partners or injecting partners of indexes. As such,
19
20 partners need not be PWID or HIV-positive but are defined by their relationships with indexes.
21
22

23
24 Indexes are largely recruited from organizations and clinics that provide services to PWID
25
26 populations, although they may also come from outreach efforts or informal referrals from other
27
28 participants. Partners are identified and recruited through peer-mediated APNS and may come
29
30 from any geographic area or community.
31
32

33 34 35 *Patient and Public Involvement*

36
37
38 Members of the community of PWID being researched were consulted in the development of
39
40 research questions and design of the study. The study is supported by a Community Advisory
41
42 Board (CAB) composed of members of the community, peer educators and employees of
43
44 organizations that provide services to the population. The CAB meets with the study team regularly
45
46 and helps inform dissemination plans.
47
48

49 50 51 *Study procedures*

52 53 54 1. Peer educator recruitment and training

1
2
3 PEs are recovering PWID with established relationships in the PWID communities that they serve.
4
5 The majority are between the ages of 25 and 50, are enrolled in Kenya's methadone program and
6
7 report having stopped injecting drugs.. These men and women have been identified by the
8
9 individual organizations at which they work as being key community members, and have
10
11 undergone extensive training for their roles as PEs. Training is an intensive 5-day course with
12
13 modules covering a broad spectrum of content including basics of drugs and drug-related harms,
14
15 harm reduction efforts including NSP and MAT, abscess prevention and management, overdose
16
17 prevention and management and behavior change communication. PEs have access to relatively
18
19 hidden PWID community spaces, and provide health counseling, linkage to support organizations,
20
21 information, and other services to this vulnerable population.
22
23
24
25
26

27 For this study, PEs who were actively carrying out basic duties were chosen by the leadership at
28
29 each organization based on several factors including awareness and knowledge of HIV in the
30
31 community and access to unique target populations (for instance, women who inject drugs are
32
33 more easily accessed by women PEs). Once identified, PEs underwent an intensive 1-day training
34
35 to educate them on the practice and ethics of research, study procedures, and their role in the study.
36
37 PEs participate in regular health education and harm reduction training and engage in quarterly
38
39 sessions with study leadership where they present barriers and lessons learned to the study team
40
41 so that study-related issues can be addressed.
42
43
44
45
46

47 2. Inclusion & exclusion criteria

48
49

50 Inclusion and exclusion criteria are different for indexes and partners (Table 1). Any interested
51
52 individuals who are under the age of 18 are referred to the site clinicians for routine counseling
53
54 and harm reduction services.
55
56
57

3. Index recruitment and enrollment

Enrollment began in March 2018. Clinicians at each site identify potential indexes using existing clinical data on known HIV-positive clients. Additionally, any client who tests positive for HIV during routine testing is invited to participate. Clinicians are employed by the sites, and are trained clinical officers (COs), or mid-level providers. For this study, HIV rapid testing is performed by COs and takes place as part of standard clinic procedures. All potential indexes are re-tested using HIV rapid tests (as per the national guidelines) to confirm HIV status prior to enrollment. If HIV-seropositive, either newly diagnosed or known to be positive, clinicians either discuss the study directly with potential participants or engage PEs to find individuals and bring them to the study office if they are not regular clients at the site. Importantly, PEs are not told whether participants are being traced as an index or a partner, protecting the confidentiality of indexes' HIV status.

Study staff health advisors (HAs) are the individuals responsible for conducting study procedures including data collection, HIV and HCV testing, and the coordination of APNS efforts (Figure 2). All HAs were trained and experienced in HIV testing services prior to working for the study, and many had previous experience working with PWID. All HAs underwent a week-long training course at the beginning of the study in which they learned the basics and purpose of research, research ethics, study procedures, unique ethical and logistical issues to consider when working with PWID, and other topics. All HAs also completed the Collaborative Institutional Training Initiative (CITI) course on Human Subjects Research and the Responsible Conduct of Research. HAs explain the benefits and rationale for providing APNS, discuss the importance of learning more about HIV and HCV, and describe the process of notifying partners without revealing the identity of the index. They ask participants to provide written informed consent for study participation, APNS, and future use of biological specimens and future contact for additional

1
2
3 studies, using an iris-scanning biometric device to record a unique identifier for each participant,
4
5 thus enabling the study team to confirm that a person does not enroll into the program as an index
6
7 more than once.
8
9

10
11 Indexes undergo a structured questionnaire administered by the HA using open data kit (ODK)
12
13 software on tablet devices (ODK, 2017, Seattle, WA, USA). Questionnaires cover a variety of
14
15 topics including demographics, sexual and injecting behaviors, drug use history, and HIV testing
16
17 and engagement history. Participants are then asked to recall all of their sexual and injecting
18
19 partners over the three years prior to enrollment, naming these partners one by one and assigning
20
21 each partner a letter (“A,” “B,” etc). Indexes are asked to give as much locator information as
22
23 possible for each partner, including names (which may be nicknames), phone numbers, and
24
25 location of employment or residence. Locator information is written on a paper form for each
26
27 partner. Indexes then complete a short ODK questionnaire about each partner mentioned, which
28
29 includes information about the relationship between the index and the partner. Indexes who wish
30
31 to notify partners themselves are given a 2-week window in which to do so, after which partners
32
33 are contacted by study staff.
34
35
36
37
38

39
40 Indexes then undergo rapid HCV antibody testing as part of routine study procedures. HAs conduct
41
42 pre- and post- test counseling and ensure individuals who test positive are available for follow-up
43
44 visits to discuss confirmatory HCV PCR testing and enrolling in a treatment program administered
45
46 by the Ministry of Health. All indexes then undergo phlebotomy with a sample of 10mL of blood
47
48 drawn for further testing (see section 6 below). Indexes receive 400 Kenya Shillings (KES,
49
50 equivalent to about \$4) as compensation for travel and time spent in the study procedures.
51
52
53

54 4. Peer-educator mediated assisted partner services and partner recruitment

55
56
57

1
2
3 For those partners who have phone numbers listed, HAs attempt phone communication first.
4
5 However, the vast majority of partners mentioned by indexes do not have working cellular phones;
6
7 therefore, with few exceptions, PEs locate and conduct the study's first interaction in person with
8
9 identified partners. PEs are given paper forms containing names and locator information for
10
11 identified partners. They are never told which index referred the team to each partner, and that
12
13 information is not listed on locator forms or any other accessible file. PEs then locate and approach
14
15 potential participants in the community. Using a standardized script, PEs inform potential
16
17 participants that they have been identified as an individual who might be eligible for a research
18
19 study on HIV and HCV. PEs do not notify partners of their exposure during initial contact for
20
21 several reasons: 1) to protect the HIV status of indexes, PEs are not told whether they are recruiting
22
23 an index or a partner, and 2) PEs have not felt comfortable discussing HIV or HCV exposure with
24
25 potential participants. Once PEs have notified potential participants of their possible eligibility,
26
27 they then accompany interested individuals to the nearest research office, where the study's HAs
28
29 conduct informed consent. Informed consent includes consent to future use of biological
30
31 specimens and future contact for additional studies. In the rare event that a potential participant
32
33 does not agree to come to the study office, an HA returns to the site with the PE and notifies the
34
35 individual of the exposure.
36
37
38
39
40
41
42

43 5. Partner enrollment

44
45
46 After informed consent and biometric identification, partners complete a structured questionnaire
47
48 similar to that of indexes, administered by HAs on a handheld device using ODK software.
49
50 Following the questionnaire, all partners undergo rapid antibody testing for both HIV and HCV.
51
52 HIV testingservices are provided in accordance with national HIV testing guidelines. Any partner
53
54 found to be positive for either HIV or HCV antibodies undergoes a 20mL blood draw. Those
55
56
57
58
59
60

1
2
3 partners who test negative for both HIV and HCV are finished with study procedures at this time
4
5 and are counseled on risk reduction measures and linked to HIV and HCV prevention services
6
7 before leaving the study site. All partners receive 400 Kenya Shillings (KES, equivalent to about
8
9 \$4) as compensation for travel and time spent in the study procedures.
10
11

12
13 HIV-positive partners are invited to undergo screening as an index once data collection procedures
14
15 for their partner enrollment are complete. If they meet eligibility criteria as an index, they may
16
17 enroll as an index. Study procedures are slightly amended for indexes that have previously enrolled
18
19 as partners. After undergoing informed consent and completing a short questionnaire that only
20
21 includes questions that were not a part of the partner enrollment questionnaire, they complete the
22
23 identification and data collection on each of their sexual and injection partners, identical to partner
24
25 identification procedures for indexes described above.
26
27
28
29

30 6. Laboratory Procedures

31
32
33 Blood samples from both index and partner enrollment visits are collected in EDTA vacutainer
34
35 tubes. Blood is mixed with the anticoagulant by inversion and the anticoagulated blood is stored
36
37 at room temperature at the sites for less than 4 hours. A motorcycle courier picks samples from
38
39 each site daily and brings them to the University of Nairobi Pediatric Research Laboratory in
40
41 Nairobi or the Malindi Sub-County Hospital Laboratory for coast sites. At each laboratory,
42
43 samples are first used to prepare two Whatman 903 Protein Saver dried blood spot (DBS) cards
44
45 with 50ul of whole blood on each spot. Blood samples are then centrifuged and used to prepare 2
46
47 to 3 aliquots of 1ml of plasma in labeled serum vials. Plasma aliquots and air-dried DBS cards
48
49 (with desiccant in sealed Ziploc bags) are then stored at -80° Celsius and shipped on dry ice to the
50
51
52
53
54
55
56
57
58
59
60

1
2
3 University of KwaZulu-Natal laboratory. There, samples undergo HIV and HCV viral load testing
4 and amplification for sequencing.
5
6

7 7. Participant follow-up

8
9
10 All indexes and any partners who were positive for HIV or HCV complete a six-month follow-up
11 visit. HAs identify which participants are due for follow-up visits on a weekly basis and give PEs
12 as list of these names. PEs then trace participants and bring them back to clinics where data
13 collection procedures are conducted. PEs make several attempts to find participants in the
14 community before considering them lost to follow-up.
15
16

17 Six-month visits involve a brief questionnaire covering questions on testing for HIV or HCV (if
18 not infected with both on enrollment), enrollment in care and treatment, engagement in care, and
19 follow-up testing. The purpose of this visit is to assess whether engagement in care has changed
20 following APNS procedures. We do not collect additional data from those lost to follow up.
21
22

23 8. Intimate partner violence (IPV) monitoring

24 Given historical concerns that APS may increase one's risk of experiencing intimate partner
25 violence, all potential participants undergo screening for IPV before enrollment. IPV is defined as
26 any physical, sexual or psychological harm inflicted on a person by a current or former sexual
27 partner. After answering a standardized set of six questions about physical, emotional and sexual
28 IPV and the timing of any previous experience of IPV based on published screening tools reviewed
29 by the Centers for Disease Control and Prevention,⁵⁷ potential participants are classified as low,
30 medium or high risk for IPV. Individuals are classified as at high risk for IPV if they report IPV
31 within the last month. Any potential index who is classified as high IPV risk is excluded from
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 study participation and provided with IPV counseling and resources. Any potential partner
4
5 participant who is classified as high IPV risk is allowed to enroll, but then receives special
6
7 monitoring for IPV following enrollment.
8
9

10
11 Potential participants are classified as at moderate risk for IPV if they report 1) IPV during their
12
13 lifetime either from a current or past partner; and/or 2) fear of IPV if they participate in the study.
14
15 All index or partner participants classified as moderate IPV risk receive special monitoring for
16
17 IPV following their enrollment in the study.
18
19

20
21 Potential participants are classified as at low risk for IPV if they report 1) no IPV during their
22
23 lifetime ; and 2) no fear of IPV if they participate in the study. These individuals undergo standard
24
25 study procedures which include completing the baseline IPV case report form and a follow-up IPV
26
27 case report to capture reports of any interim IPV.
28
29

30 31 9. Confidentiality and safety 32 33

34
35 *Participants:* All study procedures take place in private rooms at each study facility. To ensure the
36
37 safety and confidentiality of indexes, PEs who are tasked with finding partners are blinded to the
38
39 identity of the linked index through the use of partner locator forms that do not contain identifying
40
41 information about the index participant. Locator forms do contain a printed barcode label that are
42
43 then used by study staff to link the partner with the index who referred the partner.
44
45

46
47 Sexual partners are brought to independent facilities for enrollment rather than to centers that serve
48
49 PWID, in order to further protect the identity of the index participant who referred them. The
50
51 independent facilities are local healthcare clinics that serve the general population.
52
53
54
55
56
57

1
2
3 *Peer educators*: PEs have frequent interactions with police, and can be victims of harassment or
4 violence, both by police and by PWID. To reduce the risk of law enforcement troubles, PEs carry
5 identification showing that they are working on a study being conducted by the Ministry of Health.
6
7
8
9
10 Local law enforcement officials have also attended ongoing sensitization trainings by the Ministry
11 of Health and by organizations working with PWID.
12
13

14 15 16 10. Referrals to care

17
18
19 *HIV Counseling and Care*: Participants are provided with their HIV test results in the context of
20 post-test counseling, and are then referred to available medical and psychosocial care and support
21 facilities either within the research site or in close proximity to the research site or the participant's
22 home. Additionally, HIV-positive individuals are offered individual or group support sessions as
23 available within each site.
24
25
26
27
28
29

30
31 *HCV Counseling and Care*: Participants who test positive for HCV antibodies using rapid testing
32 are provided with their HCV antibody test results in the context of pre- and post-test counseling.
33 They are informed that they may have active HCV infection; however, further confirmatory testing
34 must be done prior to establishing the diagnosis. Confirmatory polymerase chain reaction (PCR)
35 testing is done in batches of samples at our partnering laboratory at the University of KwaZulu-
36 Natal, South Africa, and participants with active infection are later contacted for results and
37 counseling. Turnaround time from enrollment to PCR result notification varies, but is typically
38 between 1 and 4 months. Once notified, those with active infection are paired with a PE at their
39 site to ensure close contact is maintained. Study participants with active HCV infections will be
40 eligible to receive free treatment with direct acting antivirals, which the Kenyan MoH has
41 procured.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Data management

After each study visit, HAs review their work for omissions or errors and all data are uploaded into the study database. Electronic data are stored securely in an encrypted database on servers using Open Data Kit Aggregate, within Kenya's Ministry of Health (MoH). All errors or omissions identified at any step in the quality assurance/quality control process are revised by the staff member who originally completed the document. All additions and corrections are initialed and dated by the staff member who records the entry.

A link-log is separately encrypted to further ensure that data remains secure. Any data transferred to investigators or MoH are de-identified and encrypted during the process of transfer from the server. Each investigator maintains and stores secure, complete, accurate and current study records throughout the study. A database manager performs regular data cleaning and resolves any discrepancies that occur. Study sites also conduct quality control and quality assurance procedures. All co-investigators have access to the final dataset and this is not limited by contractual agreements. Study data will be available upon request at the completion of the study.

Outcome measures

The primary outcomes of interest to assess the success of the APNS intervention are: a) number of sexual and injection partners tested for HIV and HCV through APNS, identified by each index participant over the course of the study period; b) number of sexual and injection partners newly testing positive for HIV and HCV, per index participant; c) number of known HIV or HCV cases identified through APNS who are not engaged in care; d) number of index and partner participants with HIV and/or HCV infection who are linked to care; e) number of index and partners with HIV and/or HCV infection who remain in care and are receiving appropriate treatment at 6 months after

1
2
3 testing positive. Secondary outcomes are linked to inclusion in phylogenetic clusters identified as
4
5 high risk for onward transmission of HIV and HCV.
6
7

8 9 Sample size

10
11
12 We are enrolling 1000 HIV-positive indexes and their sexual and injecting partners. Based on
13
14 HCV data from MoH and our preliminary results, we estimate that 20% of PWID with HIV will
15
16 be co-infected with HCV and that each index will identify on average two partners who will accept
17
18 HIV and HCV testing, 20% of whom will be HIV-positive, and 20% of whom will be HCV-
19
20 infected. Thus, with provision of APNS to 1,000 HIV-positive indexes and testing of 2,000
21
22 partners, we will identify an estimated 600 indexes and partners infected with HCV and 400 HIV-
23
24 positive partners. This study was designed to have high precision in estimating the prevalence of
25
26 HIV and HCV infection among partners, providing valuable input for modeling the impact of
27
28 APNS in the population. For an observed HIV or HCV prevalence of 10% among partners,
29
30 precision is estimated at 1.9%; with an observed HIV or HCV prevalence of 30% among partners,
31
32 precision is estimated at 2.9%. Statistical methods and analysis
33
34
35
36
37

38
39 To determine efficacy of the APNS intervention, we will use generalized estimating equations
40
41 (GEE) models with a Poisson link using the following variables and offsets: 1) rate of HIV and
42
43 HCV testing of partners: number of individuals tested for HIV or HCV, offset by the number of
44
45 partners located with locator information provided by the index participant; 2) prevalence of HIV
46
47 and HCV infection: number of individuals identified as HIV or HCV-positive, offset by the
48
49 number of individuals who were HIV tested; and 3) rate of linkage to HIV and HCV care:
50
51 individuals who test HIV or HCV-positive and link to care, offset by the total number of
52
53 individuals who test HIV or HCV-positive.
54
55
56
57

1
2
3 Additionally, using both GEE and phylogenetic analysis, we will determine the following: 1)
4 identifiable and individual risk factors linked to high rates of HIV and HCV transmission, 2) risk
5 factors linked to both needle-sharing and sexual transmission, and 3) identification of transmission
6 clusters among PWID for both HIV and HCV.
7
8
9
10
11
12

13 Phylogenetic analysis

14
15
16 HIV and HCV gene sequencing are attempted for all study participants who test positive for either
17 virus. Sequencing will be performed at the KwaZulu-Natal Research Innovation and Sequencing
18 Platform (KRISP) at the University of KwaZulu-Natal in Durban, South Africa. For HIV we will
19 subsequently combine our data with additional, publicly available, HIV sequences from Kenya
20 and perform phylogenetic and phylodynamic analyses to describe patterns and rates of viral
21 transmission among key populations in Kenya and identify traits associated with relative
22 infectiousness. For HCV we will use phylogenetic methods to characterize the modes and risk
23 factors for onward transmission among PWID.
24
25
26
27
28
29
30
31
32
33
34
35

36 Ethics and Dissemination

37 General ethical considerations

38
39
40
41
42 This study is registered at clinicaltrials.gov and has ethical approval from both the University of
43 Washington Human Subjects Division and the Kenyatta National Hospital Ethics and Research
44 Committee. It also has approval from Kenya's National Commission for Science, Technology and
45 Innovation.
46
47
48
49
50

51
52
53 There are a number of potential risks to participants. Risks of conducting APNS include
54 psychological distress, social or economic hardship, criminal penalties, and loss of privacy and/or
55
56
57

1
2
3 confidentiality. Study procedures, including confidentiality and counseling procedures, are
4 specifically designed to minimize these risks to participants. While IPV has the potential to cause
5 harm, it has not increased in other US or African studies when this intervention has been
6 implemented in the general population.^{22,58,59} We recognize that risks may be different when
7 implementing APNS among key populations and study staff are highly trained in counseling about
8 risk behaviors, implications of testing HIV-positive, and protecting confidentiality to avoid
9 potential social harms. In addition, staff have undergone extensive training on IPV counseling and
10 ensure that resources have been identified in all sites so we can safely refer participants who report
11 abuse or are concerned for their safety. Participants reporting moderate IPV are monitored as
12 described in Section 8; they are counseled and referred for services if IPV is reported at any of
13 these follow-up visits.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

29 A safety monitoring board composed of researchers and policy makers in both Kenya and the US
30 reviews study safety data twice per year. The board monitors enrollments, deaths, loss to follow
31 up, adverse events, including social harms, and IPV monitoring data and makes recommendations
32 regarding study procedures.
33
34
35
36
37
38

39 Ethical considerations surrounding the use of biometric identification systems among key
40 populations in Kenya have been discussed extensively.⁶⁰ Despite early opposition from the Key
41 Populations Consortium and other organizations to the government's use of fingerprint-based
42 biometric data collection, the organizations and individuals working with PWID communities
43 continued to report no opposition to iris scanning for research purposes among PWID. In
44 November 2019, Kenya passed the Data Protection Bill, rendering it legal to collect biometric data
45 as long as the use of such data does not violate the subjects' rights.⁶¹ The use of biometrics is now
46 standard practice in many research and clinical settings, and has been found to be acceptable to
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 participants.⁶² Our participants have not reported any concerns, fears, or hesitations regarding the
4
5 use of an iris scanning biometric identification system.
6
7

8 9 Dissemination plan

10
11 Results from the study and changes to the study are presented on an ongoing basis at Kenya's
12
13 quarterly MoH harm reduction and key population technical working group meetings, and
14
15 discussed at biannual meetings by the Community Advisory Board that was established for this
16
17 study. Our study team includes several collaborators from the MoH. Ongoing study analyses are
18
19 also presented at national conferences annually, including Kenya's HIV clinicians' society
20
21 meeting, the Infectious Disease Society of Kenya (IDSK) biennial conference, or the Annual
22
23 University of Nairobi STD/HIV/SRH Collaborative Conference. Additionally, study results are
24
25 presented in at least one international conference per year, including the Conference on
26
27 Retroviruses and Opportunistic Infections (CROI), the International AIDS Conference, and the
28
29 College on Problems of Drug Dependence (CPDD) annual conference. Finally, the study team
30
31 reviews data on a weekly basis and any changes in data trends or other concerns are discussed
32
33 directly with the organizations through which study procedures take place.
34
35
36
37
38
39

40 41 Authors' contributions

42
43 CF and JH conceived of the study; AMW, BG, BC, MD, PM, BSi, JH and CF contributed to the
44
45 study design and data collection structure; AMW, LM, DB, BSa, BC, JS, PC, HM, RB, PM, SM,
46
47 EW, TDO, BSi, JH and CF contributed to data collection; AMW, LM, BG, DB, BSa, PC, HM,
48
49 RB, SM, EW, TDO, NLB, JH and CF contributed to data analysis and dissemination; AMW, BG,
50
51 JH and CF wrote the manuscript; all authors reviewed the manuscript for content.
52
53
54
55
56
57
58
59
60

Funding

This work was supported by the Division of AIDS, National Institutes of Drug Abuse, grant number R01 DA043409. 301 North Stonestreet Ave, Bethesda, MD 20892. +1 301-443-1124.

Competing interests

All authors state that they have no competing interests.

Figure 1. Map of Study Sites

Figure 2. Study Flow Diagram

References

1. UNAIDS. 90-90-90: An ambitious treatment target to help end the AIDS epidemic. Published October 2014. Accessed March 7, 2018. http://www.unaids.org/sites/default/files/media_asset/90-90-90_en.pdf
2. Levi J, Raymond A, Pozniak A, Vernazza P, Kohler P, Hill A. Can the UNAIDS 90-90-90 target be achieved? A systematic analysis of national HIV treatment cascades. *BMJ Glob Health*. 2016;1(2):e000010. doi:10.1136/bmjgh-2015-000010
3. Staveteig S, Croft TN, Kampa KT, Head SK. Reaching the 'first 90': Gaps in coverage of HIV testing among people living with HIV in 16 African countries. *PLOS ONE*. 2017;12(10):e0186316. doi:10.1371/journal.pone.0186316
4. Brodish P, Singh K, Rinyuri A, et al. Evidence of high-risk sexual behaviors among injection drug users in the Kenya PLACE study. *Drug Alcohol Depend*. 2011;119(1-2):138-141. doi:10.1016/j.drugalcdep.2011.05.030
5. Mathers BM, Degenhardt L, Phillips B, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. *Lancet Lond Engl*. 2008;372(9651):1733-1745. doi:10.1016/S0140-6736(08)61311-2
6. National AIDS Control Council NS and ACP. Kenya HIV Prevention Revolution Road Map: Count Down to 2030. Published online June 2014.

7. Kurth AE, Cleland CM, Des Jarlais DC, et al. HIV Prevalence, Estimated Incidence, and Risk Behaviors Among People Who Inject Drugs in Kenya. *J Acquir Immune Defic Syndr* 1999. 2015;70(4):420-427. doi:10.1097/QAI.0000000000000769
8. Ndetei, David M. A study on the linkages between drug abuse, injecting drug use and HIV/AIDS in Kenya: a rapid situation assessment. *U N Off Drugs Crime.*:45.
9. Odek-Ogunde M, Okoth, F, Lore, W, Owiti, F.R. Seroprevalence of HIV, HBC and HCV in Injecting Drug Users in Nairobi, Kenya: World Health Organization Drug Injecting Study Phase II Findings. The XV International AIDS Conference, Bangkok, Thailand: ; 2004.
10. National AIDS Control Council. *Kenya HIV Estimates Report 2018*. Accessed February 21, 2019. <https://nacc.or.ke/wp-content/uploads/2018/11/HIV-estimates-report-Kenya-20182.pdf>
11. Tun W, Sheehy M, Broz D, et al. HIV and STI Prevalence and Injection Behaviors Among People Who Inject Drugs in Nairobi: Results from a 2011 Bio-behavioral Study Using Respondent-Driven Sampling. *AIDS Behav*. 2015;19(Suppl 1):24-35. doi:10.1007/s10461-014-0936-3
12. Lizcano, J. Testing and Linkage to Care for Injecting Drug Users. 11th International Conference on HIV Treatment and Prevention Adherence, Ft. Lauderdale, FL, USA ; 2016.
13. Githuka G, Hladik W, Mwalili S, et al. Populations at Increased Risk for HIV Infection in Kenya: Results From a National Population-Based Household Survey, 2012. *J Acquir Immune Defic Syndr* 1999. 2014;66(Suppl 1):S46-S56. doi:10.1097/QAI.0000000000000137
14. Akiyama MJ, Cleland CM, Lizcano JA, Cherutich P, Kurth AE. Prevalence, estimated incidence, risk behaviours, and genotypic distribution of hepatitis C virus among people who inject drugs accessing harm-reduction services in Kenya: a retrospective cohort study. *Lancet Infect Dis*. 2019;19(11):1255-1263. doi:10.1016/S1473-3099(19)30264-6
15. Muasya T, Lore W, Yano K, et al. Prevalence of Hepatitis C Virus and its genotypes among a cohort of drug users in Kenya. *East Afr Med J*. 2008;85(7). doi:10.4314/eamj.v85i7.9649
16. Bartonjo G, Oundo J, Ng'ang'a Z. Prevalence and associated risk factors of transfusion transmissible infections among blood donors at Regional Blood Transfusion Center Nakuru and Tenwek Mission Hospital, Kenya. *Pan Afr Med J*. 2019;34. doi:10.11604/pamj.2019.34.31.17885
17. Loarec A, Carnimeo V, Molfino L, et al. Extremely low hepatitis C prevalence among HIV co-infected individuals in four countries in sub-Saharan Africa. *AIDS Lond Engl*. 2019;33(2):353-355. doi:10.1097/QAD.0000000000002070
18. Litwin AH, Jost J, Wagner K, et al. Rationale and design of a randomized pragmatic trial of patient-centered models of hepatitis C treatment for people who inject drugs: The HERO study. *Contemp Clin Trials*. 2019;87:105859. doi:10.1016/j.cct.2019.105859
19. Treloar C, Hull P, Dore GJ, Grebely J. Knowledge and barriers associated with assessment and treatment for hepatitis C virus infection among people who inject drugs. *Drug Alcohol Rev*. 2012;31(7):918-924. doi:10.1111/j.1465-3362.2012.00468.x

20. Enkelmann J, Gassowski M, Nielsen S, et al. High prevalence of hepatitis C virus infection and low level of awareness among people who recently started injecting drugs in a cross-sectional study in Germany, 2011-2014: missed opportunities for hepatitis C testing. *Harm Reduct J*. 2020;17(1):7. doi:10.1186/s12954-019-0338-y
21. Day E, Hellard M, Treloar C, et al. Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework. *Liver Int Off J Int Assoc Study Liver*. 2019;39(1):20-30. doi:10.1111/liv.13949
22. Dalal S, Johnson C, Fonner V, et al. Improving HIV test uptake and case finding with assisted partner notification services. *AIDS Lond Engl*. 2017;31(13):1867-1876. doi:10.1097/QAD.0000000000001555
23. Kahabuka C, Plotkin M, Christensen A, et al. Addressing the First 90: A Highly Effective Partner Notification Approach Reaches Previously Undiagnosed Sexual Partners in Tanzania. *AIDS Behav*. 2017;21(8):2551-2560. doi:10.1007/s10461-017-1750-5
24. Cherutich P, Golden MR, Wamuti B, et al. Assisted partner services for HIV in Kenya: a cluster randomised controlled trial. *Lancet HIV*. 2017;4(2):e74-e82. doi:10.1016/S2352-3018(16)30214-4
25. Plotkin M, Kahabuka C, Christensen A, et al. Outcomes and Experiences of Men and Women with Partner Notification for HIV Testing in Tanzania: Results from a Mixed Method Study. *AIDS Behav*. 2018;22(1):102. doi:10.1007/s10461-017-1936-x
26. Sharma M, Smith JA, Farquhar C, et al. Assisted partner notification services are cost-effective for decreasing HIV burden in western Kenya. *AIDS Lond Engl*. 2018;32(2):233-241. doi:10.1097/QAD.0000000000001697
27. Landis SE, Schoenbach VJ, Weber DJ, et al. Results of a randomized trial of partner notification in cases of HIV infection in North Carolina. *N Engl J Med*. 1992;326(2):101-106. doi:10.1056/NEJM199201093260205
28. Myers RS, Feldacker C, Cesár F, et al. Acceptability and Effectiveness of Assisted Human Immunodeficiency Virus Partner Services in Mozambique: Results From a Pilot Program in a Public, Urban Clinic. *Sex Transm Dis*. 2016;43(11):690-695. doi:10.1097/OLQ.0000000000000529
29. Brown LB, Miller WC, Kamanga G, et al. HIV partner notification is effective and feasible in sub-Saharan Africa: opportunities for HIV treatment and prevention. *J Acquir Immune Defic Syndr* 1999. 2011;56(5):437-442.
30. Brown LB, Miller WC, Kamanga G, et al. Predicting partner HIV testing and counseling following a partner notification intervention. *AIDS Behav*. 2012;16(5):1148-1155. doi:10.1007/s10461-011-0094-9
31. World Health Organization. WHO | WHO recommends assistance for people with HIV to notify their partners. WHO. Accessed February 22, 2019. <http://www.who.int/hiv/pub/vct/who-partner-notification-policy/en/>

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
32. Quinn C, Nakyanjo N, Ddaaki W, et al. HIV partner notification values and preferences among sex workers, fishermen, and mainland community members in Rakai, Uganda: a qualitative study. *AIDS Behav.* 2018;22(10):3407-3416. doi:10.1007/s10461-018-2035-3
 33. Rane V, Tomnay J, Fairley C, et al. Opt-Out Referral of Men Who Have Sex With Men Newly Diagnosed With HIV to Partner Notification Officers: Results and Yield of Sexual Partners Being Contacted. *Sex Transm Dis.* 2016;43(6):341-345. doi:10.1097/OLQ.0000000000000449
 34. Halkitis PN, Kupprat SA, McCree DH, et al. Evaluation of the relative effectiveness of three HIV testing strategies targeting African American men who have sex with men (MSM) in New York City. *Ann Behav Med Publ Soc Behav Med.* 2011;42(3):361-369. doi:10.1007/s12160-011-9299-4
 35. Levy JA, Fox SE. The outreach-assisted model of partner notification with IDUs. *Public Health Rep Wash DC 1974.* 1998;113 Suppl 1:160-169.
 36. Malik M, Jamil MS, Johnson CC, Pasha MS, Hermez J, Qureshi S ul H. Integrating assisted partner notification within HIV prevention service package for people who inject drugs in Pakistan. *J Int AIDS Soc.* 2019;22(Suppl Suppl 3). doi:10.1002/jia2.25317
 37. DeBeck K, Cheng T, Montaner JS, et al. HIV and the criminalisation of drug use among people who inject drugs: a systematic review. *Lancet HIV.* 2017;4(8):e357-e374. doi:10.1016/S2352-3018(17)30073-5
 38. United Nations, Office on Drugs and Crime. *World Drug Report 2016.*; 2016.
 39. Molinaro S, Resce G, Alberti A, et al. Barriers to effective management of hepatitis C virus in people who inject drugs: Evidence from outpatient clinics. *Drug Alcohol Rev.* 2019;38(6):644-655. doi:10.1111/dar.12978
 40. Phillips KT. Barriers to practicing risk reduction strategies among people who inject drugs. *Addict Res Theory.* 2016;24(1):62-68. doi:10.3109/16066359.2015.1068301
 41. Heath AJ, Kerr T, Ti L, et al. Healthcare avoidance by people who inject drugs in Bangkok, Thailand. *J Public Health Oxf Engl.* 2016;38(3):e301-e308. doi:10.1093/pubmed/fdv143
 42. Frost SDW, Pillay D. Understanding Drivers of Phylogenetic Clustering in Molecular Epidemiological Studies of HIV. *J Infect Dis.* 2015;211(6):856-858. doi:10.1093/infdis/jiu563
 43. Brenner BG, Wainberg MA. Future of phylogeny in HIV prevention. *J Acquir Immune Defic Syndr 1999.* 2013;63 Suppl 2:S248-254. doi:10.1097/QAI.0b013e3182986f96
 44. Jacka B, Applegate T, Kraiden M, et al. Phylogenetic clustering of hepatitis C virus among people who inject drugs in Vancouver, Canada. *Hepatal Baltim Md.* 2014;60(5):1571-1580. doi:10.1002/hep.27310
 45. Grabowski MK, Lessler J, Redd AD, et al. The Role of Viral Introductions in Sustaining Community-Based HIV Epidemics in Rural Uganda: Evidence from Spatial Clustering, Phylogenetics, and Egocentric Transmission Models. Hallett T, ed. *PLoS Med.* 2014;11(3):e1001610. doi:10.1371/journal.pmed.1001610

- 1
- 2
- 3 46. Worobey M, Gemmel M, Teuwen DE, et al. Direct Evidence of Extensive Diversity of HIV-1 in
- 4 Kinshasa by 1960. *Nature*. 2008;455(7213):661-664. doi:10.1038/nature07390
- 5
- 6 47. de Oliveira T, Pillay D, Gifford RJ. The HIV-1 Subtype C Epidemic in South America Is Linked to the
- 7 United Kingdom. *PLoS ONE*. 2010;5(2). doi:10.1371/journal.pone.0009311
- 8
- 9 48. Hughes GJ, Fearnhill E, Dunn D, Lycett SJ, Rambaut A, Leigh Brown AJ. Molecular Phylodynamics of
- 10 the Heterosexual HIV Epidemic in the United Kingdom. *PLoS Pathog*. 2009;5(9).
- 11 doi:10.1371/journal.ppat.1000590
- 12
- 13 49. Hué S, Clewley JP, Cane PA, Pillay D. Investigation of HIV-1 transmission events by phylogenetic
- 14 methods: requirement for scientific rigour. *AIDS Lond Engl*. 2005;19(4):449-450.
- 15 doi:10.1097/01.aids.0000161778.15568.a1
- 16
- 17 50. Dennis AM, Hué S, Hurt CB, et al. Phylogenetic insights into regional HIV transmission. *AIDS Lond*
- 18 *Engl*. 2012;26(14):1813-1822. doi:10.1097/QAD.0b013e3283573244
- 19
- 20 51. Ambrosioni J, Junier T, Delhumeau C, et al. Impact of highly active antiretroviral therapy on the
- 21 molecular epidemiology of newly diagnosed HIV infections. *AIDS Lond Engl*. 2012;26(16):2079-
- 22 2086. doi:10.1097/QAD.0b013e32835805b6
- 23
- 24 52. Kouyos RD, Rauch A, Böni J, et al. Clustering of HCV coinfections on HIV phylogeny indicates
- 25 domestic and sexual transmission of HCV. *Int J Epidemiol*. 2014;43(3):887-896.
- 26 doi:10.1093/ije/dyt276
- 27
- 28 53. Fisher M, Pao D, Brown AE, et al. Determinants of HIV-1 transmission in men who have sex with
- 29 men: a combined clinical, epidemiological and phylogenetic approach. *AIDS*. 2010;24(11):1739-
- 30 1747. doi:10.1097/QAD.0b013e32833ac9e6
- 31
- 32 54. Brenner BG, Roger M, Routy J-P, et al. High rates of forward transmission events after acute/early
- 33 HIV-1 infection. *J Infect Dis*. 2007;195(7):951-959. doi:10.1086/512088
- 34
- 35 55. Kramer MA, Cornelissen M, Paraskevis D, et al. HIV transmission patterns among The Netherlands,
- 36 Suriname, and The Netherlands Antilles: a molecular epidemiological study. *AIDS Res Hum*
- 37 *Retroviruses*. 2011;27(2):123-130. doi:10.1089/aid.2010.0115
- 38
- 39 56. Henley C, Forgewei G, Welty T, et al. Scale-up and case-finding effectiveness of an HIV partner
- 40 services program in Cameroon: an innovative HIV prevention intervention for developing
- 41 countries. *Sex Transm Dis*. 2013;40(12):909-914. doi:10.1097/OLQ.0000000000000032
- 42
- 43 57. Centers for Disease Control and Prevention (CDC). Intimate Partner Violence and Sexual Violence
- 44 Victimization Assessment Instruments for Use in Healthcare Settings: (410572008-001). Published
- 45 online 2007. doi:10.1037/e410572008-001
- 46
- 47 58. Monroe-Wise A, Maingi Mutiti P, Kimani H, Moraa H, Bukusi DE, Farquhar C. Assisted partner
- 48 notification services for patients receiving HIV care and treatment in an HIV clinic in Nairobi,
- 49 Kenya: a qualitative assessment of barriers and opportunities for scale-up. *J Int AIDS Soc*.
- 50 2019;22(Suppl Suppl 3). doi:10.1002/jia2.25315
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 1
2
3 59. Goyette MS, Mutiti PM, Bukusi D, et al. Hiv Assisted Partner Services Among Those with and
4 Without A History of Intimate Partner Violence in Kenya. *J Acquir Immune Defic Syndr* 1999.
5 Published online February 5, 2018. doi:10.1097/QAI.0000000000001638
6
7
8 60. KELIN and the Kenya Key Populations Consortium. "Everyone Said No:" *Biometrics, HIV and Human*
9 *Rights – A Kenya Case Study*. KELIN; 2018. Accessed April 10, 2020.
10 <https://www.kelinkenya.org/everyonesaidno/>
11
12 61. Gathura G. Biometrics system for identifying people living with HIV ready. *The Standard*.
13 [https://www.standardmedia.co.ke/article/2001349675/biometrics-system-for-identifying-people-](https://www.standardmedia.co.ke/article/2001349675/biometrics-system-for-identifying-people-living-with-hiv-ready)
14 [living-with-hiv-ready](https://www.standardmedia.co.ke/article/2001349675/biometrics-system-for-identifying-people-living-with-hiv-ready). Published November 17, 2019. Accessed April 10, 2020.
15
16 62. Anne N, Dunbar MD, Abuna F, et al. Feasibility and acceptability of an iris biometric system for
17 unique patient identification in routine HIV services in Kenya. *Int J Med Inf*. 2020;133:104006.
18 doi:10.1016/j.ijmedinf.2019.104006
19
20
21
22
23
24
25
26

27 **Table 1. Inclusion and Exclusion Criteria**

28
29
30
31

<u>Group</u>	<u>Inclusion</u>	<u>Exclusion</u>
<i>Index</i>	<ul style="list-style-type: none"> • 18 years of age or older • Recent intravenous drug use as defined by injecting at least once in the past year • HIV-positive • Willing and able to provide locator information for sexual and/or injecting partners • Willing and able to provide informed consent 	<ul style="list-style-type: none"> • Classified as at high risk for IPV (described below)
<i>Partner</i>	<ul style="list-style-type: none"> • 18 years of age or older • identified by an index as either having injected with the index in the past 3 years or had sexual intercourse with the index in the past three years HIV-positive • Willing and able to provide informed consent 	None

32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Map of Study Sites




Figure 2. Study Flow Diagram

683x449mm (96 x 96 DPI)



STANDARD PROTOCOL ITEMS: RECOMMENDATIONS FOR INTERVENTIONAL TRIALS

SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Addressed on page number
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	___ 1 ___
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	___ 21 ___
	2b	All items from the World Health Organization Trial Registration Data Set	___ Included ___
Protocol version	3	Date and version identifier	___ 1 ___
Funding	4	Sources and types of financial, material, and other support	___ 23 ___
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	___ 1, 23 ___
	5b	Name and contact information for the trial sponsor	___
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	___ N/A ___
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	___ N/A ___

1 Introduction

2			
3	Background and	6a	Description of research question and justification for undertaking the trial, including summary of relevant
4	rationale		studies (published and unpublished) examining benefits and harms for each intervention
5			
6		6b	Explanation for choice of comparators
7			
8	Objectives	7	Specific objectives or hypotheses
9			
10	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group),
11			allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)
12			
13			
14	Methods: Participants, interventions, and outcomes		
15			
16	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will
17			be collected. Reference to where list of study sites can be obtained
18			
19	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and
20			individuals who will perform the interventions (eg, surgeons, psychotherapists)
21			
22	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be
23			administered
24		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose
25			change in response to harms, participant request, or improving/worsening disease)
26		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence
27			(eg, drug tablet return, laboratory tests)
28		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial
29			
30	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood
31			pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg,
32			median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen
33			efficacy and harm outcomes is strongly recommended
34			
35	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for
36			participants. A schematic diagram is highly recommended (see Figure)
37			
38			
39			
40			
41			
42			
43			
44			
45			
46			

1	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	19
2				
3				
4	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	11
5				

Methods: Assignment of interventions (for controlled trials)

Allocation:

10	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	N/A
11				
12				
13				
14				
15				
16	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	N/A
17				
18				
19				
20				
21	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	N/A
22				
23				
24	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	N/A
25				
26				
27		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	N/A
28				
29				
30				

Methods: Data collection, management, and analysis

33	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	12
34				
35				
36				
37				
38				
39		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	15
40				
41				
42				

1	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	___ 18 ___
2				
3				
4				
5	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	___ 19-20 ___
6				
7				
8		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	___ N/A ___
9				
10		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	___ N/A ___
11				
12				
13				
14	Methods: Monitoring			
15				
16	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	___ N/A ___
17				
18				
19				
20				
21				
22		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	___ N/A ___
23				
24				
25	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	___ 21-22 ___
26				
27				
28	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	___ N/A ___
29				
30				
31				
32	Ethics and dissemination			
33				
34	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	___ 21 ___
35				
36				
37	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	___ 22 ___
38				
39				
40				
41				
42				
43				
44				
45				
46				

6/bmjopen-2022-041083 on 24 April 2024 Downloaded from <http://bmjopen.bmj.com/> by guest on April 24, 2024. Protected by copyright.

1	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	__12-13__
2				
3				
4		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	__12-13__
5				
6				
7	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	__16-18__
8				
9				
10	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	__23__
11				
12				
13	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	__18__
14				
15				
16	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	__17-18__
17				
18				
19				
20	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	__22-23__
21				
22				
23				
24		31b	Authorship eligibility guidelines and any intended use of professional writers	__23__
25				
26		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	__N/A__
27				
28				
29	Appendices			
30				
31	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	__Attached__
32				
33				
34	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	__14-15, 20__
35				
36				

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by/4.0/)" license.

BMJ Open

Peer-mediated HIV assisted partner services to identify and link to care HIV-positive and HCV-positive people who inject drugs: a cohort study protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-041083.R2
Article Type:	Protocol
Date Submitted by the Author:	04-Jan-2021
Complete List of Authors:	Monroe-Wise, Aliza; University of Washington, Mbogo, Loice; Kenyatta National Hospital Guthrie, Brandon; University of Washington Bukusi, David; Kenyatta National Hospital Sambai, Betsy; Kenyatta National Hospital Chohan, Bhavna; University of Washington; Kenya Medical Research Institute Scott, John; University of Washington Cherutich, Peter; Kenya Ministry of Health Musyoki, Helgar; Kenya Ministry of Health Bosire, Rose; Kenya Medical Research Institute; University of Washington Dunbar, Matthew; University of Washington Macharia, Paul; Kenya Ministry of Health Masyuko, Sarah; Kenya Ministry of Health; University of Washington Wilkinson, Eduan; University of KwaZulu-Natal De Oliveira, Tulio; University of KwaZulu-Natal Ludwig-Barron, Natasha; University of Washington Sinkele, Bill; Support for Addiction Prevention and Treatment in Africa Herbeck, Joshua; University of Washington School of Public Health, Farquhar, Carey; University of Washington
Primary Subject Heading:	HIV/AIDS
Secondary Subject Heading:	Addiction, Epidemiology, Evidence based practice, Global health, Gastroenterology and hepatology
Keywords:	HIV & AIDS < INFECTIOUS DISEASES, Hepatology < INTERNAL MEDICINE, International health services < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Epidemiology < INFECTIOUS DISEASES, Molecular diagnostics < INFECTIOUS DISEASES, VIROLOGY

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Peer-mediated HIV assisted partner services to identify and link to care HIV-positive and**
4
5 **HCV-positive people who inject drugs: a cohort study protocol**
6
7
8
9
10
11
12
13
14

15 Aliza Monroe-Wise^a, Loice Mbogo^b, Brandon Guthrie^{a,c}, David Bukusi^b, Betsy Sambai^b, Bhavna
16 Chohan^{a,d}, John Scott^e, Peter Cherutich^f, Helgar Musyoki^f, Rose Bosire^d, Matthew Dunbar^g, Paul
17 Macharia^f, Sarah Masyuko^{a,f}, Eduan Wilkinson^h, Tulio de Oliveira^h, Natasha Ludwig-Barron^b,
18
19
20 Bill Sinkeleⁱ, Joshua Herbeck^{a*}, Carey Farquhar^{a,b,e*}
21
22
23
24
25
26
27
28

29 ^aUniversity of Washington Department of Global Health, ^bKenyatta National Hospital,

30 ^cUniversity of Washington Department of Epidemiology, ^dKenya Medical Research Institute,

31 ^eUniversity of Washington Department of Medicine, ^fKenya's Ministry of Health, ^gCenter for
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Studies in Demography and Ecology, University of Washington, ^hKwaZulu-Natal Research and
Innovation Sequencing Platform, University of KwaZulu-Natal, ⁱSupport for Addiction
Prevention and Treatment in Africa

Corresponding author: Aliza Monroe-Wise, MD, MSc. Email: alizamw@uw.edu

University of Washington, 325 Ninth Avenue, Box 359909, Seattle, WA 98104-2499

*These authors share senior authorship.

V2.0 13/10/20

Abstract

Introduction

Targeted, tailored interventions to test high-risk individuals for HIV and hepatitis C (HCV) are vital to achieving HIV control and HCV micro-elimination in Africa. Compared with the general population, people who inject drugs (PWID) are at increased risk of HIV and HCV and are less likely to be tested or successfully treated. Assisted partner services (APS) increases HIV testing among partners of people living with HIV and improves case-finding and linkage to care. We describe a study in Kenya examining whether APS can be adapted to find, test, and link to HIV care the partners of HIV-positive PWID using a network of community-embedded peer educators (PEs). Our study also identifies HCV-positive partners and uses phylogenetic analysis to determine risk factors for onward transmission of both viruses.

Methods

This prospective cohort study leverages a network of PEs to identify 1,000 HIV-positive PWID for enrollment as index participants. Each index completes a questionnaire and provides names and contact information of all sexual and injecting partners during the previous 3 years. PEs then use a stepwise locator protocol to engage partners in the community and bring them to study sites for enrollment, questionnaire completion and rapid HIV and HCV testing. Outcomes include number and type of partners per index who are mentioned, enrolled, tested, diagnosed with HIV and HCV and linked to care.

Ethics and dissemination

1
2
3 Potential index participants are screened for intimate partner violence (IPV) and those at high risk
4 are not eligible to enroll. Those at medium risk are monitored for IPV following enrollment. A
5
6
7
8 community advisory board engages in feedback and discussion between the community and the
9
10
11
12 research team. A safety monitoring board discusses study progress and reviews data, including
13
14
15 IPV monitoring data. Dissemination plans include presentations at quarterly Ministry of Health
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Strengths and limitations of this study

- This cohort study investigates the use of assisted partner services (APS) to find, test for HIV and hepatitis C (HCV) and link to care the sexual and injecting partners of HIV-positive people who inject drugs (PWID) in Kenya; however, APS is not offered to HIV-negative, HCV-positive clients to identify those exposed to HCV but not HIV.
- Community embedded peer educators trained to provide harm reduction services conduct partner tracing, but there are limitations including logistical challenges and concerns for client confidentiality and safety of both the client and peer educator.
- An iris scanning biometric identification system ensures that each index participant enrolled is a unique individual and confirms that individual partner participants who enroll more than once in relation to different index participants are the same individual.
- Phylogenetic analysis of HIV and HCV viral sequences combined with APS will provide additional information about transmission dynamics within the cohort, including risk of onward transmission for different clusters and geographic regions.

Introduction

Diagnosing 90% of those living with HIV has been among the most difficult of the UNAIDS 90-90-90 goals to achieve worldwide,^{1,2} and strategies to reach individuals at high-risk for HIV who have never been tested is increasingly important.³ In Kenya, despite success in achieving or

1
2
3 approaching the 2nd and 3rd UNAIDS goals, only 79.4% of people testing for HIV know their
4 status.⁴ Sharing needles and other drug paraphernalia is the most efficient mode of HIV
5 transmission, and accounts for 13% of new infections globally.^{5,6} In Kenya, prevalence of HIV
6
7
8 among people who inject drugs (PWID) has been estimated at 15 – 50%^{6–10}—significantly higher
9
10
11 than the general population prevalence of 4.9%,¹¹ and up to 30% of PWID in Kenya have never
12
13
14 tested for HIV.^{12,13} Multiple studies have demonstrated low knowledge of HIV status and low
15
16
17 engagement in care among Kenya’s PWID.^{13,14} Retention in care and adherence to ART are also
18
19
20 both lower among PWID as compared with others worldwide.¹
21

22
23 In addition to HIV, PWID are at high risk for hepatitis C virus (HCV) globally and have the highest
24
25 HCV prevalence of any group studied in Kenya at 13-40%^{10,15,16}. This is especially high when
26
27 compared to the general population HCV prevalence in Kenya of <1-4%.^{17,18} However, multiple
28
29
30 barriers exist at individual, provider and system levels resulting in low rates of testing, engagement
31
32 in care, and completion of treatment courses for PWID.^{19–21} Although less than 20% of PWID with
33
34 chronic HCV worldwide have undergone antibody screening, the number who have completed
35
36 PCR confirmatory testing is even lower.²² Despite the introduction of highly effective direct acting
37
38
39 antivirals (DAAs) into Kenya in 2016, only a small fraction of individuals living with HCV have
40
41
42 been treated, prompting attention to micro-elimination strategies.^{23,24}
43

44 Assisted partner notification services (APS) for HIV is an evidence-based partner notification
45
46 strategy in which providers elicit information about the sexual or injecting partners of an HIV-
47
48 positive index client, and then contact, HIV test and link to care any partners found to be positive.²⁵
49
50
51 APS has been shown to significantly and safely increase the uptake of HIV testing services (HTS),
52
53 case finding, and linkage to care for partners of HIV-positive people.^{25–27} APS can also reduce
54
55
56 barriers to disclosing HIV status²⁸ and is cost-effective.²⁹ APS has been successfully implemented
57

1
2
3 among HIV-positive patients from the general population in the USA,³⁰ Mozambique,³¹
4 Malawi,^{32,33} and Kenya,²⁷ and has recently been incorporated into the World Health Organization
5 (WHO) guidelines for routine care for HIV-positive people worldwide.³⁴ While programs have
6 introduced the practice of APS in high-risk key populations (KPs) such as female sex workers
7 (FSW)³⁵ and men who have sex with men (MSM),^{36,37} this intervention has not been well-studied
8 among PWID,³⁸ an extremely high risk group.^{25,39} Similar to FSW and MSM, PWID engage in
9 behavior that is criminalized in many parts of the world⁴⁰ while experiencing high rates of
10 marginalization and displacement,⁴¹ making them difficult to study. These factors and others also
11 contribute to significant barriers in the implementation of health programs targeting PWID.^{42–44}

12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Phylogenetic analysis is a method of identifying the role of specific risk groups and risk factors
for onward transmission of HIV and HCV using the genetic sequence of each virus.^{45–47} Viral
phylogenetics can provide additional information on patterns of transmission,^{48–50} epidemic
growth,^{51,52} risk groups,^{53–55} and risk factors associated with onward transmission.^{47,56–58}

Here we describe a prospective cohort study that seeks to determine whether and how APS can be
implemented to find, test, and link to care the injection and sexual partners of HIV-positive PWID
in Kenya. Simultaneously, our study will use phylogenetic analysis to study genetic sequences of
HIV and HCV within our cohort to further understand transmission patterns and risk for onward
transmission. All index and partner participants are tested for HCV in addition to HIV. While many
partner contact methods for conducting APS have been used,²⁵ cellular telephones are the most
common first-line communication modality for reaching partners in other populations.^{26,27,31,59} In
Kenya, however, the large majority of PWID do not have regular access to cellular telephones. As
such, our APS model relies on the utilization of community-embedded peer educators (PEs) to
locate and communicate with members of this difficult to reach population. We hypothesize that

1
2
3 we will be able to employ these customized APS procedures to reach a large number of injection
4 and sexual partners, and that we will see differences between sexual and injection partners in
5 uptake of HIV testing, HIV and HCV prevalence, and engagement in care. Additionally, we
6 hypothesize that we will identify unique transmission patterns and risks for onward transmission
7 in phylogenetic analysis, which may include behavioral, geographic, or other factors.
8
9
10
11
12
13

14 **Methods and analysis**

15 *Approach*

16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

APS is a practice through which healthcare providers facilitate the notification, testing and linkage to care for partners who may have been exposed to HIV or other sexually transmitted infections by an individual known to be positive without revealing the identity of the person who may have exposed them. While there are many ways to provide partner services, APS in Kenya is often conducted by healthcare providers who elicit information about partners from an “index” patient and then call the partners over the telephone or physically trace them to alert them to their exposure and provide testing. We have designed customized procedures to ensure and improve the safety and efficacy of APS in the unique population of PWID in Kenya. Because PWID and their partners in Kenya rarely own cellular phones, we work with community-embedded peer educators (PEs) to find and engage with partners. Additionally, our protocol involves referrals to different facilities for injection partners and for sexual partners, as a precaution to ensure safety and confidentiality of index participants who may theoretically be at risk of negative outcomes if partners become aware of their HIV-positive status.

Study design

1
2
3 Our study is a prospective cohort study with two groups: index and partner participants (“indexes”
4 and “partners”). We use tailored APS procedures to identify, find, test and link to care the sexual
5 and injection partners of HIV-positive PWID. All index participants, as well as partner participants
6
7
8
9
10 who are diagnosed with HIV or HCV, complete a 6-month follow-up visit to assess linkage to and
11
12 engagement in care.
13

14 15 Study sites/setting

16
17
18
19 Study procedures take place in eight main sites including public health centers, medication-assisted
20
21 treatment (MAT) centers, and needle and syringe programs (NSPs) in Nairobi, Kilifi, and
22
23 Mombasa Counties in Kenya (Figure 1). Each site is staffed by at least one clinical officer (mid-
24
25 level clinician) who works with researchers to ensure that only participants with documented HIV
26
27 infection are enrolled as indexes, verifying HIV status through re-testing if documentation is not
28
29 provided. In Nairobi County, the activities are centered at two NSP sites and one MAT center in
30
31 the Mathare North area. The NSP sites, run by Support for Addiction Prevention and Treatment in
32
33 Africa (SAPTA), offer routine HIV testing services. Referrals are made to local clinics providing
34
35 care for those who test positive for HIV or HCV. We also recruit indexes from a government-run
36
37 methadone clinic in Nairobi in the Ngara area. The Ngara Health Center MAT clinic offers HIV
38
39 testing, care and treatment in addition to daily methadone administration, psychosocial services
40
41 and treatment for other health conditions. In Kilifi county, participant recruitment and enrollment
42
43 takes place at three needle and syringe program centers and one government hospital. The Omari
44
45 Project is located in Malindi town and offers HIV counseling, testing, care and treatment in
46
47 addition to harm reduction services. Malindi Sub-County Hospital’s MAT center is a recruitment
48
49 site in Kilifi County within a mid-sized government hospital that offers a large range of medical
50
51 and social services. Malindi Sub-County Hospital also has a large laboratory that houses the
52
53
54
55
56
57
58
59
60

1
2
3 study's samples collected in both Kilifi and Mombasa Counties. The Muslim Education and
4 Welfare Association (MEWA) NSP sites in Kilifi and Mtwapa towns offer HIV counseling and
5 testing, in addition to HIV care and treatment and harm reduction services. In Mombasa county,
6 participants are recruited from the ReachOut Center, an NSP site in Mombasa city that offers a
7 full range of harm reduction services in addition to HIV counseling, testing, care and treatment.
8 All recruitment sites offer routine HCV testing when kits are available through specific donor-
9 driven projects.
10
11
12
13
14
15
16
17
18
19

20 Population

21
22
23 This study includes index participants and their sexual and/or drug-injecting partners . All indexes
24 are HIV-positive PWID. Partners are either sexual partners or injecting partners of indexes.
25
26
27
28

29 Indexes are largely recruited from organizations and clinics that provide services to PWID
30 populations, although they may also come from outreach efforts or informal referrals from other
31 participants. Partners are identified and recruited through peer-mediated APS and may come from
32 any geographic area or community.
33
34
35
36
37
38

39 Patient and Public Involvement

40
41
42 Members of the community of PWID being researched were consulted in the development of
43 research questions and design of the study. The study is supported by a Community Advisory
44 Board (CAB) composed of members of the community, peer educators and employees of
45 organizations that provide services to the population. The CAB meets with the study team regularly
46 and helps inform dissemination plans.
47
48
49
50
51
52
53
54

55 Study procedures

1. Peer educator recruitment and training

PEs are recovering PWID with established relationships in the PWID communities that they serve. The majority are between the ages of 25 and 50, are enrolled in Kenya's methadone program and report having stopped injecting drugs. These men and women have been identified by the individual organizations at which they work as being key community members, and have undergone extensive training for their roles as PEs. Training is an intensive 5-day course with modules covering a broad spectrum of content including basics of drugs and drug-related harms, harm reduction efforts including NSP and MAT, abscess prevention and management, overdose prevention and management and behavior change communication. PEs have access to relatively hidden PWID community spaces, and provide health counseling, linkage to support organizations, information, and other services to this vulnerable population.

For this study, PEs who were actively carrying out basic duties were chosen by the leadership at each organization based on several factors including awareness and knowledge of HIV in the community and access to unique target populations (for instance, women who inject drugs may be more easily accessed by women PEs). Once identified, PEs underwent an intensive 1-day training to educate them on the practice and ethics of research, study procedures, and their role in the study. PEs are supervised by clinic managers, who are all collaborators in the study. PEs participate in regular health education and harm reduction training and engage in quarterly sessions with study leadership where they present barriers and lessons learned to the study team so that study-related issues can be addressed.

2. Inclusion & exclusion criteria

1
2
3 Inclusion and exclusion criteria are different for indexes and partners (Table 1). Any interested
4 individuals who are under the age of 18 are referred to the site clinicians for routine counseling
5 and harm reduction services.
6
7
8
9

10 11 3. Index recruitment and enrollment 12

13
14 Enrollment began in March 2018. Clinicians at each site identify potential indexes using existing
15 clinical data on known HIV-positive clients. Additionally, any client who tests positive for HIV
16 during routine testing is invited to participate. Clinicians are employed by the sites, and are trained
17 clinical officers (COs), or mid-level providers. For this study, HIV rapid testing is performed by
18 non-study COs and takes place as part of standard clinic procedures. All potential indexes are re-
19 tested using HIV rapid tests (as per the national guidelines) to confirm HIV status prior to
20 enrollment. If HIV positive, either newly diagnosed or known to be positive, clinicians approach
21 potential indexes with one of two strategies. Either the clinicians discuss the study directly with
22 potential participants or engage PEs to find individuals and bring them to the study office if they
23 are not regular clients at the site. Importantly, PEs are not told whether participants are being traced
24 as an index or a partner, protecting the confidentiality of indexes' HIV status.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39

40 Study staff health advisors (HAs) are the individuals responsible for conducting study procedures
41 including notification of exposure, data collection, HIV and HCV testing, and the coordination of
42 APS efforts (Figure 2). All HAs were trained and experienced in HIV testing services prior to
43 working for the study, and many had previous experience working with PWID. All HAs underwent
44 a week-long training course at the beginning of the study in which they learned the basics and
45 purpose of research, research ethics, study procedures, unique ethical and logistical issues to
46 consider when working with PWID, and other topics. All HAs also completed the Collaborative
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Institutional Training Initiative (CITI) course on Human Subjects Research and the Responsible
4 Conduct of Research. HAs explain the benefits and rationale for providing APS, discuss the
5 importance of learning more about HIV and HCV, and describe the process of notifying partners
6 without revealing the identity of the index. They ask participants to provide written informed
7 consent for study participation, APS, and future use of biological specimens and future contact for
8 additional studies, using an iris-scanning biometric device to record a unique identifier for each
9 participant, thus enabling the study team to confirm that a person does not enroll into the program
10 as an index more than once.
11
12

13
14
15
16
17
18
19
20
21
22 Indexes undergo a structured questionnaire administered by the HA using open data kit (ODK)
23 software on tablet devices (ODK, 2017, Seattle, WA, USA). Questionnaires cover a variety of
24 topics including demographics, sexual and injecting behaviors, drug use history, and HIV testing
25 and history of engagement in HIV care. Participants are then asked to recall all of their sexual and
26 injecting partners over the three years prior to enrollment, naming these partners one by one and
27 assigning each partner a letter (“A,” “B,” etc). Sexual intercourse is defined as vaginal, oral, or
28 anal sex and drug injecting partner is defined as a friend that you inject with frequently. Indexes
29 are asked to give as much locator information as possible for each partner, including names (which
30 may be nicknames), phone numbers, and location of employment or residence. Locator
31 information is written on a paper form for each partner. Indexes then complete a short ODK
32 questionnaire about each partner mentioned, which includes information about the relationship
33 between the index and the partner. Indexes who wish to notify partners themselves are given a 2-
34 week window in which to do so, after which partners are contacted by study staff. Partners notified
35 by indexes through passive referral are told to present to the study site for enrollment in the study,
36 and mode of referral is recorded for each partner in the study.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Indexes then undergo rapid HCV antibody testing as part of routine study procedures. HAs conduct
4 pre- and post- test counseling and ensure individuals who test positive are available for follow-up
5 visits to discuss confirmatory HCV PCR testing and enrolling in a treatment program administered
6 by the Ministry of Health. All indexes then undergo phlebotomy with a sample of 10mL of blood
7 drawn for further testing (see section 6 below). Indexes receive 400 Kenya Shillings (KES,
8 equivalent to about \$4) as compensation for travel and time spent in the study procedures.
9

18 4. Peer-educator mediated assisted partner services and partner recruitment

21 For those partners who have phone numbers listed, HAs attempt phone communication first.
22 However, the vast majority of partners mentioned by indexes do not have working cellular phones;
23 therefore, with few exceptions, PEs locate and conduct the study's first interaction in person with
24 identified partners. PEs are given paper forms containing names and locator information for
25 identified partners, and they verify that the names and locations provided on the locator form
26 matches those of the person they have contacted. They are never told which index referred the
27 team to each partner, and that information is not listed on locator forms or any other accessible
28 file. PEs then locate and approach potential participants in the community and inform them that
29 they have been identified as an individual who might need to be seen in a clinic due to a health
30 concern. When approaching a partner, PEs alert partners that the PEs are working with a research
31 study, and that the partner may have a health issue that should be addressed. The PEs then urge
32 the partner to accompany them to a health facility for testing and possible enrollment in the study.
33 Although PEs are trained using a standardized script, they are encouraged to allow the conversation
34 to progress naturally, responding to questions and concerns that may arise and urging partners to
35 come to the site for further information. PEs do not notify partners of their exposure during initial
36 contact for several reasons: 1) to protect the HIV status of indexes, PEs are not told whether they
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 are recruiting an index or a partner, and 2) PEs have not felt comfortable discussing HIV or HCV
4 exposure with potential participants. Once PEs have notified potential participants of their possible
5 eligibility, they then accompany interested individuals to the nearest research office, where the
6 study's HAs inform partners of their potential exposure to HIV and/or HCV, and conduct informed
7 consent. Informed consent includes consent to future use of biological specimens and future
8 contact for additional studies. In the rare event that a potential participant does not agree to come
9 to the study office, an HA returns to the site with the PE and notifies the individual of the exposure,
10 and in the rare event that a potential participant agrees to come to the study office but does not
11 want to enroll in the study, the health advisor notifies the individual of the exposure and encourages
12 the individual to undergo testing for HIV and HCV outside of study procedures.
13
14
15
16
17
18
19
20
21
22
23
24
25
26

27 5. Partner enrollment

28
29
30 After informed consent and biometric identification, partners complete a structured questionnaire
31 similar to that of indexes, administered by HAs on a handheld device using ODK software.
32 Following the questionnaire, all partners undergo rapid antibody testing for both HIV and HCV.
33 HIV testing services are provided in accordance with national HIV testing guidelines. Any partner
34 found to be positive for either HIV or HCV antibodies undergoes a 20mL blood draw. Those
35 partners who test negative for both HIV and HCV are finished with study procedures at this time
36 and are counseled on risk reduction measures and provided information about HIV and HCV
37 prevention services before leaving the study site. All partners receive 400 Kenya Shillings (KES,
38 equivalent to about \$4) as compensation for travel and time spent in the study procedures.
39
40
41
42
43
44
45
46
47
48
49
50
51

52 HIV-positive partners are invited to undergo screening as an index once data collection procedures
53 for their partner enrollment are complete. If they meet eligibility criteria as an index, they may
54
55
56
57
58
59
60

1
2
3 enroll as an index. Study procedures are slightly amended for indexes that have previously enrolled
4 as partners. After undergoing informed consent and completing a short questionnaire that only
5 includes questions that were not a part of the partner enrollment questionnaire, they complete the
6 identification and data collection on each of their sexual and injection partners, identical to partner
7 identification procedures for indexes described above.
8
9
10
11
12
13
14

15 6. Laboratory Procedures

16
17
18 Blood samples from both index and partner enrollment visits are collected in EDTA vacutainer
19 tubes. Blood is mixed with the anticoagulant by inversion and the anticoagulated blood is stored
20 at room temperature at the sites for less than 4 hours. A motorcycle courier picks samples from
21 each site daily and brings them to the University of Nairobi Pediatric Research Laboratory in
22 Nairobi or the Malindi Sub-County Hospital Laboratory for coast sites. At each laboratory,
23 samples are first used to prepare two Whatman 903 Protein Saver dried blood spot (DBS) cards
24 with 50ul of whole blood on each spot. Blood samples are then centrifuged and used to prepare 2
25 to 3 aliquots of 1ml of plasma in labeled serum vials. Plasma aliquots and air-dried DBS cards
26 (with desiccant in sealed Ziploc bags) are then stored at -80° Celsius and shipped on dry ice to the
27 University of KwaZulu-Natal laboratory. There, samples undergo HIV and HCV viral load testing
28 and amplification for sequencing.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

45 7. Participant follow-up

46
47
48 All indexes and any partners who were positive for HIV or HCV complete a six-month follow-up
49 visit. HAs identify which participants are due for follow-up visits on a weekly basis and give PEs
50 as list of these names. PEs then trace participants and bring them back to clinics where data
51
52
53
54
55
56
57
58
59
60

1
2
3 collection procedures are conducted. PEs make several attempts to find participants in the
4
5 community before considering them lost to follow-up.
6
7

8
9 Six-month visits involve a brief questionnaire covering questions on testing for HIV or HCV (if
10
11 not infected with both on enrollment), enrollment in care and treatment, engagement in care, and
12
13 follow-up testing. The purpose of this visit is to assess whether engagement in care has changed
14
15 following APS procedures, for both indexes and partners. We do not collect additional data from
16
17 those lost to follow up.
18
19

20 21 8. Intimate partner violence (IPV) monitoring

22

23
24 Given historical concerns that APS may increase one's risk of experiencing intimate partner
25
26 violence, all potential participants undergo screening for IPV before enrollment. IPV is defined as
27
28 any physical, sexual or psychological harm inflicted on a person by a current or former sexual
29
30 partner. After answering a standardized set of six questions about physical, emotional and sexual
31
32 IPV and the timing of any previous experience of IPV based on published screening tools reviewed
33
34 by the Centers for Disease Control and Prevention,⁶⁰ potential participants are classified as low,
35
36 medium or high risk for IPV. Individuals are classified as at high risk for IPV if they report IPV
37
38 within the last month. Any potential index who is classified as high IPV risk is excluded from
39
40 study participation and provided with IPV counseling and resources. Any potential partner
41
42 participant who is classified as high IPV risk is allowed to enroll, but then receives special
43
44 monitoring for IPV following enrollment.
45
46
47
48
49

50
51 Potential participants are classified as at moderate risk for IPV if they report 1) IPV during their
52
53 lifetime either from a current or past partner; and/or 2) fear of IPV if they participate in the study.
54
55
56
57

1
2
3 All index or partner participants classified as moderate IPV risk receive special monitoring for
4
5 IPV following their enrollment in the study.
6
7

8
9 Potential participants are classified as at low risk for IPV if they report 1) no IPV during their
10
11 lifetime ; and 2) no fear of IPV if they participate in the study. These individuals undergo standard
12
13 study procedures which include completing the baseline IPV case report form and a follow-up IPV
14
15 case report to capture reports of any interim IPV.
16
17

18 19 9. Confidentiality and safety 20 21

22 *Participants:* All study procedures take place in private rooms at each study facility. To ensure the
23
24 safety and confidentiality of indexes, PEs who are tasked with finding partners are blinded to the
25
26 identity of the linked index through the use of partner locator forms that do not contain identifying
27
28 information about the index participant. Locator forms do contain a printed barcode label that are
29
30 then used by study staff to link the partner with the index who referred the partner.
31
32
33

34
35 Sexual partners are brought to independent facilities for enrollment rather than to centers that serve
36
37 PWID, in order to further protect the identity of the index participant who referred them. The
38
39 independent facilities are local healthcare clinics that serve the general population.
40
41

42
43 *Peer educators:* PEs have frequent interactions with police, and can be victims of harassment or
44
45 violence, both by police and by PWID. To reduce the risk of law enforcement troubles, PEs carry
46
47 identification showing that they are working on a study being conducted by the Ministry of Health.
48
49 Local law enforcement officials have also attended ongoing sensitization trainings by the Ministry
50
51 of Health and by organizations working with PWID.
52
53

54 55 10. Referrals to care 56 57

1
2
3 *HIV Counseling and Care:* Participants are provided with their HIV test results in the context of
4 post-test counseling, and are then referred to available medical and psychosocial care and support
5 facilities either within the research site or in close proximity to the research site or the participant's
6 home. Additionally, HIV-positive individuals are offered individual or group support sessions as
7 available within each site.
8
9

10
11
12
13
14
15 *HCV Counseling and Care:* Participants who test positive for HCV antibodies using rapid testing
16 are provided with their HCV antibody test results in the context of pre- and post-test counseling.
17 They are informed that they may have active HCV infection; however, further confirmatory testing
18 must be done prior to establishing the diagnosis. Confirmatory polymerase chain reaction (PCR)
19 testing is done in batches of samples at our partnering laboratory at the University of KwaZulu-
20 Natal, South Africa, and participants with active infection are later contacted for results and
21 counseling. Turnaround time from enrollment to PCR result notification varies, but is typically
22 between 1 and 4 months. Once notified of their PCR results, those with active infection are paired
23 with a PE at their site to ensure close contact is maintained. Study participants with active HCV
24 infections will be eligible to receive free treatment with direct acting antivirals, which the Kenyan
25 MoH has procured.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

42 Data management

43
44

45 After each study visit, HAs review their work for omissions or errors and all data are uploaded
46 into the study database. Electronic data are stored securely in an encrypted database on servers
47 using Open Data Kit Aggregate, within Kenya's Ministry of Health (MoH). All errors or omissions
48 identified at any step in the quality assurance/quality control process are revised by the staff
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 member who originally completed the document. All additions and corrections are initialed and
4
5 dated by the staff member who records the entry.
6
7

8
9 A link-log is separately encrypted to further ensure that data remains secure. Any data transferred
10
11 to investigators or MoH are de-identified and encrypted during the process of transfer from the
12
13 server. Each investigator maintains and stores secure, complete, accurate and current study records
14
15 throughout the study. A database manager performs regular data cleaning and resolves any
16
17 discrepancies that occur. Study sites also conduct quality control and quality assurance procedures.
18
19 All co-investigators have access to the final dataset and this is not limited by contractual
20
21 agreements. Study data will be available upon request at the completion of the study.
22
23
24
25

26 Outcome measures

27
28
29 The primary outcomes of interest to assess the success of the APS intervention are: a) number of
30
31 sexual and injection partners tested for HIV and HCV through APS, identified by each index
32
33 participant over the course of the study period; b) number of sexual and injection partners newly
34
35 testing positive for HIV and HCV, per index participant; c) number of known HIV or HCV cases
36
37 identified through APS who are not engaged in care; d) number of index and partner participants
38
39 with HIV and/or HCV infection who are linked to care; e) number of index and partners with HIV
40
41 and/or HCV infection who remain in care and are receiving appropriate treatment at 6 months after
42
43 testing positive. Secondary outcomes are linked to inclusion in phylogenetic clusters identified as
44
45 high risk for onward transmission of HIV and HCV.
46
47
48
49

50 Sample size

1
2
3 We are enrolling 1000 HIV-positive indexes and their sexual and injecting partners. Based on
4 HCV data from MoH and our preliminary results, we estimate that 20% of PWID with HIV will
5 be co-infected with HCV and that each index will identify on average two partners who will accept
6 HIV and HCV testing, 20% of whom will be HIV-positive, and 20% of whom will be HCV-
7 infected. Thus, with provision of APS to 1,000 HIV-positive indexes and testing of 2,000 partners,
8 we will identify an estimated 600 indexes and partners infected with HCV and 400 HIV-positive
9 partners. This study was designed to have high precision in estimating the prevalence of HIV and
10 HCV infection among partners, providing valuable input for modeling the impact of APS in the
11 population. For an observed HIV or HCV prevalence of 10% among partners, precision is
12 estimated at 1.9%; with an observed HIV or HCV prevalence of 30% among partners, precision is
13 estimated at 2.9%. *Statistical methods and analysis*

14
15 To determine efficacy of the APS intervention, we will use generalized estimating equations
16 (GEE) models with a Poisson link using the following variables and offsets: 1) rate of HIV and
17 HCV testing of partners: number of individuals tested for HIV or HCV, offset by the number of
18 partners located with locator information provided by the index participant; 2) prevalence of HIV
19 and HCV infection: number of individuals identified as HIV or HCV-positive, offset by the
20 number of individuals who were HIV tested; and 3) rate of linkage to HIV and HCV care:
21 individuals who test HIV or HCV-positive and link to care, offset by the total number of
22 individuals who test HIV or HCV-positive.

23
24 Additionally, using both GEE and phylogenetic analysis, we will determine the following: 1)
25 identifiable and individual risk factors linked to high rates of HIV and HCV transmission, 2) risk
26 factors linked to both needle-sharing and sexual transmission, and 3) identification of transmission
27 clusters among PWID for both HIV and HCV.

Phylogenetic analysis

HIV and HCV gene sequencing are attempted for all study participants who test positive for either virus. Sequencing will be performed at the KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP) at the University of KwaZulu-Natal in Durban, South Africa. For HIV we will subsequently combine our data with additional, publicly available, HIV sequences from Kenya and perform phylogenetic and phylodynamic analyses to describe patterns and rates of viral transmission among key populations in Kenya and identify traits associated with relative infectiousness. For HCV we will use phylogenetic methods to characterize the modes and risk factors for onward transmission among PWID.

Ethics and Dissemination

General ethical considerations

This study is registered at clinicaltrials.gov (NCT03447210) and has ethical approval from both the University of Washington Human Subjects Division and the Kenyatta National Hospital Ethics and Research Committee. It also has approval from Kenya's National Commission for Science, Technology and Innovation.

There are a number of potential risks to participants. Risks of conducting APS include psychological distress, social or economic hardship, criminal penalties, and loss of privacy and/or confidentiality. Study procedures, including confidentiality and counseling procedures, are specifically designed to minimize these risks to participants. While IPV has the potential to cause harm, it has not increased in other US or African studies when this intervention has been implemented in the general population.^{25,61,62} We recognize that risks may be different when

1
2
3 implementing APS among key populations and study staff are highly trained in counseling about
4 risk behaviors, implications of testing HIV-positive, and protecting confidentiality to avoid
5 potential social harms. In addition, staff have undergone extensive training on IPV counseling and
6 ensure that resources have been identified in all sites so we can safely refer participants who report
7 abuse or are concerned for their safety. Participants reporting moderate IPV are monitored as
8 described in Section 8; they are counseled and referred for services if IPV is reported at any of
9 these follow-up visits.

10
11 A safety monitoring board composed of researchers and policy makers in both Kenya and the US
12 reviews study safety data twice per year. The board monitors enrollments, deaths, loss to follow
13 up, adverse events, including social harms, and IPV monitoring data and makes recommendations
14 regarding study procedures.

15
16 Ethical considerations surrounding the use of biometric identification systems among key
17 populations in Kenya have been discussed extensively.⁶³ Despite early opposition from the Key
18 Populations Consortium and other organizations to the government's use of fingerprint-based
19 biometric data collection, the organizations and individuals working with PWID communities
20 continued to report no opposition to iris scanning for research purposes among PWID. In
21 November 2019, Kenya passed the Data Protection Bill, rendering it legal to collect biometric data
22 as long as the use of such data does not violate the subjects' rights.⁶⁴ The use of biometrics is now
23 standard practice in many research and clinical settings, and has been found to be acceptable to
24 participants.⁶⁵ Our participants have not reported any concerns, fears, or hesitations regarding the
25 use of an iris scanning biometric identification system.

26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 *Dissemination plan*

1
2
3 Results from the study and changes to the study are presented on an ongoing basis at Kenya's
4 quarterly MoH harm reduction and key population technical working group meetings, and
5
6 discussed at biannual meetings by the Community Advisory Board that was established for this
7
8 study. Our study team includes several collaborators from the MoH. Ongoing study analyses are
9
10 also presented at national conferences annually. Additionally, study results are presented in at least
11
12 one international conference per year. Finally, the study team reviews data on a weekly basis and
13
14 any changes in data trends or other concerns are discussed directly with the organizations through
15
16 which study procedures take place.
17
18
19
20
21

Authors' contributions

22
23
24
25
26 CF and JH conceived of the study; AMW, BG, BC, MD, PM, BSi, JH and CF contributed to the
27
28 study design and data collection structure; AMW, LM, DB, BSa, BC, JS, PC, HM, RB, PM, SM,
29
30 EW, TDO, BSi, JH and CF contributed to data collection; AMW, LM, BG, DB, BSa, PC, HM,
31
32 RB, SM, EW, TDO, NLB, JH and CF contributed to data analysis and dissemination; AMW, BG,
33
34 JH and CF wrote the manuscript; all authors reviewed the manuscript for content.
35
36
37

Funding

38
39
40
41
42 This work was supported by the Division of AIDS, National Institute of Drug Abuse, grant number
43
44 R01 DA043409. 301 North Stonestreet Ave, Bethesda, MD 20892. +1 301-443-1124.
45
46

Competing interests

47
48
49
50
51 All authors state that they have no competing interests.
52

53
54 Figure 1. Map of Study Sites
55
56
57
58
59
60

Figure 2. Study Flow Diagram

References

1. Levi J, Raymond A, Pozniak A, Vernazza P, Kohler P, Hill A. Can the UNAIDS 90-90-90 target be achieved? A systematic analysis of national HIV treatment cascades. *BMJ Glob Health*. 2016;1(2):e000010. doi:10.1136/bmjgh-2015-000010
2. UNAIDS. 90-90-90: An ambitious treatment target to help end the AIDS epidemic. Published October 2014. Accessed March 7, 2018. http://www.unaids.org/sites/default/files/media_asset/90-90-90_en.pdf
3. Staveteig S, Croft TN, Kampa KT, Head SK. Reaching the 'first 90': Gaps in coverage of HIV testing among people living with HIV in 16 African countries. *PLOS ONE*. 2017;12(10):e0186316. doi:10.1371/journal.pone.0186316
4. National AIDS and STI Control Programme (NASCOP). *Preliminary KENPHIA 2018 Report*.; 2020. Accessed December 16, 2020. https://phia.icap.columbia.edu/wp-content/uploads/2020/04/KENPHIA-2018_Preliminary-Report_final-web.pdf
5. Brodish P, Singh K, Rinyuri A, et al. Evidence of high-risk sexual behaviors among injection drug users in the Kenya PLACE study. *Drug Alcohol Depend*. 2011;119(1-2):138-141. doi:10.1016/j.drugalcdep.2011.05.030
6. Mathers BM, Degenhardt L, Phillips B, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. *Lancet Lond Engl*. 2008;372(9651):1733-1745. doi:10.1016/S0140-6736(08)61311-2
7. National AIDS Control Council NS and ACP. Kenya HIV Prevention Revolution Road Map: Count Down to 2030. Published online June 2014.
8. Kurth AE, Cleland CM, Des Jarlais DC, et al. HIV Prevalence, Estimated Incidence, and Risk Behaviors Among People Who Inject Drugs in Kenya. *J Acquir Immune Defic Syndr* 1999. 2015;70(4):420-427. doi:10.1097/QAI.0000000000000769
9. Ndetei, David M. A study on the linkages between drug abuse, injecting drug use and HIV/AIDS in Kenya: a rapid situation assessment. *U N Off Drugs Crime*.:45.
10. Odek-Ogunde M, Okoth, F, Lore, W, Owiti, F.R. Seroprevalence of HIV, HBC and HCV in Injecting Drug Users in Nairobi, Kenya: World Health Organization Drug Injecting Study Phase II Findings. In: ; 2004.
11. National AIDS Control Council. *Kenya HIV Estimates Report 2018*. Accessed February 21, 2019. <https://nacc.or.ke/wp-content/uploads/2018/11/HIV-estimates-report-Kenya-20182.pdf>

12. Tun W, Sheehy M, Broz D, et al. HIV and STI Prevalence and Injection Behaviors Among People Who Inject Drugs in Nairobi: Results from a 2011 Bio-behavioral Study Using Respondent-Driven Sampling. *AIDS Behav.* 2015;19(Suppl 1):24-35. doi:10.1007/s10461-014-0936-3
13. Lizcano, J. Testing and Linkage to Care for Injecting Drug Users. In: ; 2016.
14. Githuka G, Hladik W, Mwalili S, et al. Populations at Increased Risk for HIV Infection in Kenya: Results From a National Population-Based Household Survey, 2012. *J Acquir Immune Defic Syndr* 1999. 2014;66(Suppl 1):S46-S56. doi:10.1097/QAI.000000000000137
15. Akiyama MJ, Cleland CM, Lizcano JA, Cherutich P, Kurth AE. Prevalence, estimated incidence, risk behaviours, and genotypic distribution of hepatitis C virus among people who inject drugs accessing harm-reduction services in Kenya: a retrospective cohort study. *Lancet Infect Dis.* 2019;19(11):1255-1263. doi:10.1016/S1473-3099(19)30264-6
16. Muasya T, Lore W, Yano K, et al. Prevalence of Hepatitis C Virus and its genotypes among a cohort of drug users in Kenya. *East Afr Med J.* 2008;85(7). doi:10.4314/eamj.v85i7.9649
17. Bartonjo G, Oundo J, Ng'ang'a Z. Prevalence and associated risk factors of transfusion transmissible infections among blood donors at Regional Blood Transfusion Center Nakuru and Tenwek Mission Hospital, Kenya. *Pan Afr Med J.* 2019;34. doi:10.11604/pamj.2019.34.31.17885
18. Loarec A, Carnimeo V, Molino L, et al. Extremely low hepatitis C prevalence among HIV co-infected individuals in four countries in sub-Saharan Africa. *AIDS Lond Engl.* 2019;33(2):353-355. doi:10.1097/QAD.0000000000002070
19. Litwin AH, Jost J, Wagner K, et al. Rationale and design of a randomized pragmatic trial of patient-centered models of hepatitis C treatment for people who inject drugs: The HERO study. *Contemp Clin Trials.* 2019;87:105859. doi:10.1016/j.cct.2019.105859
20. Treloar C, Hull P, Dore GJ, Grebely J. Knowledge and barriers associated with assessment and treatment for hepatitis C virus infection among people who inject drugs. *Drug Alcohol Rev.* 2012;31(7):918-924. doi:10.1111/j.1465-3362.2012.00468.x
21. Enkelmann J, Gassowski M, Nielsen S, et al. High prevalence of hepatitis C virus infection and low level of awareness among people who recently started injecting drugs in a cross-sectional study in Germany, 2011-2014: missed opportunities for hepatitis C testing. *Harm Reduct J.* 2020;17(1):7. doi:10.1186/s12954-019-0338-y
22. Day E, Hellard M, Treloar C, et al. Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework. *Liver Int Off J Int Assoc Study Liver.* 2019;39(1):20-30. doi:10.1111/liv.13949
23. Medecins du Monde. Our Activities in Kenya. Accessed November 24, 2020. <https://www.medecinsdumonde.org/en/countries/africa/kenya>
24. Cherutich P, Kurth A, Lizcano JA, Akiyama MJ. Integration of Hepatitis C treatment services with harm reduction service centers for people who inject drugs in Kenya: experience from test and link to care for injecting drug users study. In: *Reviews in Antiviral Therapy & Infectious Diseases.* ; 2019.

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
25. Dalal S, Johnson C, Fonner V, et al. Improving HIV test uptake and case finding with assisted partner notification services. *AIDS Lond Engl*. 2017;31(13):1867-1876. doi:10.1097/QAD.0000000000001555
26. Kahabuka C, Plotkin M, Christensen A, et al. Addressing the First 90: A Highly Effective Partner Notification Approach Reaches Previously Undiagnosed Sexual Partners in Tanzania. *AIDS Behav*. 2017;21(8):2551-2560. doi:10.1007/s10461-017-1750-5
27. Cherutich P, Golden MR, Wamuti B, et al. Assisted partner services for HIV in Kenya: a cluster randomised controlled trial. *Lancet HIV*. 2017;4(2):e74-e82. doi:10.1016/S2352-3018(16)30214-4
28. Plotkin M, Kahabuka C, Christensen A, et al. Outcomes and Experiences of Men and Women with Partner Notification for HIV Testing in Tanzania: Results from a Mixed Method Study. *AIDS Behav*. 2018;22(1):102. doi:10.1007/s10461-017-1936-x
29. Sharma M, Smith JA, Farquhar C, et al. Assisted partner notification services are cost-effective for decreasing HIV burden in western Kenya. *AIDS Lond Engl*. 2018;32(2):233-241. doi:10.1097/QAD.0000000000001697
30. Landis SE, Schoenbach VJ, Weber DJ, et al. Results of a randomized trial of partner notification in cases of HIV infection in North Carolina. *N Engl J Med*. 1992;326(2):101-106. doi:10.1056/NEJM199201093260205
31. Myers RS, Feldacker C, Cesár F, et al. Acceptability and Effectiveness of Assisted Human Immunodeficiency Virus Partner Services in Mozambique: Results From a Pilot Program in a Public, Urban Clinic. *Sex Transm Dis*. 2016;43(11):690-695. doi:10.1097/OLQ.0000000000000529
32. Brown LB, Miller WC, Kamanga G, et al. HIV partner notification is effective and feasible in sub-Saharan Africa: opportunities for HIV treatment and prevention. *J Acquir Immune Defic Syndr* 1999. 2011;56(5):437-442.
33. Brown LB, Miller WC, Kamanga G, et al. Predicting partner HIV testing and counseling following a partner notification intervention. *AIDS Behav*. 2012;16(5):1148-1155. doi:10.1007/s10461-011-0094-9
34. World Health Organization. WHO | WHO recommends assistance for people with HIV to notify their partners. WHO. Accessed February 22, 2019. <http://www.who.int/hiv/pub/vct/who-partner-notification-policy/en/>
35. Quinn C, Nakyanjo N, Ddaaki W, et al. HIV partner notification values and preferences among sex workers, fishermen, and mainland community members in Rakai, Uganda: a qualitative study. *AIDS Behav*. 2018;22(10):3407-3416. doi:10.1007/s10461-018-2035-3
36. Rane V, Tomnay J, Fairley C, et al. Opt-Out Referral of Men Who Have Sex With Men Newly Diagnosed With HIV to Partner Notification Officers: Results and Yield of Sexual Partners Being Contacted. *Sex Transm Dis*. 2016;43(6):341-345. doi:10.1097/OLQ.0000000000000449

- 1
- 2
- 3
- 4 37. Halkitis PN, Kupprat SA, McCree DH, et al. Evaluation of the relative effectiveness of three HIV
- 5 testing strategies targeting African American men who have sex with men (MSM) in New York City.
- 6 *Ann Behav Med Publ Soc Behav Med.* 2011;42(3):361-369. doi:10.1007/s12160-011-9299-4
- 7
- 8 38. Levy JA, Fox SE. The outreach-assisted model of partner notification with IDUs. *Public Health Rep*
- 9 *Wash DC 1974.* 1998;113 Suppl 1:160-169.
- 10
- 11 39. Malik M, Jamil MS, Johnson CC, Pasha MS, Hermez J, Qureshi S ul H. Integrating assisted partner
- 12 notification within HIV prevention service package for people who inject drugs in Pakistan. *J Int*
- 13 *AIDS Soc.* 2019;22(Suppl Suppl 3). doi:10.1002/jia2.25317
- 14
- 15 40. DeBeck K, Cheng T, Montaner JS, et al. HIV and the criminalisation of drug use among people who
- 16 inject drugs: a systematic review. *Lancet HIV.* 2017;4(8):e357-e374. doi:10.1016/S2352-
- 17 3018(17)30073-5
- 18
- 19 41. United Nations, Office on Drugs and Crime. *World Drug Report 2016.*; 2016.
- 20
- 21 42. Molinaro S, Resce G, Alberti A, et al. Barriers to effective management of hepatitis C virus in
- 22 people who inject drugs: Evidence from outpatient clinics. *Drug Alcohol Rev.* 2019;38(6):644-655.
- 23 doi:10.1111/dar.12978
- 24
- 25 43. Phillips KT. Barriers to practicing risk reduction strategies among people who inject drugs. *Addict*
- 26 *Res Theory.* 2016;24(1):62-68. doi:10.3109/16066359.2015.1068301
- 27
- 28 44. Heath AJ, Kerr T, Ti L, et al. Healthcare avoidance by people who inject drugs in Bangkok, Thailand.
- 29 *J Public Health Oxf Engl.* 2016;38(3):e301-e308. doi:10.1093/pubmed/fdv143
- 30
- 31 45. Frost SDW, Pillay D. Understanding Drivers of Phylogenetic Clustering in Molecular Epidemiological
- 32 Studies of HIV. *J Infect Dis.* 2015;211(6):856-858. doi:10.1093/infdis/jiu563
- 33
- 34 46. Brenner BG, Wainberg MA. Future of phylogeny in HIV prevention. *J Acquir Immune Defic Syndr*
- 35 *1999.* 2013;63 Suppl 2:S248-254. doi:10.1097/QAI.0b013e3182986f96
- 36
- 37 47. Jacka B, Applegate T, Kraiden M, et al. Phylogenetic clustering of hepatitis C virus among people
- 38 who inject drugs in Vancouver, Canada. *Hepatol Baltim Md.* 2014;60(5):1571-1580.
- 39 doi:10.1002/hep.27310
- 40
- 41 48. Grabowski MK, Lessler J, Redd AD, et al. The Role of Viral Introductions in Sustaining Community-
- 42 Based HIV Epidemics in Rural Uganda: Evidence from Spatial Clustering, Phylogenetics, and
- 43 Egocentric Transmission Models. Hallett T, ed. *PLoS Med.* 2014;11(3):e1001610.
- 44 doi:10.1371/journal.pmed.1001610
- 45
- 46 49. Worobey M, Gemmel M, Teuwen DE, et al. Direct Evidence of Extensive Diversity of HIV-1 in
- 47 Kinshasa by 1960. *Nature.* 2008;455(7213):661-664. doi:10.1038/nature07390
- 48
- 49 50. de Oliveira T, Pillay D, Gifford RJ. The HIV-1 Subtype C Epidemic in South America Is Linked to the
- 50 United Kingdom. *PLoS ONE.* 2010;5(2). doi:10.1371/journal.pone.0009311
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 1
2
3 51. Hughes GJ, Fearnhill E, Dunn D, Lycett SJ, Rambaut A, Leigh Brown AJ. Molecular Phylodynamics of
4 the Heterosexual HIV Epidemic in the United Kingdom. *PLoS Pathog*. 2009;5(9).
5 doi:10.1371/journal.ppat.1000590
6
- 7 52. Hué S, Clewley JP, Cane PA, Pillay D. Investigation of HIV-1 transmission events by phylogenetic
8 methods: requirement for scientific rigour. *AIDS Lond Engl*. 2005;19(4):449-450.
9 doi:10.1097/01.aids.0000161778.15568.a1
10
- 11 53. Dennis AM, Hué S, Hurt CB, et al. Phylogenetic insights into regional HIV transmission. *AIDS Lond*
12 *Engl*. 2012;26(14):1813-1822. doi:10.1097/QAD.0b013e3283573244
13
- 14 54. Ambrosioni J, Junier T, Delhumeau C, et al. Impact of highly active antiretroviral therapy on the
15 molecular epidemiology of newly diagnosed HIV infections. *AIDS Lond Engl*. 2012;26(16):2079-
16 2086. doi:10.1097/QAD.0b013e32835805b6
17
- 18 55. Kouyos RD, Rauch A, Böni J, et al. Clustering of HCV coinfections on HIV phylogeny indicates
19 domestic and sexual transmission of HCV. *Int J Epidemiol*. 2014;43(3):887-896.
20 doi:10.1093/ije/dyt276
21
- 22 56. Fisher M, Pao D, Brown AE, et al. Determinants of HIV-1 transmission in men who have sex with
23 men: a combined clinical, epidemiological and phylogenetic approach. *AIDS*. 2010;24(11):1739-
24 1747. doi:10.1097/QAD.0b013e32833ac9e6
25
- 26 57. Brenner BG, Roger M, Routy J-P, et al. High rates of forward transmission events after acute/early
27 HIV-1 infection. *J Infect Dis*. 2007;195(7):951-959. doi:10.1086/512088
28
- 29 58. Kramer MA, Cornelissen M, Paraskevis D, et al. HIV transmission patterns among The Netherlands,
30 Suriname, and The Netherlands Antilles: a molecular epidemiological study. *AIDS Res Hum*
31 *Retroviruses*. 2011;27(2):123-130. doi:10.1089/aid.2010.0115
32
- 33 59. Henley C, Forgewei G, Welty T, et al. Scale-up and case-finding effectiveness of an HIV partner
34 services program in Cameroon: an innovative HIV prevention intervention for developing
35 countries. *Sex Transm Dis*. 2013;40(12):909-914. doi:10.1097/OLQ.0000000000000032
36
- 37 60. Centers for Disease Control and Prevention (CDC). Intimate Partner Violence and Sexual Violence
38 Victimization Assessment Instruments for Use in Healthcare Settings: (410572008-001). Published
39 online 2007. doi:10.1037/e410572008-001
40
- 41 61. Monroe-Wise A, Maingi Mutiti P, Kimani H, Moraa H, Bukusi DE, Farquhar C. Assisted partner
42 notification services for patients receiving HIV care and treatment in an HIV clinic in Nairobi,
43 Kenya: a qualitative assessment of barriers and opportunities for scale-up. *J Int AIDS Soc*.
44 2019;22(Suppl Suppl 3). doi:10.1002/jia2.25315
45
- 46 62. Goyette MS, Mutiti PM, Bukusi D, et al. Hiv Assisted Partner Services Among Those with and
47 Without A History of Intimate Partner Violence in Kenya. *J Acquir Immune Defic Syndr* 1999.
48 Published online February 5, 2018. doi:10.1097/QAI.0000000000001638
49
- 50
51
52
53
54
55
56
57
58
59

63. KELIN and the Kenya Key Populations Consortium. "Everyone Said No:" *Biometrics, HIV and Human Rights – A Kenya Case Study*. KELIN; 2018. Accessed April 10, 2020. <https://www.kelinkenya.org/everyonesaidno/>
64. Gathura G. Biometrics system for identifying people living with HIV ready. *The Standard*. <https://www.standardmedia.co.ke/article/2001349675/biometrics-system-for-identifying-people-living-with-hiv-ready>. Published November 17, 2019. Accessed April 10, 2020.
65. Anne N, Dunbar MD, Abuna F, et al. Feasibility and acceptability of an iris biometric system for unique patient identification in routine HIV services in Kenya. *Int J Med Inf*. 2020;133:104006. doi:10.1016/j.ijmedinf.2019.104006

Table 1. Inclusion and Exclusion Criteria

<u>Group</u>	<u>Inclusion</u>	<u>Exclusion</u>
<i>Index</i>	<ul style="list-style-type: none"> • 18 years of age or older • Recent intravenous drug use as defined by injecting at least once in the past year • HIV-positive • Willing and able to provide locator information for sexual and/or injecting partners • Willing and able to provide informed consent 	<ul style="list-style-type: none"> • Classified as at high risk for IPV (described below)
<i>Partner</i>	<ul style="list-style-type: none"> • 18 years of age or older • identified by an index as either having injected with the index in the past 3 years or had sexual intercourse with the index in the past three years • Willing and able to provide informed consent 	None




Figure 1. Map of Study Sites

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2. Study Flow Diagram

683x449mm (96 x 96 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Addressed on page number
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	___ 1 ___
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	___ 21 ___
	2b	All items from the World Health Organization Trial Registration Data Set	___ Included ___
Protocol version	3	Date and version identifier	___ 1 ___
Funding	4	Sources and types of financial, material, and other support	___ 23 ___
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	___ 1, 23 ___
	5b	Name and contact information for the trial sponsor	_____
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	___ N/A ___
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	___ N/A ___

6/bmjopen-2020-041083 on 24 April 2021. Downloaded from <http://bmjopen.bmj.com/> on April 17, 2021 by guest. Protected by copyright.

For peer review only

1	Introduction			
2				
3	Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	___ 5-7 ___
4				
5				
6		6b	Explanation for choice of comparators	___ N/A ___
7				
8	Objectives	7	Specific objectives or hypotheses	___ 6-7 ___
9				
10	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	___ 8 ___
11				
12				
13				
14	Methods: Participants, interventions, and outcomes			
15				
16	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	___ 8 ___
17				
18				
19	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	___ 10-11 ___
20				
21				
22	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	___ 11-14 ___
23				
24		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	___ N/A ___
25				
26		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	___ N/A ___
27				
28		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	___ 17 ___
29				
30	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	___ 18 ___
31				
32				
33				
34	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	___ 15 ___
35				
36				
37				
38				
39				
40				
41				
42				
43				
44				
45				
46				

1	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	_____19_____
2				
3				
4	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	_____11_____
5				

6 **Methods: Assignment of interventions (for controlled trials)**

7 Allocation:

8				
9				
10	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	_____N/A_____
11				
12				
13				
14				
15				
16	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	_____N/A_____
17				
18				
19				
20	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	_____N/A_____
21				
22				
23				
24	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	_____N/A_____
25				
26				
27		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	_____N/A_____
28				
29				
30				

31 **Methods: Data collection, management, and analysis**

32				
33	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	_____12_____
34				
35				
36				
37				
38				
39		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	_____15_____
40				
41				
42				

1	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	___ 18 ___
2				
3				
4				
5	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	___ 19-20 ___
6				
7				
8		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	___ N/A ___
9				
10		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	___ N/A ___
11				
12				
13				
14	Methods: Monitoring			
15				
16	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	___ N/A ___
17				
18				
19				
20				
21				
22		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	___ N/A ___
23				
24				
25	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	___ 21-22 ___
26				
27				
28	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	___ N/A ___
29				
30				
31				
32	Ethics and dissemination			
33				
34	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	___ 21 ___
35				
36				
37	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	___ 22 ___
38				
39				
40				
41				
42				
43				
44				
45				
46				

1	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	__12-13__
2				
3				
4		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	__12-13__
5				
6				
7	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	__16-18__
8				
9				
10	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	__23__
11				
12				
13	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	__18__
14				
15				
16	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	__17-18__
17				
18				
19				
20	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	__22-23__
21				
22				
23				
24		31b	Authorship eligibility guidelines and any intended use of professional writers	__23__
25				
26		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	__N/A__
27				
28				
29	Appendices			
30				
31	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	__Attached__
32				
33				
34	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	__14-15, 20__
35				
36				

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by/4.0/)" license.

BMJ Open

Peer-mediated HIV assisted partner services to identify and link to care HIV-positive and HCV-positive people who inject drugs: a cohort study protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-041083.R3
Article Type:	Protocol
Date Submitted by the Author:	15-Feb-2021
Complete List of Authors:	Monroe-Wise, Aliza; University of Washington, Mbogo, Loice; Kenyatta National Hospital Guthrie, Brandon; University of Washington Bukusi, David; Kenyatta National Hospital Sambai, Betsy; Kenyatta National Hospital Chohan, Bhavna; University of Washington; Kenya Medical Research Institute Scott, John; University of Washington Cherutich, Peter; Kenya Ministry of Health Musyoki, Helgar; Kenya Ministry of Health Bosire, Rose; Kenya Medical Research Institute; University of Washington Dunbar, Matthew; University of Washington Macharia, Paul; Kenya Ministry of Health Masyuko, Sarah; Kenya Ministry of Health; University of Washington Wilkinson, Eduan; University of KwaZulu-Natal De Oliveira, Tulio; University of KwaZulu-Natal Ludwig-Barron, Natasha; University of Washington Sinkele, Bill; Support for Addiction Prevention and Treatment in Africa Herbeck, Joshua; University of Washington School of Public Health, Farquhar, Carey; University of Washington
Primary Subject Heading:	HIV/AIDS
Secondary Subject Heading:	Addiction, Epidemiology, Evidence based practice, Global health, Gastroenterology and hepatology
Keywords:	HIV & AIDS < INFECTIOUS DISEASES, Hepatology < INTERNAL MEDICINE, International health services < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Epidemiology < INFECTIOUS DISEASES, Molecular diagnostics < INFECTIOUS DISEASES, VIROLOGY

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Peer-mediated HIV assisted partner services to identify and link to care HIV-positive and**
4 **HCV-positive people who inject drugs: a cohort study protocol**
5
6
7
8
9
10
11
12
13
14

15 Aliza Monroe-Wise^a, Loice Mbogo^b, Brandon Guthrie^{a,c}, David Bukusi^b, Betsy Sambai^b, Bhavna
16 Chohan^{a,d}, John Scott^e, Peter Cherutich^f, Helgar Musyoki^f, Rose Bosire^d, Matthew Dunbar^g, Paul
17 Macharia^f, Sarah Masyuko^{a,f}, Eduan Wilkinson^h, Tulio de Oliveira^h, Natasha Ludwig-Barron^b,
18
19
20 Bill Sinkeleⁱ, Joshua Herbeck^{a*}, Carey Farquhar^{a,b,e*}
21
22
23
24
25
26
27
28

29 ^aUniversity of Washington Department of Global Health, ^bKenyatta National Hospital,
30

31 ^cUniversity of Washington Department of Epidemiology, ^dKenya Medical Research Institute,
32

33 ^eUniversity of Washington Department of Medicine, ^fKenya's Ministry of Health, ^gCenter for
34 Studies in Demography and Ecology, University of Washington, ^hKwaZulu-Natal Research and
35 Innovation Sequencing Platform, University of KwaZulu-Natal, ⁱSupport for Addiction
36 Prevention and Treatment in Africa
37
38
39
40
41
42

43 Corresponding author: Aliza Monroe-Wise, MD, MSc. Email: alizamw@uw.edu
44
45
46

47 University of Washington, 325 Ninth Avenue, Box 359909, Seattle, WA 98104-2499
48
49

50 *These authors share senior authorship.
51
52

53 V2.0 13/10/20
54
55
56
57
58
59
60

Abstract

Introduction

Targeted, tailored interventions to test high-risk individuals for HIV and hepatitis C (HCV) are vital to achieving HIV control and HCV micro-elimination in Africa. Compared with the general population, people who inject drugs (PWID) are at increased risk of HIV and HCV and are less likely to be tested or successfully treated. Assisted partner services (APS) increases HIV testing among partners of people living with HIV and improves case-finding and linkage to care. We describe a study in Kenya examining whether APS can be adapted to find, test, and link to HIV care the partners of HIV-positive PWID using a network of community-embedded peer educators (PEs). Our study also identifies HCV-positive partners and uses phylogenetic analysis to determine risk factors for onward transmission of both viruses.

Methods

This prospective cohort study leverages a network of PEs to identify 1,000 HIV-positive PWID for enrollment as index participants. Each index completes a questionnaire and provides names and contact information of all sexual and injecting partners during the previous 3 years. PEs then use a stepwise locator protocol to engage partners in the community and bring them to study sites for enrollment, questionnaire completion and rapid HIV and HCV testing. Outcomes include number and type of partners per index who are mentioned, enrolled, tested, diagnosed with HIV and HCV and linked to care.

Ethics and dissemination

1
2
3 Potential index participants are screened for intimate partner violence (IPV) and those at high risk
4 are not eligible to enroll. Those at medium risk are monitored for IPV following enrollment. A
5
6
7
8 community advisory board engages in feedback and discussion between the community and the
9
10
11
12 research team. A safety monitoring board discusses study progress and reviews data, including
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

IPV monitoring data. Dissemination plans include presentations at quarterly Ministry of Health meetings, local and international conferences, and publications.

For peer review only

Strengths and limitations of this study

- This cohort study investigates the use of assisted partner services (APS) to find, test for HIV and hepatitis C (HCV) and link to care the sexual and injecting partners of HIV-positive people who inject drugs (PWID) in Kenya; however, APS is not offered to HIV-negative, HCV-positive clients to identify those exposed to HCV but not HIV.
- Community embedded peer educators trained to provide harm reduction services conduct partner tracing, but there are limitations including logistical challenges and concerns for client confidentiality and safety of both the client and peer educator.
- An iris scanning biometric identification system ensures that each index participant enrolled is a unique individual and confirms that individual partner participants who enroll more than once in relation to different index participants are the same individual.
- Phylogenetic analysis of HIV and HCV viral sequences combined with APS will provide additional information about transmission dynamics within the cohort, including risk of onward transmission for different clusters and geographic regions.

Introduction

Diagnosing 90% of those living with HIV has been among the most difficult of the UNAIDS 90-90-90 goals to achieve worldwide,^{1,2} and strategies to reach individuals at high-risk for HIV who have never been tested is increasingly important.³ In Kenya, despite success in achieving or

1
2
3 approaching the 2nd and 3rd UNAIDS goals, only 79.4% of people testing for HIV know their
4 status.⁴ Sharing needles and other drug paraphernalia is the most efficient mode of HIV
5 transmission, and accounts for 13% of new infections globally.^{5,6} In Kenya, prevalence of HIV
6
7
8 among people who inject drugs (PWID) has been estimated at 15 – 50%^{6–10}—significantly higher
9
10
11 than the general population prevalence of 4.9%,¹¹ and up to 30% of PWID in Kenya have never
12
13
14 tested for HIV.^{12,13} Multiple studies have demonstrated low knowledge of HIV status and low
15
16
17 engagement in care among Kenya's PWID.^{13,14} Retention in care and adherence to ART are also
18
19
20 both lower among PWID as compared with others worldwide.¹
21

22
23 In addition to HIV, PWID are at high risk for hepatitis C virus (HCV) globally and have the highest
24
25 HCV prevalence of any group studied in Kenya at 13-40%^{10,15,16}. This is especially high when
26
27 compared to the general population HCV prevalence in Kenya of <1-4%.^{17,18} However, multiple
28
29 barriers exist at individual, provider and system levels resulting in low rates of testing, engagement
30
31 in care, and completion of treatment courses for PWID.^{19–21} Although less than 20% of PWID with
32
33 chronic HCV worldwide have undergone antibody screening, the number who have completed
34
35 PCR confirmatory testing is even lower.²² Despite the introduction of highly effective direct acting
36
37 antivirals (DAAs) into Kenya in 2016, only a small fraction of individuals living with HCV have
38
39 been treated, prompting attention to micro-elimination strategies.^{23,24}
40
41
42
43

44 Assisted partner notification services (APS) for HIV is an evidence-based partner notification
45
46 strategy in which providers elicit information about the sexual or injecting partners of an HIV-
47
48 positive index client, and then contact, HIV test and link to care any partners found to be positive.²⁵
49
50 APS has been shown to significantly and safely increase the uptake of HIV testing services (HTS),
51
52 case finding, and linkage to care for partners of HIV-positive people.^{25–27} APS can also reduce
53
54 barriers to disclosing HIV status²⁸ and is cost-effective.²⁹ APS has been successfully implemented
55
56
57
58
59
60

1
2
3 among HIV-positive patients from the general population in the USA,³⁰ Mozambique,³¹
4 Malawi,^{32,33} and Kenya,²⁷ and has recently been incorporated into the World Health Organization
5 (WHO) guidelines for routine care for HIV-positive people worldwide.³⁴ While programs have
6 introduced the practice of APS in high-risk key populations (KPs) such as female sex workers
7 (FSW)³⁵ and men who have sex with men (MSM),^{36,37} this intervention has not been well-studied
8 among PWID,³⁸ an extremely high risk group.^{25,39} Similar to FSW and MSM, PWID engage in
9 behavior that is criminalized in many parts of the world⁴⁰ while experiencing high rates of
10 marginalization and displacement,⁴¹ making them difficult to study. These factors and others also
11 contribute to significant barriers in the implementation of health programs targeting PWID.^{42–44}

12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Phylogenetic analysis is a method of identifying the role of specific risk groups and risk factors
for onward transmission of HIV and HCV using the genetic sequence of each virus.^{45–47} Viral
phylogenetics can provide additional information on patterns of transmission,^{48–50} epidemic
growth,^{51,52} risk groups,^{53–55} and risk factors associated with onward transmission.^{47,56–58}

Here we describe a prospective cohort study that seeks to determine whether and how APS can be
implemented to find, test, and link to care the injection and sexual partners of HIV-positive PWID
in Kenya. Simultaneously, our study will use phylogenetic analysis to study genetic sequences of
HIV and HCV within our cohort to further understand transmission patterns and risk for onward
transmission. All index and partner participants are tested for HCV in addition to HIV. While many
partner contact methods for conducting APS have been used,²⁵ cellular telephones are the most
common first-line communication modality for reaching partners in other populations.^{26,27,31,59} In
Kenya, however, the large majority of PWID do not have regular access to cellular telephones. As
such, our APS model relies on the utilization of community-embedded peer educators (PEs) to
locate and communicate with members of this difficult to reach population. We hypothesize that

1
2
3 we will be able to employ these customized APS procedures to reach a large number of injection
4 and sexual partners, and that we will see differences between sexual and injection partners in
5 uptake of HIV testing, HIV and HCV prevalence, and engagement in care. Additionally, we
6 hypothesize that we will identify unique transmission patterns and risks for onward transmission
7 in phylogenetic analysis, which may include behavioral, geographic, or other factors.
8
9
10
11
12
13
14

15 **Methods and analysis**

16 *Approach*

17
18
19
20
21
22 APS is a practice through which healthcare providers facilitate the notification, testing and linkage
23 to care for partners who may have been exposed to HIV or other sexually transmitted infections
24 by an individual known to be positive without revealing the identity of the person who may have
25 exposed them. While there are many ways to provide partner services, APS in Kenya is often
26 conducted by healthcare providers who elicit information about partners from an “index” patient
27 and then call the partners over the telephone or physically trace them to alert them to their exposure
28 and provide testing. We have designed customized procedures to ensure and improve the safety
29 and efficacy of APS in the unique population of PWID in Kenya. Because PWID and their partners
30 in Kenya rarely own cellular phones, we work with community-embedded peer educators (PEs) to
31 find and engage with partners. Additionally, our protocol involves referrals to different facilities
32 for injection partners and for sexual partners, as a precaution to ensure safety and confidentiality
33 of index participants who may theoretically be at risk of negative outcomes if partners become
34 aware of their HIV-positive status.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52

53 *Study design*

1
2
3 Our study is a prospective cohort study with two groups: index and partner participants (“indexes”
4 and “partners”). We use tailored APS procedures to identify, find, test and link to care the sexual
5 and injection partners of HIV-positive PWID. All index participants, as well as partner participants
6
7
8
9
10 who are diagnosed with HIV or HCV, complete a 6-month follow-up visit to assess linkage to and
11
12 engagement in care.
13

14 15 Study sites/setting

16
17
18
19 Study procedures take place in eight main sites including public health centers, medication-assisted
20
21 treatment (MAT) centers, and needle and syringe programs (NSPs) in Nairobi, Kilifi, and
22
23 Mombasa Counties in Kenya (Figure 1). Each site is staffed by at least one clinical officer (mid-
24
25 level clinician) who works with researchers to ensure that only participants with documented HIV
26
27 infection are enrolled as indexes, verifying HIV status through re-testing if documentation is not
28
29 provided. In Nairobi County, the activities are centered at two NSP sites and one MAT center in
30
31 the Mathare North area. The NSP sites, run by Support for Addiction Prevention and Treatment in
32
33 Africa (SAPTA), offer routine HIV testing services. Referrals are made to local clinics providing
34
35 care for those who test positive for HIV or HCV. We also recruit indexes from a government-run
36
37 methadone clinic in Nairobi in the Ngara area. The Ngara Health Center MAT clinic offers HIV
38
39 testing, care and treatment in addition to daily methadone administration, psychosocial services
40
41 and treatment for other health conditions. In Kilifi county, participant recruitment and enrollment
42
43 takes place at three needle and syringe program centers and one government hospital. The Omari
44
45 Project is located in Malindi town and offers HIV counseling, testing, care and treatment in
46
47 addition to harm reduction services. Malindi Sub-County Hospital’s MAT center is a recruitment
48
49 site in Kilifi County within a mid-sized government hospital that offers a large range of medical
50
51 and social services. Malindi Sub-County Hospital also has a large laboratory that houses the
52
53
54
55
56
57
58
59
60

1
2
3 study's samples collected in both Kilifi and Mombasa Counties. The Muslim Education and
4 Welfare Association (MEWA) NSP sites in Kilifi and Mtwapa towns offer HIV counseling and
5
6
7
8 testing, in addition to HIV care and treatment and harm reduction services. In Mombasa county,
9
10 participants are recruited from the ReachOut Center, an NSP site in Mombasa city that offers a
11
12 full range of harm reduction services in addition to HIV counseling, testing, care and treatment.
13
14 All recruitment sites offer routine HCV testing when kits are available through specific donor-
15
16 driven projects.
17
18

19 20 *Population*

21
22
23 This study includes index participants and their sexual and/or drug-injecting partners . All indexes
24
25 are HIV-positive PWID. Partners are either sexual partners or injecting partners of indexes.
26
27

28
29 Indexes are largely recruited from organizations and clinics that provide services to PWID
30
31 populations, although they may also come from outreach efforts or informal referrals from other
32
33 participants. Partners are identified and recruited through peer-mediated APS and may come from
34
35 any geographic area or community.
36
37

38 39 *Patient and Public Involvement*

40
41
42 Members of the community of PWID being researched were consulted in the development of
43
44 research questions and design of the study. The study is supported by a Community Advisory
45
46 Board (CAB) composed of members of the community, peer educators and employees of
47
48 organizations that provide services to the population. The CAB meets with the study team regularly
49
50 and helps inform dissemination plans.
51
52
53

54 55 *Study procedures*

1. Peer educator recruitment and training

PEs are recovering PWID with established relationships in the PWID communities that they serve. The majority are between the ages of 25 and 50, are enrolled in Kenya's methadone program and report having stopped injecting drugs. These men and women have been identified by the individual organizations at which they work as being key community members, and have undergone extensive training for their roles as PEs. Training is an intensive 5-day course with modules covering a broad spectrum of content including basics of drugs and drug-related harms, harm reduction efforts including NSP and MAT, abscess prevention and management, overdose prevention and management and behavior change communication. PEs have access to relatively hidden PWID community spaces, and provide health counseling, linkage to support organizations, information, and other services to this vulnerable population.

For this study, PEs who were actively carrying out basic duties were chosen by the leadership at each organization based on several factors including awareness and knowledge of HIV in the community and access to unique target populations (for instance, women who inject drugs may be more easily accessed by women PEs). Once identified, PEs underwent an intensive 1-day training to educate them on the practice and ethics of research, study procedures, and their role in the study. PEs are supervised by clinic managers, who are all collaborators in the study. PEs participate in regular health education and harm reduction training and engage in quarterly sessions with study leadership where they present barriers and lessons learned to the study team so that study-related issues can be addressed.

2. Inclusion & exclusion criteria

1
2
3 Inclusion and exclusion criteria are different for indexes and partners (Table 1). Any interested
4 individuals who are under the age of 18 are referred to the site clinicians for routine counseling
5 and harm reduction services.
6
7
8
9

10 11 3. Index recruitment and enrollment 12

13
14 Enrollment began in March 2018. Clinicians at each site identify potential indexes using existing
15 clinical data on known HIV-positive clients. Additionally, any client who tests positive for HIV
16 during routine testing is invited to participate. Clinicians are employed by the sites, and are trained
17 clinical officers (COs), or mid-level providers. For this study, HIV rapid testing is performed by
18 non-study COs and takes place as part of standard clinic procedures. All potential indexes are re-
19 tested using HIV rapid tests (as per the national guidelines) to confirm HIV status prior to
20 enrollment. If HIVpositive, either newly diagnosed or known to be positive, clinicians approach
21 potential indexes with one of two strategies. Either the clinicians discuss the study directly with
22 potential participants or engage PEs to find individuals and bring them to the study office if they
23 are not regular clients at the site. Importantly, PEs are not told whether participants are being traced
24 as an index or a partner, protecting the confidentiality of indexes' HIV status.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39

40
41 Study staff health advisors (HAs) are the individuals responsible for conducting study procedures
42 including notification of exposure, data collection, HIV and HCV testing, and the coordination of
43 APS efforts (Figure 2). All HAs were trained and experienced in HIV testing services prior to
44 working for the study, and many had previous experience working with PWID. All HAs underwent
45 a week-long training course at the beginning of the study in which they learned the basics and
46 purpose of research, research ethics, study procedures, unique ethical and logistical issues to
47 consider when working with PWID, and other topics. All HAs also completed the Collaborative
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Institutional Training Initiative (CITI) course on Human Subjects Research and the Responsible
4 Conduct of Research. HAs explain the benefits and rationale for providing APS, discuss the
5 importance of learning more about HIV and HCV, and describe the process of notifying partners
6 without revealing the identity of the index. They ask participants to provide written informed
7 consent for study participation, APS, and future use of biological specimens and future contact for
8 additional studies, using an iris-scanning biometric device to record a unique identifier for each
9 participant, thus enabling the study team to confirm that a person does not enroll into the program
10 as an index more than once.
11
12

13
14
15
16
17
18
19
20
21
22 Indexes undergo a structured questionnaire administered by the HA using open data kit (ODK)
23 software on tablet devices (ODK, 2017, Seattle, WA, USA). Questionnaires cover a variety of
24 topics including demographics, sexual and injecting behaviors, drug use history, and HIV testing
25 and history of engagement in HIV care. Participants are then asked to recall all of their sexual and
26 injecting partners over the three years prior to enrollment, naming these partners one by one and
27 assigning each partner a letter (“A,” “B,” etc). Sexual intercourse is defined as vaginal, oral, or
28 anal sex and drug injecting partner is defined as a friend that you inject with frequently. Indexes
29 are asked to give as much locator information as possible for each partner, including names (which
30 may be nicknames), phone numbers, and location of employment or residence. Locator
31 information is written on a paper form for each partner. Indexes then complete a short ODK
32 questionnaire about each partner mentioned, which includes information about the relationship
33 between the index and the partner. Indexes who wish to notify partners themselves are given a 2-
34 week window in which to do so, after which partners are contacted by study staff. Partners notified
35 by indexes through passive referral are told to present to the study site for enrollment in the study,
36 and mode of referral is recorded for each partner in the study.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Indexes then undergo rapid HCV antibody testing as part of routine study procedures. HAs conduct
4 pre- and post- test counseling and ensure individuals who test positive are available for follow-up
5 visits to discuss confirmatory HCV PCR testing and enrolling in a treatment program administered
6 by the Ministry of Health. All indexes then undergo phlebotomy with a sample of 10mL of blood
7 drawn for further testing (see section 6 below). Indexes receive 400 Kenya Shillings (KES,
8 equivalent to about \$4) as compensation for travel and time spent in the study procedures.
9

18 4. Peer-educator mediated assisted partner services and partner recruitment

21 For those partners who have phone numbers listed, HAs attempt phone communication first.
22 However, the vast majority of partners mentioned by indexes do not have working cellular phones;
23 therefore, with few exceptions, PEs locate and conduct the study's first interaction in person with
24 identified partners. PEs are given paper forms containing names and locator information for
25 identified partners, and they verify that the names and locations provided on the locator form
26 matches those of the person they have contacted. They are never told which index referred the
27 team to each partner, and that information is not listed on locator forms or any other accessible
28 file. PEs then locate and approach potential participants in the community and inform them that
29 they have been identified as an individual who might need to be seen in a clinic due to a health
30 concern. When approaching a partner, PEs alert partners that the PEs are working with a research
31 study, and that the partner may have a health issue that should be addressed. The PEs then urge
32 the partner to accompany them to a health facility for testing and possible enrollment in the study.
33 Although PEs are trained using a standardized script (Appendix A), they are encouraged to allow
34 the conversation to progress naturally, responding to questions and concerns that may arise and
35 urging partners to come to the site for further information. PEs do not notify partners of their
36 exposure during initial contact for several reasons: 1) to protect the HIV status of indexes, PEs are
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57

1
2
3 not told whether they are recruiting an index or a partner, and 2) PEs have not felt comfortable
4 discussing HIV or HCV exposure with potential participants. Once PEs have notified potential
5 participants of their possible eligibility, they then accompany interested individuals to the nearest
6 research office, where the study's HAs inform partners of their potential exposure to HIV and/or
7 HCV (Appendix B), and conduct informed consent. Informed consent includes consent to future
8 use of biological specimens and future contact for additional studies. In the rare event that a
9 potential participant does not agree to come to the study office, an HA returns to the site with the
10 PE and notifies the individual of the exposure, and in the rare event that a potential participant
11 agrees to come to the study office but does not want to enroll in the study, the health advisor
12 notifies the individual of the exposure and encourages the individual to undergo testing for HIV
13 and HCV outside of study procedures.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

29 5. Partner enrollment

30
31
32 After informed consent and biometric identification, partners complete a structured questionnaire
33 similar to that of indexes, administered by HAs on a handheld device using ODK software.
34 Following the questionnaire, all partners undergo rapid antibody testing for both HIV and HCV.
35 HIV testingservices are provided in accordance with national HIV testing guidelines. Any partner
36 found to be positive for either HIV or HCV antibodies undergoes a 20mL blood draw. Those
37 partners who test negative for both HIV and HCV are finished with study procedures at this time
38 and are counseled on risk reduction measures and provided information about HIV and HCV
39 prevention services before leaving the study site. All partners receive 400 Kenya Shillings (KES,
40 equivalent to about \$4) as compensation for travel and time spent in the study procedures.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 HIV-positive partners are invited to undergo screening as an index once data collection procedures
4 for their partner enrollment are complete. If they meet eligibility criteria as an index, they may
5 enroll as an index. Study procedures are slightly amended for indexes that have previously enrolled
6 as partners. After undergoing informed consent and completing a short questionnaire that only
7 includes questions that were not a part of the partner enrollment questionnaire, they complete the
8 identification and data collection on each of their sexual and injection partners, identical to partner
9 identification procedures for indexes described above.
10
11
12
13
14
15
16
17
18
19

20 6. Laboratory Procedures

21
22
23 Blood samples from both index and partner enrollment visits are collected in EDTA vacutainer
24 tubes. Blood is mixed with the anticoagulant by inversion and the anticoagulated blood is stored
25 at room temperature at the sites for less than 4 hours. A motorcycle courier picks samples from
26 each site daily and brings them to the University of Nairobi Pediatric Research Laboratory in
27 Nairobi or the Malindi Sub-County Hospital Laboratory for coast sites. At each laboratory,
28 samples are first used to prepare two Whatman 903 Protein Saver dried blood spot (DBS) cards
29 with 50ul of whole blood on each spot. Blood samples are then centrifuged and used to prepare 2
30 to 3 aliquots of 1ml of plasma in labeled serum vials. Plasma aliquots and air-dried DBS cards
31 (with desiccant in sealed Ziploc bags) are then stored at -80° Celsius and shipped on dry ice to the
32 University of KwaZulu-Natal laboratory. There, samples undergo HIV and HCV viral load testing
33 and amplification for sequencing.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

50 7. Participant follow-up

51
52
53 All indexes and any partners who were positive for HIV or HCV complete a six-month follow-up
54 visit. HAs identify which participants are due for follow-up visits on a weekly basis and give PEs
55
56
57

1
2
3 as list of these names. PEs then trace participants and bring them back to clinics where data
4 collection procedures are conducted. PEs make several attempts to find participants in the
5
6 community before considering them lost to follow-up.
7
8
9

10
11 Six-month visits involve a brief questionnaire covering questions on testing for HIV or HCV (if
12 not infected with both on enrollment), enrollment in care and treatment, engagement in care, and
13 follow-up testing. The purpose of this visit is to assess whether engagement in care has changed
14 following APS procedures, for both indexes and partners. We do not collect additional data from
15 those lost to follow up.
16
17
18
19
20
21
22

23 8. Intimate partner violence (IPV) monitoring

24
25
26
27 Given historical concerns that APS may increase one's risk of experiencing intimate partner
28 violence, all potential participants undergo screening for IPV before enrollment. IPV is defined as
29 any physical, sexual or psychological harm inflicted on a person by a current or former sexual
30 partner. After answering a standardized set of six questions about physical, emotional and sexual
31 IPV and the timing of any previous experience of IPV based on published screening tools reviewed
32 by the Centers for Disease Control and Prevention,⁶⁰ potential participants are classified as low,
33 medium or high risk for IPV. Individuals are classified as at high risk for IPV if they report IPV
34 within the last month. Any potential index who is classified as high IPV risk is excluded from
35 study participation and provided with IPV counseling and resources. Any potential partner
36 participant who is classified as high IPV risk is allowed to enroll, but then receives special
37 monitoring for IPV following enrollment.
38
39
40
41
42
43
44
45
46
47
48
49
50
51

52
53 Potential participants are classified as at moderate risk for IPV if they report 1) IPV during their
54 lifetime either from a current or past partner; and/or 2) fear of IPV if they participate in the study.
55
56
57

1
2
3 All index or partner participants classified as moderate IPV risk receive special monitoring for
4
5 IPV following their enrollment in the study.
6
7

8
9 Potential participants are classified as at low risk for IPV if they report 1) no IPV during their
10
11 lifetime ; and 2) no fear of IPV if they participate in the study. These individuals undergo standard
12
13 study procedures which include completing the baseline IPV case report form and a follow-up IPV
14
15 case report to capture reports of any interim IPV.
16
17

18 19 9. Confidentiality and safety 20 21

22 *Participants:* All study procedures take place in private rooms at each study facility. To ensure the
23
24 safety and confidentiality of indexes, PEs who are tasked with finding partners are blinded to the
25
26 identity of the linked index through the use of partner locator forms that do not contain identifying
27
28 information about the index participant. Locator forms do contain a printed barcode label that are
29
30 then used by study staff to link the partner with the index who referred the partner.
31
32

33
34 Sexual partners are brought to independent facilities for enrollment rather than to centers that serve
35
36 PWID, in order to further protect the identity of the index participant who referred them. The
37
38 independent facilities are local healthcare clinics that serve the general population.
39
40

41
42 *Peer educators:* PEs have frequent interactions with police, and can be victims of harassment or
43
44 violence, both by police and by PWID. To reduce the risk of law enforcement troubles, PEs carry
45
46 identification showing that they are working on a study being conducted by the Ministry of Health.
47
48 Local law enforcement officials have also attended ongoing sensitization trainings by the Ministry
49
50 of Health and by organizations working with PWID.
51
52

53 54 55 10. Referrals to care 56 57

1
2
3 *HIV Counseling and Care:* Participants are provided with their HIV test results in the context of
4 post-test counseling, and are then referred to available medical and psychosocial care and support
5 facilities either within the research site or in close proximity to the research site or the participant's
6 home. Additionally, HIV-positive individuals are offered individual or group support sessions as
7 available within each site.
8
9

10
11
12
13
14
15 *HCV Counseling and Care:* Participants who test positive for HCV antibodies using rapid testing
16 are provided with their HCV antibody test results in the context of pre- and post-test counseling.
17 They are informed that they may have active HCV infection; however, further confirmatory testing
18 must be done prior to establishing the diagnosis. Confirmatory polymerase chain reaction (PCR)
19 testing is done in batches of samples at our partnering laboratory at the University of KwaZulu-
20 Natal, South Africa, and participants with active infection are later contacted for results and
21 counseling. Turnaround time from enrollment to PCR result notification varies, but is typically
22 between 1 and 4 months. Once notified of their PCR results, those with active infection are paired
23 with a PE at their site to ensure close contact is maintained. Study participants with active HCV
24 infections will be eligible to receive free treatment with direct acting antivirals, which the Kenyan
25 MoH has procured.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

42 Data management

43
44

45 After each study visit, HAs review their work for omissions or errors and all data are uploaded
46 into the study database. Electronic data are stored securely in an encrypted database on servers
47 using Open Data Kit Aggregate, within Kenya's Ministry of Health (MoH). All errors or omissions
48 identified at any step in the quality assurance/quality control process are revised by the staff
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 member who originally completed the document. All additions and corrections are initialed and
4
5 dated by the staff member who records the entry.
6
7

8
9 A link-log is separately encrypted to further ensure that data remains secure. Any data transferred
10
11 to investigators or MoH are de-identified and encrypted during the process of transfer from the
12
13 server. Each investigator maintains and stores secure, complete, accurate and current study records
14
15 throughout the study. A database manager performs regular data cleaning and resolves any
16
17 discrepancies that occur. Study sites also conduct quality control and quality assurance procedures.
18
19 All co-investigators have access to the final dataset and this is not limited by contractual
20
21 agreements. Study data will be available upon request at the completion of the study.
22
23
24

25 26 Outcome measures

27
28
29 The primary outcomes of interest to assess the success of the APS intervention are: a) number of
30
31 sexual and injection partners tested for HIV and HCV through APS, identified by each index
32
33 participant over the course of the study period; b) number of sexual and injection partners newly
34
35 testing positive for HIV and HCV, per index participant; c) number of known HIV or HCV cases
36
37 identified through APS who are not engaged in care; d) number of index and partner participants
38
39 with HIV and/or HCV infection who are linked to care; e) number of index and partners with HIV
40
41 and/or HCV infection who remain in care and are receiving appropriate treatment at 6 months after
42
43 testing positive. Secondary outcomes are linked to inclusion in phylogenetic clusters identified as
44
45 high risk for onward transmission of HIV and HCV.
46
47
48
49

50 51 Sample size

1
2
3 We are enrolling 1000 HIV-positive indexes and their sexual and injecting partners. Based on
4 HCV data from MoH and our preliminary results, we estimate that 20% of PWID with HIV will
5 be co-infected with HCV and that each index will identify on average two partners who will accept
6 HIV and HCV testing, 20% of whom will be HIV-positive, and 20% of whom will be HCV-
7 infected. Thus, with provision of APS to 1,000 HIV-positive indexes and testing of 2,000 partners,
8 we will identify an estimated 600 indexes and partners infected with HCV and 400 HIV-positive
9 partners. This study was designed to have high precision in estimating the prevalence of HIV and
10 HCV infection among partners, providing valuable input for modeling the impact of APS in the
11 population. For an observed HIV or HCV prevalence of 10% among partners, precision is
12 estimated at 1.9%; with an observed HIV or HCV prevalence of 30% among partners, precision is
13 estimated at 2.9%. *Statistical methods and analysis*

14
15 To determine efficacy of the APS intervention, we will use generalized estimating equations
16 (GEE) models with a Poisson link using the following variables and offsets: 1) rate of HIV and
17 HCV testing of partners: number of individuals tested for HIV or HCV, offset by the number of
18 partners located with locator information provided by the index participant; 2) prevalence of HIV
19 and HCV infection: number of individuals identified as HIV or HCV-positive, offset by the
20 number of individuals who were HIV tested; and 3) rate of linkage to HIV and HCV care:
21 individuals who test HIV or HCV-positive and link to care, offset by the total number of
22 individuals who test HIV or HCV-positive.

23
24 Additionally, using both GEE and phylogenetic analysis, we will determine the following: 1)
25 identifiable and individual risk factors linked to high rates of HIV and HCV transmission, 2) risk
26 factors linked to both needle-sharing and sexual transmission, and 3) identification of transmission
27 clusters among PWID for both HIV and HCV.

Phylogenetic analysis

HIV and HCV gene sequencing are attempted for all study participants who test positive for either virus. Sequencing will be performed at the KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP) at the University of KwaZulu-Natal in Durban, South Africa. For HIV we will subsequently combine our data with additional, publicly available, HIV sequences from Kenya and perform phylogenetic and phylodynamic analyses to describe patterns and rates of viral transmission among key populations in Kenya and identify traits associated with relative infectiousness. For HCV we will use phylogenetic methods to characterize the modes and risk factors for onward transmission among PWID.

Ethics and Dissemination

General ethical considerations

This study is registered at clinicaltrials.gov (NCT03447210) and has ethical approval from both the University of Washington Human Subjects Division and the Kenyatta National Hospital Ethics and Research Committee. It also has approval from Kenya's National Commission for Science, Technology and Innovation.

There are a number of potential risks to participants. Risks of conducting APS include psychological distress, social or economic hardship, criminal penalties, and loss of privacy and/or confidentiality. Study procedures, including confidentiality and counseling procedures, are specifically designed to minimize these risks to participants. While IPV has the potential to cause harm, it has not increased in other US or African studies when this intervention has been implemented in the general population.^{25,61,62} We recognize that risks may be different when

1
2
3 implementing APS among key populations and study staff are highly trained in counseling about
4 risk behaviors, implications of testing HIV-positive, and protecting confidentiality to avoid
5 potential social harms. In addition, staff have undergone extensive training on IPV counseling and
6 ensure that resources have been identified in all sites so we can safely refer participants who report
7 abuse or are concerned for their safety. Participants reporting moderate IPV are monitored as
8 described in Section 8; they are counseled and referred for services if IPV is reported at any of
9 these follow-up visits.

10
11 A safety monitoring board composed of researchers and policy makers in both Kenya and the US
12 reviews study safety data twice per year. The board monitors enrollments, deaths, loss to follow
13 up, adverse events, including social harms, and IPV monitoring data and makes recommendations
14 regarding study procedures.

15
16 Ethical considerations surrounding the use of biometric identification systems among key
17 populations in Kenya have been discussed extensively.⁶³ Despite early opposition from the Key
18 Populations Consortium and other organizations to the government's use of fingerprint-based
19 biometric data collection, the organizations and individuals working with PWID communities
20 continued to report no opposition to iris scanning for research purposes among PWID. In
21 November 2019, Kenya passed the Data Protection Bill, rendering it legal to collect biometric data
22 as long as the use of such data does not violate the subjects' rights.⁶⁴ The use of biometrics is now
23 standard practice in many research and clinical settings, and has been found to be acceptable to
24 participants.⁶⁵ Our participants have not reported any concerns, fears, or hesitations regarding the
25 use of an iris scanning biometric identification system.

26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 Dissemination plan

1
2
3 Results from the study and changes to the study are presented on an ongoing basis at Kenya's
4 quarterly MoH harm reduction and key population technical working group meetings, and
5
6 discussed at biannual meetings by the Community Advisory Board that was established for this
7
8 study. Our study team includes several collaborators from the MoH. Ongoing study analyses are
9
10 also presented at national conferences annually. Additionally, study results are presented in at least
11
12 one international conference per year. Finally, the study team reviews data on a weekly basis and
13
14 any changes in data trends or other concerns are discussed directly with the organizations through
15
16 which study procedures take place.
17
18
19
20
21

Authors' contributions

22
23
24
25
26 CF and JH conceived of the study; AMW, BG, BC, MD, PM, BSi, JH and CF contributed to the
27
28 study design and data collection structure; AMW, LM, DB, BSa, BC, JS, PC, HM, RB, PM, SM,
29
30 EW, TDO, BSi, JH and CF contributed to data collection; AMW, LM, BG, DB, BSa, PC, HM,
31
32 RB, SM, EW, TDO, NLB, JH and CF contributed to data analysis and dissemination; AMW, BG,
33
34 JH and CF wrote the manuscript; all authors reviewed the manuscript for content.
35
36
37

Funding

38
39
40
41
42 This work was supported by the Division of AIDS, National Institute of Drug Abuse, grant number
43
44 R01 DA043409. 301 North Stonestreet Ave, Bethesda, MD 20892. +1 301-443-1124.
45
46

Competing interests

47
48
49
50
51 All authors state that they have no competing interests.
52

53
54 Figure 1. Map of Study Sites
55
56
57
58
59
60

Figure 2. Study Flow Diagram

References

1. Levi J, Raymond A, Pozniak A, Vernazza P, Kohler P, Hill A. Can the UNAIDS 90-90-90 target be achieved? A systematic analysis of national HIV treatment cascades. *BMJ Glob Health*. 2016;1(2):e000010. doi:10.1136/bmjgh-2015-000010
2. UNAIDS. 90-90-90: An ambitious treatment target to help end the AIDS epidemic. Published October 2014. Accessed March 7, 2018. http://www.unaids.org/sites/default/files/media_asset/90-90-90_en.pdf
3. Staveteig S, Croft TN, Kampa KT, Head SK. Reaching the 'first 90': Gaps in coverage of HIV testing among people living with HIV in 16 African countries. *PLOS ONE*. 2017;12(10):e0186316. doi:10.1371/journal.pone.0186316
4. National AIDS and STI Control Programme (NASCOP). *Preliminary KENPHIA 2018 Report*.; 2020. Accessed December 16, 2020. https://phia.icap.columbia.edu/wp-content/uploads/2020/04/KENPHIA-2018_Preliminary-Report_final-web.pdf
5. Brodish P, Singh K, Rinyuri A, et al. Evidence of high-risk sexual behaviors among injection drug users in the Kenya PLACE study. *Drug Alcohol Depend*. 2011;119(1-2):138-141. doi:10.1016/j.drugalcdep.2011.05.030
6. Mathers BM, Degenhardt L, Phillips B, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. *Lancet Lond Engl*. 2008;372(9651):1733-1745. doi:10.1016/S0140-6736(08)61311-2
7. National AIDS Control Council NS and ACP. Kenya HIV Prevention Revolution Road Map: Count Down to 2030. Published online June 2014.
8. Kurth AE, Cleland CM, Des Jarlais DC, et al. HIV Prevalence, Estimated Incidence, and Risk Behaviors Among People Who Inject Drugs in Kenya. *J Acquir Immune Defic Syndr* 1999. 2015;70(4):420-427. doi:10.1097/QAI.0000000000000769
9. Ndetei, David M. A study on the linkages between drug abuse, injecting drug use and HIV/AIDS in Kenya: a rapid situation assessment. *U N Off Drugs Crime*.:45.
10. Odek-Ogunde M, Okoth, F, Lore, W, Owiti, F.R. Seroprevalence of HIV, HBC and HCV in Injecting Drug Users in Nairobi, Kenya: World Health Organization Drug Injecting Study Phase II Findings. In: ; 2004.
11. National AIDS Control Council. *Kenya HIV Estimates Report 2018*. Accessed February 21, 2019. <https://nacc.or.ke/wp-content/uploads/2018/11/HIV-estimates-report-Kenya-20182.pdf>

12. Tun W, Sheehy M, Broz D, et al. HIV and STI Prevalence and Injection Behaviors Among People Who Inject Drugs in Nairobi: Results from a 2011 Bio-behavioral Study Using Respondent-Driven Sampling. *AIDS Behav.* 2015;19(Suppl 1):24-35. doi:10.1007/s10461-014-0936-3
13. Lizcano, J. Testing and Linkage to Care for Injecting Drug Users. In: ; 2016.
14. Githuka G, Hladik W, Mwalili S, et al. Populations at Increased Risk for HIV Infection in Kenya: Results From a National Population-Based Household Survey, 2012. *J Acquir Immune Defic Syndr* 1999. 2014;66(Suppl 1):S46-S56. doi:10.1097/QAI.0000000000000137
15. Akiyama MJ, Cleland CM, Lizcano JA, Cherutich P, Kurth AE. Prevalence, estimated incidence, risk behaviours, and genotypic distribution of hepatitis C virus among people who inject drugs accessing harm-reduction services in Kenya: a retrospective cohort study. *Lancet Infect Dis.* 2019;19(11):1255-1263. doi:10.1016/S1473-3099(19)30264-6
16. Muasya T, Lore W, Yano K, et al. Prevalence of Hepatitis C Virus and its genotypes among a cohort of drug users in Kenya. *East Afr Med J.* 2008;85(7). doi:10.4314/eamj.v85i7.9649
17. Bartonjo G, Oundo J, Ng'ang'a Z. Prevalence and associated risk factors of transfusion transmissible infections among blood donors at Regional Blood Transfusion Center Nakuru and Tenwek Mission Hospital, Kenya. *Pan Afr Med J.* 2019;34. doi:10.11604/pamj.2019.34.31.17885
18. Loarec A, Carnimeo V, Molfino L, et al. Extremely low hepatitis C prevalence among HIV co-infected individuals in four countries in sub-Saharan Africa. *AIDS Lond Engl.* 2019;33(2):353-355. doi:10.1097/QAD.0000000000002070
19. Litwin AH, Jost J, Wagner K, et al. Rationale and design of a randomized pragmatic trial of patient-centered models of hepatitis C treatment for people who inject drugs: The HERO study. *Contemp Clin Trials.* 2019;87:105859. doi:10.1016/j.cct.2019.105859
20. Treloar C, Hull P, Dore GJ, Grebely J. Knowledge and barriers associated with assessment and treatment for hepatitis C virus infection among people who inject drugs. *Drug Alcohol Rev.* 2012;31(7):918-924. doi:10.1111/j.1465-3362.2012.00468.x
21. Enkelmann J, Gassowski M, Nielsen S, et al. High prevalence of hepatitis C virus infection and low level of awareness among people who recently started injecting drugs in a cross-sectional study in Germany, 2011-2014: missed opportunities for hepatitis C testing. *Harm Reduct J.* 2020;17(1):7. doi:10.1186/s12954-019-0338-y
22. Day E, Hellard M, Treloar C, et al. Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework. *Liver Int Off J Int Assoc Study Liver.* 2019;39(1):20-30. doi:10.1111/liv.13949
23. Medecins du Monde. Our Activities in Kenya. Accessed November 24, 2020. <https://www.medecinsdumonde.org/en/countries/africa/kenya>
24. Cherutich P, Kurth A, Lizcano JA, Akiyama MJ. Integration of Hepatitis C treatment services with harm reduction service centers for people who inject drugs in Kenya: experience from test and link to care for injecting drug users study. In: *Reviews in Antiviral Therapy & Infectious Diseases.* ; 2019.

- 1
- 2
- 3
- 4 25. Dalal S, Johnson C, Fonner V, et al. Improving HIV test uptake and case finding with assisted
- 5 partner notification services. *AIDS Lond Engl*. 2017;31(13):1867-1876.
- 6 doi:10.1097/QAD.0000000000001555
- 7
- 8 26. Kahabuka C, Plotkin M, Christensen A, et al. Addressing the First 90: A Highly Effective Partner
- 9 Notification Approach Reaches Previously Undiagnosed Sexual Partners in Tanzania. *AIDS Behav*.
- 10 2017;21(8):2551-2560. doi:10.1007/s10461-017-1750-5
- 11
- 12 27. Cherutich P, Golden MR, Wamuti B, et al. Assisted partner services for HIV in Kenya: a cluster
- 13 randomised controlled trial. *Lancet HIV*. 2017;4(2):e74-e82. doi:10.1016/S2352-3018(16)30214-4
- 14
- 15 28. Plotkin M, Kahabuka C, Christensen A, et al. Outcomes and Experiences of Men and Women with
- 16 Partner Notification for HIV Testing in Tanzania: Results from a Mixed Method Study. *AIDS Behav*.
- 17 2018;22(1):102. doi:10.1007/s10461-017-1936-x
- 18
- 19 29. Sharma M, Smith JA, Farquhar C, et al. Assisted partner notification services are cost-effective for
- 20 decreasing HIV burden in western Kenya. *AIDS Lond Engl*. 2018;32(2):233-241.
- 21 doi:10.1097/QAD.0000000000001697
- 22
- 23 30. Landis SE, Schoenbach VJ, Weber DJ, et al. Results of a randomized trial of partner notification in
- 24 cases of HIV infection in North Carolina. *N Engl J Med*. 1992;326(2):101-106.
- 25 doi:10.1056/NEJM199201093260205
- 26
- 27 31. Myers RS, Feldacker C, Cesár F, et al. Acceptability and Effectiveness of Assisted Human
- 28 Immunodeficiency Virus Partner Services in Mozambique: Results From a Pilot Program in a Public,
- 29 Urban Clinic. *Sex Transm Dis*. 2016;43(11):690-695. doi:10.1097/OLQ.0000000000000529
- 30
- 31 32. Brown LB, Miller WC, Kamanga G, et al. HIV partner notification is effective and feasible in sub-
- 32 Saharan Africa: opportunities for HIV treatment and prevention. *J Acquir Immune Defic Syndr*
- 33 1999. 2011;56(5):437-442.
- 34
- 35 33. Brown LB, Miller WC, Kamanga G, et al. Predicting partner HIV testing and counseling following a
- 36 partner notification intervention. *AIDS Behav*. 2012;16(5):1148-1155. doi:10.1007/s10461-011-
- 37 0094-9
- 38
- 39 34. World Health Organization. WHO | WHO recommends assistance for people with HIV to notify
- 40 their partners. WHO. Accessed February 22, 2019. [http://www.who.int/hiv/pub/vct/who-partner-](http://www.who.int/hiv/pub/vct/who-partner-notification-policy/en/)
- 41 [notification-policy/en/](http://www.who.int/hiv/pub/vct/who-partner-notification-policy/en/)
- 42
- 43 35. Quinn C, Nakyanjo N, Ddaaki W, et al. HIV partner notification values and preferences among sex
- 44 workers, fishermen, and mainland community members in Rakai, Uganda: a qualitative study. *AIDS*
- 45 *Behav*. 2018;22(10):3407-3416. doi:10.1007/s10461-018-2035-3
- 46
- 47 36. Rane V, Tomnay J, Fairley C, et al. Opt-Out Referral of Men Who Have Sex With Men Newly
- 48 Diagnosed With HIV to Partner Notification Officers: Results and Yield of Sexual Partners Being
- 49 Contacted. *Sex Transm Dis*. 2016;43(6):341-345. doi:10.1097/OLQ.0000000000000449
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 1
- 2
- 3
- 4 37. Halkitis PN, Kupprat SA, McCree DH, et al. Evaluation of the relative effectiveness of three HIV
- 5 testing strategies targeting African American men who have sex with men (MSM) in New York City.
- 6 *Ann Behav Med Publ Soc Behav Med.* 2011;42(3):361-369. doi:10.1007/s12160-011-9299-4
- 7
- 8 38. Levy JA, Fox SE. The outreach-assisted model of partner notification with IDUs. *Public Health Rep*
- 9 *Wash DC 1974.* 1998;113 Suppl 1:160-169.
- 10
- 11 39. Malik M, Jamil MS, Johnson CC, Pasha MS, Hermez J, Qureshi S ul H. Integrating assisted partner
- 12 notification within HIV prevention service package for people who inject drugs in Pakistan. *J Int*
- 13 *AIDS Soc.* 2019;22(Suppl Suppl 3). doi:10.1002/jia2.25317
- 14
- 15 40. DeBeck K, Cheng T, Montaner JS, et al. HIV and the criminalisation of drug use among people who
- 16 inject drugs: a systematic review. *Lancet HIV.* 2017;4(8):e357-e374. doi:10.1016/S2352-
- 17 3018(17)30073-5
- 18
- 19 41. United Nations, Office on Drugs and Crime. *World Drug Report 2016.*; 2016.
- 20
- 21 42. Molinaro S, Resce G, Alberti A, et al. Barriers to effective management of hepatitis C virus in
- 22 people who inject drugs: Evidence from outpatient clinics. *Drug Alcohol Rev.* 2019;38(6):644-655.
- 23 doi:10.1111/dar.12978
- 24
- 25 43. Phillips KT. Barriers to practicing risk reduction strategies among people who inject drugs. *Addict*
- 26 *Res Theory.* 2016;24(1):62-68. doi:10.3109/16066359.2015.1068301
- 27
- 28 44. Heath AJ, Kerr T, Ti L, et al. Healthcare avoidance by people who inject drugs in Bangkok, Thailand.
- 29 *J Public Health Oxf Engl.* 2016;38(3):e301-e308. doi:10.1093/pubmed/fdv143
- 30
- 31 45. Frost SDW, Pillay D. Understanding Drivers of Phylogenetic Clustering in Molecular Epidemiological
- 32 Studies of HIV. *J Infect Dis.* 2015;211(6):856-858. doi:10.1093/infdis/jiu563
- 33
- 34 46. Brenner BG, Wainberg MA. Future of phylogeny in HIV prevention. *J Acquir Immune Defic Syndr*
- 35 *1999.* 2013;63 Suppl 2:S248-254. doi:10.1097/QAI.0b013e3182986f96
- 36
- 37 47. Jacka B, Applegate T, Kraiden M, et al. Phylogenetic clustering of hepatitis C virus among people
- 38 who inject drugs in Vancouver, Canada. *Hepatol Baltim Md.* 2014;60(5):1571-1580.
- 39 doi:10.1002/hep.27310
- 40
- 41 48. Grabowski MK, Lessler J, Redd AD, et al. The Role of Viral Introductions in Sustaining Community-
- 42 Based HIV Epidemics in Rural Uganda: Evidence from Spatial Clustering, Phylogenetics, and
- 43 Egocentric Transmission Models. Hallett T, ed. *PLoS Med.* 2014;11(3):e1001610.
- 44 doi:10.1371/journal.pmed.1001610
- 45
- 46 49. Worobey M, Gemmel M, Teuwen DE, et al. Direct Evidence of Extensive Diversity of HIV-1 in
- 47 Kinshasa by 1960. *Nature.* 2008;455(7213):661-664. doi:10.1038/nature07390
- 48
- 49 50. de Oliveira T, Pillay D, Gifford RJ. The HIV-1 Subtype C Epidemic in South America Is Linked to the
- 50 United Kingdom. *PLoS ONE.* 2010;5(2). doi:10.1371/journal.pone.0009311
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 1
2
3 51. Hughes GJ, Fearnhill E, Dunn D, Lycett SJ, Rambaut A, Leigh Brown AJ. Molecular Phylodynamics of
4 the Heterosexual HIV Epidemic in the United Kingdom. *PLoS Pathog*. 2009;5(9).
5 doi:10.1371/journal.ppat.1000590
6
- 7 52. Hué S, Clewley JP, Cane PA, Pillay D. Investigation of HIV-1 transmission events by phylogenetic
8 methods: requirement for scientific rigour. *AIDS Lond Engl*. 2005;19(4):449-450.
9 doi:10.1097/01.aids.0000161778.15568.a1
10
- 11 53. Dennis AM, Hué S, Hurt CB, et al. Phylogenetic insights into regional HIV transmission. *AIDS Lond*
12 *Engl*. 2012;26(14):1813-1822. doi:10.1097/QAD.0b013e3283573244
13
- 14 54. Ambrosioni J, Junier T, Delhumeau C, et al. Impact of highly active antiretroviral therapy on the
15 molecular epidemiology of newly diagnosed HIV infections. *AIDS Lond Engl*. 2012;26(16):2079-
16 2086. doi:10.1097/QAD.0b013e32835805b6
17
- 18 55. Kouyos RD, Rauch A, Böni J, et al. Clustering of HCV coinfections on HIV phylogeny indicates
19 domestic and sexual transmission of HCV. *Int J Epidemiol*. 2014;43(3):887-896.
20 doi:10.1093/ije/dyt276
21
- 22 56. Fisher M, Pao D, Brown AE, et al. Determinants of HIV-1 transmission in men who have sex with
23 men: a combined clinical, epidemiological and phylogenetic approach. *AIDS*. 2010;24(11):1739-
24 1747. doi:10.1097/QAD.0b013e32833ac9e6
25
- 26 57. Brenner BG, Roger M, Routy J-P, et al. High rates of forward transmission events after acute/early
27 HIV-1 infection. *J Infect Dis*. 2007;195(7):951-959. doi:10.1086/512088
28
- 29 58. Kramer MA, Cornelissen M, Paraskevis D, et al. HIV transmission patterns among The Netherlands,
30 Suriname, and The Netherlands Antilles: a molecular epidemiological study. *AIDS Res Hum*
31 *Retroviruses*. 2011;27(2):123-130. doi:10.1089/aid.2010.0115
32
- 33 59. Henley C, Forgewei G, Welty T, et al. Scale-up and case-finding effectiveness of an HIV partner
34 services program in Cameroon: an innovative HIV prevention intervention for developing
35 countries. *Sex Transm Dis*. 2013;40(12):909-914. doi:10.1097/OLQ.0000000000000032
36
- 37 60. Centers for Disease Control and Prevention (CDC). Intimate Partner Violence and Sexual Violence
38 Victimization Assessment Instruments for Use in Healthcare Settings: (410572008-001). Published
39 online 2007. doi:10.1037/e410572008-001
40
- 41 61. Monroe-Wise A, Maingi Mutiti P, Kimani H, Moraa H, Bukusi DE, Farquhar C. Assisted partner
42 notification services for patients receiving HIV care and treatment in an HIV clinic in Nairobi,
43 Kenya: a qualitative assessment of barriers and opportunities for scale-up. *J Int AIDS Soc*.
44 2019;22(Suppl Suppl 3). doi:10.1002/jia2.25315
45
- 46 62. Goyette MS, Mutiti PM, Bukusi D, et al. Hiv Assisted Partner Services Among Those with and
47 Without A History of Intimate Partner Violence in Kenya. *J Acquir Immune Defic Syndr* 1999.
48 Published online February 5, 2018. doi:10.1097/QAI.0000000000001638
49
- 50
51
52
53
54
55
56
57
58
59

63. KELIN and the Kenya Key Populations Consortium. "Everyone Said No:" *Biometrics, HIV and Human Rights – A Kenya Case Study*. KELIN; 2018. Accessed April 10, 2020. <https://www.kelinkenya.org/everyonesaidno/>
64. Gathura G. Biometrics system for identifying people living with HIV ready. *The Standard*. <https://www.standardmedia.co.ke/article/2001349675/biometrics-system-for-identifying-people-living-with-hiv-ready>. Published November 17, 2019. Accessed April 10, 2020.
65. Anne N, Dunbar MD, Abuna F, et al. Feasibility and acceptability of an iris biometric system for unique patient identification in routine HIV services in Kenya. *Int J Med Inf*. 2020;133:104006. doi:10.1016/j.ijmedinf.2019.104006

Table 1. Inclusion and Exclusion Criteria

<u>Group</u>	<u>Inclusion</u>	<u>Exclusion</u>
<i>Index</i>	<ul style="list-style-type: none"> • 18 years of age or older • Recent intravenous drug use as defined by injecting at least once in the past year • HIV-positive • Willing and able to provide locator information for sexual and/or injecting partners • Willing and able to provide informed consent 	<ul style="list-style-type: none"> • Classified as at high risk for IPV (described below)
<i>Partner</i>	<ul style="list-style-type: none"> • 18 years of age or older • identified by an index as either having injected with the index in the past 3 years or had sexual intercourse with the index in the past three years • Willing and able to provide informed consent 	None




Figure 1. Map of Study Sites

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2. Study Flow Diagram

683x449mm (96 x 96 DPI)

APPENDIX A: PEER EDUCATOR INTRODUCTION SCRIPT

Hello, I am _____, a Peer Educator from _____. Am I speaking with Ms/Mr. _____? I want to be sure I have the right person in front of me. I work at the clinic and have come to talk with you about a health matter that concerns you. This is confidential information for you. Is this a good time to talk? This will not take long and I assure you that our discussion will be confidential.

The information I have concerns your health but it does not mean that something is wrong with your health. We have reason to believe that you may have a health problem, and that you may also be eligible for a research study. You will have to come to the clinic to get more information about both your health issue and the research study. If you agree, you can come to the clinic with me now and I will bring you to the clinician.

Do you have any questions about what I have said so far?

If you do not want to come to the clinic, I will return to find you again tomorrow with someone from the clinic who can talk to you about the health issue.

Have you made a decision about whether you'd like to come with me?

If yes, I will take you to [name of closest clinic] center for further discussions with the clinician at the clinic. If no, we will come back and find you again at a later date to discuss this issue with you further.

Thank you.

APPENDIX B: HEALTH ADVISOR INTRODUCTION SCRIPT

Hello, I am _____, a Health Advisor from the Kenya Ministry of Health. Am I speaking with Ms/Mr. _____? I want to be sure I have the right person in front of me. I work at the clinic and have come to talk with you about a health matter that concerns you. This is confidential information for you. Is this a good time to talk? This will not take long and I assure you that our discussion will be confidential.

The information I have concerns your health but it does not mean that something is wrong with your health.

I wish to inform you that you may have been exposed to HIV infection. I do not know who gave me information on your exposure to HIV infection.

This does not mean you are infected. It just means that you have been exposed to HIV and will need to test yourself soon to see what your HIV status is.

This HIV test will help you to know your status early and if you are not infected, you can plan to avoid future infections. If you are infected, you will receive advice on how to live positively.

You can do your test anywhere you choose, but it is advisable that you do it as soon as possible.

Do you have any questions about what I have said so far?

If you choose to do your HIV test now, I will do it for you free of charge, but before doing it, I will give you more information on voluntary counseling and testing for HIV.

1
2
3 If you want to do it later, I will give you more information on health facilities where you can go
4 and do your test.
5
6

7
8 I will be in touch with you for any assistance which you made need. Would you like to have my
9 telephone number? Would you like me to call you?
10
11

12
13 I have this information for you and would like you to read it carefully and discuss it with me. If it
14 is ok with you, please sign it. I will keep it confidential. You do not have to sign it if you do not
15 want to.
16
17
18

19
20 Have you made a decision to do the test? When and where will you like to do it?
21
22

23
24 Would you like for us to test you?
25
26

27
28 If yes, would you like to come to the [name of closest clinic] center for testing or where would
29 you want us to offer the test for you? If at home or work, please arrange for a private place where
30 we can offer the service. If no, we would still encourage you to seek services at [name of nearest
31 clinic].
32
33
34

35
36 Thank you.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



STANDARD PROTOCOL ITEMS: RECOMMENDATIONS FOR INTERVENTIONAL TRIALS

SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Addressed on page number
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	___ 1 ___
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	___ 21 ___
	2b	All items from the World Health Organization Trial Registration Data Set	___ Included ___
Protocol version	3	Date and version identifier	___ 1 ___
Funding	4	Sources and types of financial, material, and other support	___ 23 ___
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	___ 1, 23 ___
	5b	Name and contact information for the trial sponsor	___
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	___ N/A ___
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	___ N/A ___

1 Introduction

2				
3	Background and	6a	Description of research question and justification for undertaking the trial, including summary of relevant	___ 5-7 ___
4	rationale		studies (published and unpublished) examining benefits and harms for each intervention	
5				
6		6b	Explanation for choice of comparators	___ N/A ___
7				
8	Objectives	7	Specific objectives or hypotheses	___ 6-7 ___
9				
10	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group),	
11			allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	___ 8 ___
12				
13				
14	Methods: Participants, interventions, and outcomes			
15				
16	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will	___ 8 ___
17			be collected. Reference to where list of study sites can be obtained	
18				
19	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and	___ 10-11 ___
20			individuals who will perform the interventions (eg, surgeons, psychotherapists)	
21				
22	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be	___ 11-14 ___
23			administered	
24				
25		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose	___ N/A ___
26			change in response to harms, participant request, or improving/worsening disease)	
27				
28		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence	___ N/A ___
29			(eg, drug tablet return, laboratory tests)	
30				
31		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	___ 17 ___
32				
33	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood	___ 18 ___
34			pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg,	
35			median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen	
36			efficacy and harm outcomes is strongly recommended	
37				
38	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for	___ 15 ___
39			participants. A schematic diagram is highly recommended (see Figure)	
40				
41				
42				
43				
44				
45				
46				

1	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	19
2				
3				
4	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	11
5				
6	Methods: Assignment of interventions (for controlled trials)			
7	Allocation:			
8				
9				
10	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	N/A
11				
12				
13				
14				
15				
16	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	N/A
17				
18				
19				
20	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	N/A
21				
22				
23				
24	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	N/A
25				
26				
27		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	N/A
28				
29				
30				
31	Methods: Data collection, management, and analysis			
32				
33	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	12
34				
35				
36				
37				
38				
39		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	15
40				
41				
42				
43				
44				
45				
46				

1	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	___ 18 ___
2				
3				
4				
5	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	___ 19-20 ___
6				
7				
8		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	___ N/A ___
9				
10		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	___ N/A ___
11				
12				
13				
14	Methods: Monitoring			
15				
16	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	___ N/A ___
17				
18				
19				
20				
21				
22		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	___ N/A ___
23				
24				
25	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	___ 21-22 ___
26				
27				
28	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	___ N/A ___
29				
30				
31				
32	Ethics and dissemination			
33				
34	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	___ 21 ___
35				
36				
37	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	___ 22 ___
38				
39				
40				
41				
42				
43				
44				
45				
46				

6/bmjopen-2022-041083 on 24 April 2024 Downloaded from <http://bmjopen.bmj.com/> by guest on April 24, 2024. Protected by copyright.

1	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	__12-13__
2				
3				
4		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	__12-13__
5				
6				
7	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	__16-18__
8				
9				
10	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	__23__
11				
12				
13	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	__18__
14				
15				
16	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	__17-18__
17				
18				
19				
20	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	__22-23__
21				
22				
23				
24		31b	Authorship eligibility guidelines and any intended use of professional writers	__23__
25				
26		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	__N/A__
27				
28				
29	Appendices			
30				
31	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	__Attached__
32				
33				
34	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	__14-15, 20__
35				
36				

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by/4.0/)" license.